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Preface 
 
Many people travel to mountainous regions for exploration and recreation.  This 
imposes a physiological challenge and brings about changes in every organ 
system within the body.  This physiological challenge is unique within healthy 
individuals and may provide an insight into mechanisms relevant to ill health.  This 
work aimed to investigate mechanisms behind the hormonal and physiological 
adaptation to high altitude and why, in some individuals, this extreme physiological 
challenge leads to serious and potentially life threatening illness. 
 
For the military rapid deployment of elite forces to high altitude can result in altitude 
illness, the need for aeromedical evacuation and a degradation of the ability to 
perform an operational role.  For those travelling to mountainous areas for 
recreational reasons the lack of a diagnostic test for altitude illness may lead to 
unnecessary, dangerous and expensive evacuation to lower altitudes. 
 
Brain natriuretic peptide (BNP) is released from the heart in response to ventricular 
wall stress and has a well-established role in diagnosing heart failure.  BNP 
increases with raised pulmonary artery systolic pressure (PASP), raised PASP is a 
key feature of high altitude pulmonary oedema (HAPE) and as such BNP may be 
raised with HAPE.  Furthermore BNP is expressed in hypoxic cells and may 
therefore be raised as a marker of altitude illness. 
 
During the work for this thesis investigating BNP in 48 subjects on an ascent to 
5129m, it has been demonstrated that there is a significant rise in BNP with those 
with acute mountain sickness vs. those without.  RoC analysis for this change in 
BNP demonstrated an area under the curve (AUC) of 0.601 for detecting AMS and 
an AUC of 0.675 for detecting severe AMS.  Similarly the AUC was 0.645 for BNP 
detecting a PASP greater than 40 mmHg.  It is important to note that these findings 
were across all subjects, i.e. the pretest probability of a positive result was low.  In 
asymptomatic populations the AUC for BNP in detecting mild left ventricular 
systolic dysfunction is 0.6 for women and 0.72 for men. 
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These findings raise the possibility that BNP may be a useful diagnostic adjunct to 
current scoring systems in identifying significant pathology at high altitude.  
Specifically a low or normal BNP could be used to “rule out” altitude illness making 
an alternative diagnosis more likely and reducing the risk of the patient remaining 
at altitude.  During the course of the study one subject who developed HAPE was 
monitored with serial BNP and cardiac echo studies which was reported in the 
International Journal of Cardiology and shows the utility of this approach. 
 
Amongst the other findings of the studies that make up this thesis the importance 
of exercise in adaptation to high altitude was highlighted.  Subjects reporting high 
perceived exertion scores (Borg RPE >15 which is around the aerobic threshold) 
had significantly different values of stress hormones (cortisol and copeptin), as well 
as higher scores for acute mountain sickness, lower oxygen saturations and higher 
heart rates.  These physiological effects were present post exercise but also 
persisted the following day at rest. 
 
This finding highlights that future studies relating to physiological adaptation to high 
altitude need to use relevant exercise intensities and may explain some of the 
inconsistencies in other published studies. 
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Structured Abstract 
Data was collected in two main phases; 
1. A field study undertaken in the Cordillera Real Region of Bolivia. 
2. Laboratory investigation of terrestrial, hypobaric and normobaric hypoxia. 
Phase 1 
The aim of phase one of the studies was to investigate the endocrine changes 
(specifically brain natriuretic peptide (BNP), arginine vasopressin (AVP), cortisol, 
catecholamine and copeptin) with ascent to high altitude.  These changes were 
investigated during a “real world” trekking expedition to Bolivia.  Other potential 
markers for AMS namely high-sensitivity C reactive protein (hs-CRP), high-
sensitivity cardiac troponin T (hs-cTnT) and neutrophil gelatinase associated 
lipocalin (NGAL) were also studied. 
The overarching hypothesis was that Acute Mountain Sickness (AMS) would be 
associated with fluid retention and elevated BNP and that changes in other 
hormones involved in fluid balance such as AVP, copeptin and cortisol may also 
reflect AMS.  
The hypotheses investigated included; 
 That BNP would rise with high altitude (HA) illness and be associated with 
both AMS and a high pulmonary artery systolic pressure (PASP).  
 That copeptin would accurately reflect changes in AVP at altitude and 
therefore have utility in future field studies as a surrogate for AVP.  
 That AMS would be associated with either elevated copeptin/AVP or with 
failure to suppress the copeptin/AVP response to exercise. 
 Inflammation and/or rises in PASP occur with the development of high 
altitude illness and would lead to a detectable rise in hs-cTnT, NGAL or hs-
CRP.  
 The dynamic changes in stress hormones associated with exercise are key 
in the pathogenesis of altitude illness. 
 The physiological stress of HA would lead to a rise in cortisol.  This would 
contribute to fluid retention and be linked to the development of AMS. 
 There would be no difference between total body water (TBW) measured by 
single or multifrequency bioimpedance analysis. 
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Methods: 
This was an observational study with data collection at sea-level and then 
subsequently over a 10 day ascent from 3800m to 5129m.  Daily physiological data 
was collected with more detailed investigation performed at 3833m, 4450m and 
5129m.  At these altitudes, data was collected post exercise (after the ascent) and 
at rest (the following day).  Venous blood samples were collected for hormonal 
assays. BNP and NGAL were analysed in situ using point of care testing 
technology.  Assessment of TBW was performed using bioimpedance devices and 
pulmonary artery systolic pressure (PASP) was estimated using transthoracic 
echocardiography. 
Results and implications: 
50 subjects were recruited to the study, 48 of whom were studied at 3833m and 
4450m with 47 subjects studied at 5129m.  Results presented as mean (range, 
SD) unless otherwise stated. 
Significant findings were: 
Oxygen saturations fell with ascent to altitude to a nadir of 79% (SD 4.4., range 68-
88) at 5129m. 
Fluid balance showed no significant change with altitude or relation to AMS. 
Plasma osmolality did not change with ascent. 
AVP and copeptin did not increase until extreme altitude (5129m) and both 
increased by a greater degree in those recording higher levels of perceived 
exertion.  This was despite no change in osmolality which suggests a non-osmotic 
stimulus to their secretion. 
Cortisol secretion increased at 5129m and may support the possibility that the rise 
in copeptin and AVP was related to physiological stress at extreme altitude. 
Plasma normetanephrine increased with increasing altitude reaching a maximum 
of 1423.72 (786.0, 355–4159 pmol/L) at 5129m. 
Thirst proved difficult to quantify and the visual analogue scale used showed no 
correlation with total body water, osmolality or AVP.  
BNP (and NT-proBNP) increased with increasing severity of AMS as assessed by 
Lake Louise Score (LLS). 
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BNP (and NT-proBNP) were higher in those with a high PASP.  
Hs-cTnT showed an increase with PASP and but no association with AMS.   
Hs-CRP showed an increase with altitude but no association with AMS. 
NGAL showed no association with change in altitude. 
A consistent finding was an evident separation between subjects recording a low 
Borg score and those recording a Borg rating consistent with “hard work”.  Subjects 
recording a Borg score > 15 (“hard work”) had higher cortisol, AVP, copeptin and 
an increased LLS.  This led to investigation of an additional hypothesis that a 
higher rating of perceived exertion will lead to an increase in reported AMS 
symptoms.  This was found to be the case with significantly lower SpO2 at rest, 
higher heart rates and higher LLS in those reporting a Borg RPE > 15. 
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Phase 2 
The difficulties of conducting a field study of this nature, especially where 
controlling exercise is so difficult, prompted investigation as to the comparison 
between laboratory conditions (normobaric or hypobaric hypoxia) with the real 
world. 
Hypothesis: 
1. There will be no difference in the response to hypoxia in normobaric, 
hypobaric or “real world” environments.  
Methods: 
Sixteen subjects were recruited and underwent cardiopulmonary exercise testing at 
baseline, at the Torino hut in the Italian Alps (3380m), in a normobaric hypoxic 
chamber and hypobaric chamber at equivalent simulated altitudes.  Subjects 
performed 2 hours’ work on a cycle ergometer at 60% altitude adjusted maximal 
oxygen uptake.  Data were collected on heart rate, oxygen saturations, oxygen 
uptake, RPE (Borg), LLS and lactate. 
Results: 
Sixteen subjects were recruited.  Fifteen completed testing in the Alps, 14 in 
normobaric hypoxia and 6 in hypobaric hypoxia. 
There were no differences in heart rate, RPE, oxygen uptake or lactate across the 
three hypoxic environments. 
Summary: 
During the course of this research there was a progression from trying to 
understand the importance of individual hormonal changes in the pathophysiology 
of AMS, to identifying the role of exercise as a very important factor and then 
looking at laboratory models to replicate the physiology of high altitude.   
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Summary 
The understanding of hormonal changes pertinent to high altitude illness relies 
upon an understanding of normal physiology at sea level and at high altitude.   As 
exercise is an almost inevitable part of ascending to altitude the changes that occur 
with exercise are also of crucial importance. 
This chapter provides an introduction to those changes in order to set the context 
of subsequent chapters. 
1.1   Definitions of High Altitude 
• Intermediate Altitude  (1500m – 2500m) 
Physiological changes occur, SpO2>90%, altitude illness possible but rare 
• High Altitude  (2500m – 3500m)  
Altitude illness common with rapid ascent 
• Very High Altitude (3500m – 5800m) 
Altitude illness common, SpO2<90%, marked hypoxia with exercise 
• Extreme Altitude  (>5800m) 
Marked hypoxia at rest, progressive deterioration, permanent survival not 
possible 
 
1.2   Normal Physiology Of High Altitude 
Unacclimatised lowlanders arriving at high altitude experience profound hypoxia.  
Oxygen saturations on arrival at 3800m average 90% and, after a trek to 5200m 
over several days, average 81% (Mellor, Boos et al. 2014).  This physiological 
challenge brings about multisystem changes to adapt to hypoxia and maintain 
oxygen delivery.  Many of these adaptations are beneficial but if unchecked can 
lead to the development of altitude illness. 
Atmospheric pressure changes at high altitude with consequent reduction in the 
available fraction of oxygen.  This effect is further exaggerated by the fact that 
inspired gases are warmed and moistened as they pass through the nose, mouth 
and trachea.  The saturated vapour pressure of water is constant despite the 
change in pressure and this reduces the partial pressure of inspired oxygen still 
further as described in the equation below. 
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PiO2 = FiO2 (PB – PH2O) 
 
Where PiO2 is the partial pressure of oxygen, FiO2 is the fraction of oxygen in the 
air, PB is barometric pressure and PH2O is the saturated vapour pressure of water. 
 
At, for example, 5800m PB is 380mmHg and therefore the PiO2 is reduced to 
0.21(380-47) = 70mmHg.  This contrasts with a PiO2 of 0.21(760-47) = 150mmHg 
at sea level. 
 
Adaptive mechanisms develop over time on exposure to hypoxia to mitigate 
against these effects and include cardiovascular, respiratory and endocrine 
responses. 
 
1.2.1   Cardiovascular Responses To Altitude 
Cardiac Output - On acute exposure to a hypoxic environment it is generally 
accepted that cardiac output increases. This makes good physiological sense; as 
the partial pressure of oxygen falls in the atmosphere then so does the arterial 
oxygen content (SaO2) and in order to maintain oxygen delivery to the tissues 
cardiac output must increase.  
 
Once acclimatised cardiac output returns towards sea level values both at rest and 
for any given work rate, except at a maximal level where cardiac output and 
maximum work rate is reduced (Reeves, Groves et al. 1987, Richalet 2010).  This 
seems paradoxical but is probably due in part to the fact that maximum oxygen 
uptake (VO2 max) is reduced at extreme altitude because oxygen transfer from the 
lung and to the tissue is limited by diffusion, rather than perfusion.  This means that 
the uptake of oxygen at the alveolar/capillary membrane and offload at the 
capillary/cell membrane is limited by the properties of the membrane rather than 
the flow of blood to those areas (alternative explanations discussed below). 
  
Heart Rate - Acute hypoxia causes an increase in both resting and exercising heart 
rate, due to increased sympathetic drive. The higher the altitude then the greater 
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the increase in heart rate.  As a subject acclimatises the resting heart rate 
generally returns to that of sea level values up to an altitude of approximately 
4500m.  On exercise however, even in acclimatised subjects, heart rate for a given 
work load is greater than at sea level except at maximal exercise where maximal 
heart rate is reduced compared to sea level values.  
There are a number of different theories as to why maximal heart rate should be 
lower at altitude compared to sea level. Pugh et al noted in 1964 that oxygen 
consumption at maximal heart rate at altitude was reduced compared to sea level 
values, suggesting for the given work rate much was achieved using anaerobic 
respiration (Pugh, Gill et al. 1964).  Later Richalet and colleagues suggested the 
reduction is a physiological adaptation that reduces cardiac work in environments 
with limited oxygen availability - it has been shown that hypoxia down regulates β-
adrenergic receptors in animal models (Richalet, Merlet et al. 1990).  This 
adaptation of limited maximum heart rate seems likely to be beneficial given the 
diffusion limitation of oxygen uptake in the lungs. 
 
Interestingly breathing oxygen at high altitude may reduce the heart rate for a given 
work load to below sea level values (Pugh, Gill et al. 1964).  This may be due to 
the higher haemoglobin levels (see later) and therefore increased oxygen content 
in comparison to sea level. 
 
Blood Pressure - Blood pressure shows a variable and highly individual response 
to acute exposure to altitude; overall there is usually an increase for the first few 
weeks when lowlanders travel to altitude.  This is probably due to an increase in 
the sympathetic drive and vascular tone.  Conversely lowlanders resident at 
altitude for some years show a decrease in both systolic and diastolic pressures 
and subjects with known systemic hypertension often show an improvement in 
blood pressure (Marticorena E 1969). On the Defence Medical Services (DMS) 
expedition to Aconcagua in 2007 resting systolic blood pressure (SBP) increased 
from 116 +/- 15 mmHg at sea level to 136 +/-13 mmHg at 4250m (Hooper, Levett 
et al. 2010).  The Birmingham Medical Research Expeditionary Society similarly 
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report changes in SBP of 131+/-23 mmHg at sea level increasing to 145 +/- 23 
mmHg at 3450m (Rhodes, Chesterman et al. 2011).  
 
Pulmonary Circulation - Increases in pulmonary vascular resistance secondary to 
hypoxic pulmonary vasoconstriction (HPV) lead to pulmonary hypertension at 
altitude.  This is seen in subjects exposed to acute hypoxia, acclimatised 
lowlanders and high altitude natives alike.  
In certain disease states such as asthma and chronic obstructive pulmonary 
disease, HPV is of value in that it limits ventilation/perfusion mismatch i.e. in areas 
of the lung that are not being ventilated HPV occurs diverting blood away from 
these regions.  However at altitude, with global hypoxia, HPV serves no purpose 
and is thought to be the major cause of high altitude pulmonary oedema (HAPE). 
 
During Operation Everest II (Sutton, Maher et al. 1983) pulmonary vascular 
pressures were measured using pulmonary artery flotation catheters.  The 
pulmonary vascular pressure gradient (mean pulmonary arterial – pulmonary 
wedge) was measured at different cardiac outputs at various altitudes.  At rest the 
gradient increased with increasing altitude but most striking was the increase in 
slope of pressure gradient against cardiac output at the higher altitudes (Groves, 
Reeves et al. 1987).  This indicates the marked increase in resistance at high 
altitude. 
 
The pulmonary hypertension associated with altitude leads to right ventricular and 
atrial hypertrophy. Changes associated with this hypertrophy are often seen on the 
ECG with right axis deviation of the QRS axis and increase in amplitude of the P 
wave in lead II. 
 
Exercising at Altitude - Cardiac output for a given workload returns towards sea 
level values in acclimatised subjects (except at maximal work rates), the heart rate 
remains increased and stroke volume is reduced.  
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Uniquely at extreme altitude both oxygen loading at the alveolus and offloading at 
the muscles becomes diffusion limited (West 1982, Calbet and Lundby 2009).  The 
diffusion limitation at the muscle level is a relatively new concept, previously it was 
thought that the work able to be done by muscles at altitude was determined by the 
oxygen delivery to that muscle.  It seems likely that diffusion is the limiting factor at 
extreme altitude even though the average distance over which oxygen has to 
diffuse from the capillary to the mitochondria is reduced due to muscle fibres 
reducing in size (Lundby, Pilegaard et al. 2004) and increasing capillary density 
(Mizuno, Savard et al. 2008). 
  
Maximal Oxygen Consumption - Maximal oxygen consumption (VO2 max) in 
acclimatised subjects at altitude is reduced.  The reason is unclear but may be 
caused by a reduction in muscle mass or the increased blood viscosity at altitude 
leading to interference in capillary blood flow and oxygen exchange at the tissue 
level.  Other reasons suggested include the diffusion limitation in the lung or 
exercising muscle (discussed above).  An alternative explanation is that blood flow 
to the muscles of locomotion is reduced as a consequence of the increased 
demand of the respiratory muscles.  Cibella et al looked at the increased oxygen 
needs of the respiratory muscles at altitude due to the increased workload.  They 
found that at altitude breathing accounted for 26% of VO2 max compared to only 
5.5% at sea level (Cibella, Cuttitta et al. 1999) 
 
1.2.2   Respiratory Changes 
Ventilation is regulated by three stimuli; carbon dioxide (CO2), oxygen (O2) and pH. 
These stimuli are sensed and transduced by peripheral and central 
chemoreceptors.  The efferent response is co-ordinated by the medullary 
respiratory centres. 
 
The carotid bodies are highly vascularised areas of tissue and respond to 
decreasing levels of oxygen dissolved in the blood.  At normal arterial oxygen 
tensions they have little output but as the partial pressure falls below 8kPa output 
increases rapidly. The effector response to the detected hypoxia is increased 
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ventilation via the cardiorespiratory centre in the medulla. The resulting increased 
minute volume serves to reduce alveolar partial pressure of carbon dioxide.  This 
increases the available alveolar oxygen as dictated by the alveolar gas equation 
(below). 
 
PAO2 = PiO2 – PACO2/R  
 
Where PAO2 = alveolar oxygen tension, PiO2 is the inspired oxygen tension, 
PACO2 = alveolar carbon dioxide tension and R = respiratory quotient.  
 
This effect of increased minute ventilation due to hypoxia is known as the hypoxic 
ventilatory response (HVR). 
 
The response to pH, and by extension carbon dioxide, is largely regulated by the 
central chemoreceptors.  These chemoreceptors are on the ventrolateral surface of 
the medulla and respond to pH changes in the cerebrospinal fluid (CSF).  
 
As plasma carbon dioxide levels rise the gas diffuses freely into the CSF and 
increases the concentration of H+ ions.  The blood brain barrier is much less 
permeable to H+ ions and bicarbonate than it is to carbon dioxide.  Thus changes 
in the partial pressure of carbon dioxide in arterial blood are reflected quickly in the 
CSF.  The effector response of the central chemoreceptors is to increase 
ventilation via stimulation of the medullary respiratory centre. This is the 
hypercapnic ventilatory response (HCVR).  
 
Prolonged exposure to the hypoxia of altitude causes a respiratory alkalosis. The 
result of this would ordinarily be to reduce respiratory drive via the peripheral 
chemoreceptors.  Renal compensation occurs and HCO3- is excreted in the urine. 
Subsequent loss of HCO3- from the plasma creates a concentration gradient of 
HCO3- from CSF to plasma and HCO3- moves out of the CSF. This reduction in 
CSF HCO3- causes an increase in free H+ ions in the CSF which then stimulate 
the central chemoreceptors which effects an increase in ventilation to reduce CO2 
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levels and hence H+ levels within the CSF.  Physiologically this occurs to ensure 
that CSF pH remains constant.  With adaptation the level of CO2 at which 
increased ventilation will occur is reset to lower levels and the HCVR response 
curve has been shifted to the left, producing a much more rapid response to 
smaller changes in CO2 (Kellog 1963). 
 
1.3  Altitude Illness 
It is not surprising that, given the degree of physiological changes at high altitude 
(HA), specific health effects can occur.  Altitude illness is typically classified as 
acute (onset within hours to a few days) or chronic (onset after years of habitation 
at HA).  Chronic mountain sickness is characterised by polycythaemia and is not 
considered further. 
Acute mountain sickness (AMS) is a collection of symptoms including headache, 
anorexia, nausea and vomiting, poor co-ordination with fatigue and difficulty 
sleeping.  It is most frequently diagnosed according to the Lake Louise Score 
(Hackett and Oelz 1992).  Pathognomic to the condition is the presence of a 
headache and the scoring system requires the presence of a headache and other 
symptoms in order to generate a score from 0 – 18 (table 3.1).  A score of >3 is 
taken to indicate mild AMS and >6 severe AMS.  This is purely a self-reported 
score and is the principal method used to diagnose the condition.  This is 
described in more detail in chapter 2. 
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Diagnosis of AMS is based on a recent gain in altitude, a headache plus at 
least one of the other symptoms. 
A total score of 3-5 is diagnostic of AMS, a score of > 6 is diagnostic of 
severe AMS. 
 
Symptom Severity Score 
 
Headache 
No headache 0 
Mild headache 1 
Moderate headache 2 
Severe headache 3 
 
 
Gastrointestinal 
Symptoms 
None 0 
Poor appetite or nausea 1 
Moderate nausea +/- vomiting 2 
Severe nausea +/- vomiting 3 
 
 
Fatigue and/or weakness 
Not tired or weak 0 
Mild fatigue or weakness 1 
Moderate fatigue or weakness 2 
Severe fatigue or weakness 3 
 
Dizziness/lightheadedness Not dizzy 0 
Mild dizziness 1 
Moderate dizziness 2 
Severe, incapacitating dizziness 3 
 
Difficulty sleeping Slept as well as usual 0 
Did not sleep as well as usual 1 
Woke many times, poor sleep 2 
Could not sleep at all 3 
 
Table 1.1   Lake Louise Score for the Diagnosis of Acute Mountain Sickness 
 
An alternative self-reported system is the AMS-C score of the Environmental 
Symptom Questionnaire (ESQ) (Sampson, Cymerman et al. 1983).  The AMS-C 
score of the ESQ is assessed according to the method outlined by Sampson et al 
(Sampson, Cymerman et al. 1983).  In essence the AMS-C score is composed of 
11 questions graded from 0-5 covering lightheadedness, nausea, dizziness, 
headache etc.  Each symptom is given a factorial weighting, the resultant scores 
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totalled and then multiplied by 0.1927 to give a score in the range 0-5.  AMS is 
defined as a score ≥ 0.70. 
 
AMS is usually a self-limiting disease and recovers after a rest at the new altitude 
or more rapidly with descent.  Occasionally the condition leads to the more serious 
High Altitude Cerebral Oedema (HACE), which is usually preceded by AMS and 
probably part of a spectrum of disease (Hackett and Roach 2004).  High altitude 
pulmonary oedema is a separate entity which results from pulmonary capillary 
damage and oedema secondary to raised pulmonary artery pressures (Hall, 
Duncan et al. 2011).  The pathophysiological mechanisms underlying the 
development of AMS and indeed HACE are not completely understood.  It does 
seem, however, relatively consistent that fluid retention and increased plasma 
aldosterone (which is responsible for sodium and fluid retention) occur in AMS 
(Hackett, Rennie et al. 1982, Bartsch, Maggiorini et al. 1991, Bartsch, Pfluger et al. 
1991). 
 
The incidence of AMS is largely related to the speed of ascent and ranges from 
84% with tourists flying direct to the Everest View hotel in Namche Bazaar at 
3860m to 30% at 6190m on Denali in North America (Barry and Pollard 2003).  
Predicting AMS is problematic.  Factors such as age, obesity, pre-existing disease 
and fitness level are all poor indicators of HA performance.  There is no simple 
relationship to hypoxia as measured by pulse oximetry, although post exercise 
oxygen saturations may be more useful (Karinen, Peltonen et al. 2008).   
 
1.4   Natriuretic Peptide Physiology 
1.4.1   Normal Physiology 
Atrial Natriuretic Peptide (ANP), Brain Natriuretic Peptide (BNP) and C Type 
Natriuretic peptide (CNP) are structurally related peptides that, along with urodilatin 
comprise the natriuretic system.  ANP, BNP and CNP share a 17-amino acid 
internal ring structure and have a role in fluid homeostasis, opposing the renin-
angiotensin-aldosterone system and are secreted from cardiomyocytes (Liang, 
Kapoun et al. 2007).  Atrial natriuretic peptide (ANP) was the first cardiac related 
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natriuretic peptide to be discovered.  It is stored in granules in the cardiac atria with 
a high concentration in the atrial appendage and secreted in response to an 
increase in atrial distension.  The main stimulus seems to be increased atrial 
transmural pressure.  ANP is known to rise acutely under hypoxic conditions in 
both animal and human models. 
 
BNP was first described in 1988 by Sudoh in porcine brain (Sudoh, Kangawa et al. 
1988).  It is very species specific (unlike ANP).  BNP is stored in cardiomyocytes 
as proBNP, once release is stimulated proBNP is cleaved into the active hormone 
BNP and the inactive peptide NT-proBNP.  60-80% of BNP comes from ventricular 
tissue (Espiner 1994).  Resting levels of BNP, in young people at sea level, are an 
average of 7.1 pg/ml (Woods, Hooper et al. 2011).  Levels may rise within two 
minutes of a stimulus but are transistory as there is limited storage capacity.  
Plasma half-life is 22 minutes (Davidson and Struthers 1994). 
 
Brain natriuretic peptide (BNP) is secreted as a prohormone and cleaved into the 
biologically active BNP and the more stable N Terminal prohormone (NT-pro) BNP.  
Comparative studies demonstrate that BNP and NT-proBNP give equivalent results 
in a large population of patients with cardiac disease (Park, Baek et al. 2010) and 
in healthy subjects at high altitude (Woods, Begley et al. 2012). 
 
BNP levels rise with age. Mean BNP levels in males are (Felker, Petersen et al. 
2006):  
 26.2 pg/ml in those aged 55-64 years. 
 31.0 pg/ml in those aged 65-74 years. 
 63.7 pg/ml in those aged 75 years and older. 
 
Corresponding levels for NT-pro BNP means (male subjects) are (Galasko, Lahiri 
et al. 2005) 
 28 pg/ml in those 45-59 
 53 pg/ml in those over 60 
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Women without CHF tend to have higher BNP and NT-pro BNP levels than males 
of the same age 
 
BNP levels show positive correlation with increases in left ventricular end diastolic 
pressure, pulmonary artery occlusion pressure and pulmonary artery pressure 
(Davidson and Struthers 1994).  The most important stimulus to BNP release is 
cardiac stretch (Hall 2005) but BNP also increases with an increased sodium diet, 
increased blood pressure, chronic renal failure and with increases in 
catecholamines (Espiner 1994, Hall 2005).  Recently BNP levels have been linked 
to markers of inflammation (see below) and it may have use as a measure of the 
acute phase response rather than be a specific cardiac marker in some settings. 
The actions of BNP include the following; 
 Renal – increase urinary excretion of sodium 
 Cardiovascular system – decrease intravascular volume, decrease SVR, 
increase cardiac output, decrease right atrial pressure, pulmonary artery 
occlusion pressure (PAOP) and possibly coronary vasodilation 
 Endocrine – inhibit aldosterone secretion, decrease renin activity 
 Central Nervous System – possibly acts as a neurotransmitter in CVS 
control centres  
 
A BNP rise of 20-30 pmol/l results in a two-fold increase in sodium excretion and 
suppressed renin and aldosterone activity.  When infused into human subjects 
doses resulting in plasma levels 20 fold above baseline, but within the range seen 
in heart failure and other diseases, decrease mean arterial pressure, pulmonary 
artery occlusion pressures and right atrial pressures (Espiner 1994). 
 
1.4.2   BNP As A Disease Marker 
Due to the fact that BNP is released from the ventricles in response to ventricular 
stress most interest has focused on its use as a marker of heart failure.  In this 
setting a BNP value of 100pg/ml is highly suggestive of cardiac failure and it can 
be used to discriminate between pulmonary or cardiac causes of shortness of 
breath (Felker, Petersen et al. 2006).  Whether BNP or NT-pro BNP is measured 
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seems to have no relationship to its utility as a marker and both are used 
throughout the literature.  The majority of the published literature focuses on the 
use of BNP and NT-proBNP in heart failure, both for risk stratification (Baggish, 
van Kimmenade et al. 2008) and response to treatment (Karlstrom, Alehagen et al. 
2011). 
 
Not surprisingly natriuretic peptides have also been investigated as markers of 
outcome after cardiac surgery and after myocardial infarction (MI) (Eliasdottir, 
Klemenzson et al. 2008, Fazlinezhad, Rezaeian et al. 2011).  The levels of BNP 
recorded after acute MI are very high indeed 4436.63 (+/- 6188.2 pg/ml) whereas 
more subtle changes are reported with RV dysfunction after acute pulmonary 
embolus (APE) (527 – 1300 pg/ml being associated with RV dysfunction)(Pieralli, 
Olivotto et al. 2006).  A pre-operative NT-proBNP of >1028 pg/ml in patients 
undergoing coronary artery bypass grafting (CABG) was associated with increased 
hospital mortality, severe circulatory failure and decreased long term survival 
(Holm, Vidlund et al. 2013).  These findings are probably reflective of the fact that 
cardiac failure is an indicator of poor outcome after MI or a risk factor for cardiac 
surgery and is associated with a high BNP.  However, the same remains true for 
non-cardiac surgery and other conditions (see below). 
 
In patients with community acquired pneumonia, BNP has been demonstrated to 
be a powerful independent predictor of death and treatment failure with BNP levels 
of (median) 439.2pg/ml  in the non survivors v’s 114.3 in the survivors (p<0.001) 
(Christ-Crain, Breidthardt et al. 2008).  Levels of BNP have also been shown to be 
high in rheumatoid arthritis and systemic lupus erythematosus despite no obvious 
cardiac disease (Karadag, Calguneri et al. 2007, Provan, Angel et al. 2008). 
 
NT-proBNP has been used as a biomarker to assess risk of death in intensive care 
units (ICU).  De Geer and colleagues found an odds ratio for 30 day mortality of 2.6 
(95% CI 1.5 to 4.4) for those with NT-proBNP above 1380 ng/ml vs. those below 
that threshold (De Geer, Fredrikson et al. 2012).  In patients with Systemic 
Inflammatory Response Syndrome following CABG, Kerbaul found very high levels 
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of NT-proBNP with peak values of 8887 pg/ml (range 2940 – 29372)(Kerbaul, 
Giorgi et al. 2004).  BNP seems to specifically increase in septic shock rather than 
shock per se (Wolff, Haase et al. 2007).  
 
BNP has a role in modulating the inflammatory mediators in macrophages 
(Chiurchiu, Izzi et al. 2008) and with inflammation, BNP is stimulated at the 
transcriptional and translational levels (Ogawa and de Bold 2012).  This may 
explain the high levels in septic shock and other conditions where there is no 
obvious cardiac pathology.  BNP (and NT-proBNP) correlates with other 
inflammatory markers such as interleukin 6, C reactive protein and tumour necrosis 
factor (Mehra, Uber et al. 2006, Haugen, Chen et al. 2007, Vila, Resl et al. 2008, 
Guo, Barany et al. 2009, Jensen, Ma et al. 2010, Vaz Perez, Doehner et al. 2010, 
Moraes, Ribeiro et al. 2013). 
 
In summary BNP seems to act as a modulator of acute inflammation as well as 
being released in response to ventricular stretch. 
 
1.4.3   BNP At High Altitude 
BNP has a role in inducing a natriuresis and diuresis (albeit mild) and reducing 
renin and aldosterone secretion (Hall 2005) which are effects that should be 
beneficial at HA.  BNP also has pulmonary vasorelaxant activity, attenuating acute 
hypoxic pulmonary vasoconstriction and reducing pulmonary hypertension, (Cargill 
and Lipworth 1995).  This effect could protect against the development of HAPE 
which is associated with an increase in capillary pressure and pulmonary 
vasoconstriction (Maggiorini, Melot et al. 2001).  These actions make it a likely 
candidate hormone to be involved in acclimatisation. 
 
In animal models, isolated rat hearts increase ANP and BNP with an acute (30 
minutes) hypoxic exposure (Toth, Vuorinen et al. 1994).  Cultured adult rat 
cardiomyocytes have demonstrated an increase in BNP mRNA expression after 
the induction of systemic hypoxia (Weidemann, Klanke et al. 2008), as have rats 
exposed to hypobaric hypoxia equivalent to an altitude of 5500 metres (Nakanishi, 
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Tajima et al. 2001).  Ex vivo studies of human ventricular myocytes cultured under 
hypoxic conditions also demonstrated an increase in the synthesis and secretion of 
BNP (Casals, Ros et al. 2009).  Results of in vivo human studies are mixed; in one 
report involving 10 human subjects there was no apparent rise in BNP despite 
oxygen saturations of 75-80% being induced (Cargill, McFarlane et al. 1996) whilst 
a more recent study with humans exposed to acute hypoxia, inducing oxygen 
saturations (SpO2) of around 82% over 60 minutes, a 9% rise in NT-proBNP was 
reported (Due-Andersen, Pedersen-Bjergaard et al. 2008).  Both these studies 
involved breathing hypoxic gas mixtures in normobaricity.  
 
Considering these findings, and that there are BNP receptors on the adrenal gland 
(Nawata, Ohashi et al. 1991) and that BNP causes a reduction in aldosterone 
secretion from the adrenals (McGregor, Richards et al. 1990, Hall 2005) (which as 
discussed above has beneficial effects at HA) it is not surprising that there has 
been recent investigations regarding BNP at HA.  BNP rises with prolonged 
exercise under normoxic conditions (Hew-Butler, Noakes et al. 2008) and ANP, a 
related peptide, rises in acute hypoxia and altitude illness (Bartsch, Shaw et al. 
1988, Cargill, McFarlane et al. 1996). It therefore would seem reasonable to expect 
that HA would lead to a rise in BNP.   
 
However, two field studies have found no increase in BNP or NT-proBNP 
measured during rest at high altitude. Feddersen and colleagues (Feddersen, 
Ausserer et al. 2009) found no rise in BNP at rest measured the day after arrival at 
a new altitude with ascent up to 5050 m and SpO2 of 84.5+/-1.3%. Similarly, 
another study (Toshner, Thompson et al. 2008) found no rise in NT-proBNP in 10 
healthy subjects at 5200 m.  These subjects had ascended to 5200 m by vehicle 
following a 5 day acclimatization period at 3650 m. Samples were again taken at 
rest with a mean SpO2 on the day of sampling of 77.6% i.e. lower than that 
associated with a rise in NT-proBNP with acute hypoxia (Due-Andersen, Pedersen-
Bjergaard et al. 2008).  Moderate exercise at SL is generally not associated with a 
rise in BNP or NT-proBNP (Nicholson, Richards et al. 1993, Marumoto, Hamada et 
al. 1995) and neither is high intensity short duration exercise (Hew-Butler, Noakes 
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et al. 2008).  However, prolonged endurance exercise at SL such as running an 
ultramarathon (Scharhag, Herrmann et al. 2005, Hew-Butler, Noakes et al. 2008) 
or prolonged cycling (Scharhag, Meyer et al. 2008) may cause a rise in BNP or NT-
proBNP.  It is notable that Scharhag found that NT-proBNP levels measured the 
day after intense cycling have returned to baseline, pre-exercise levels, a fact that 
could explain the negative findings of Feddersen and colleagues at HA who only 
measured BNP at rest the day after arrival at a new altitude.  Similarly, the 
acclimatisation at 3650 m followed by vehicular ascent to 5200 m with samples 
taken at rest the next day could explain the negative findings of Toshner and 
colleagues.  Studies by the DMS hypoxia study group have investigated the BNP 
response with exercise in the field setting.  In 2009 we undertook a field study at 
altitude in Nepal during the course of a trek to Everest Base Camp, using an 
ascent profile of a typical recreational trek.  BNP was measured using point of care 
monitors (Alere Triage Biosite Pro, Cheshire, UK) which reduced any reliance on 
electrical power or requirement to freeze samples.  Following this we reported that 
BNP (mean+/-SEM) rises between sea-level (7.1+/-1 pg/ml) and 5150 metres 
(17.7+/-5.1 pg/ml, range 6.70-119 pg/ml, p=0.001) in a cohort of 23 subjects 
(Woods, Hooper et al. 2011).  We also found that mean Lake Louise scores 
(mean+/-SEM) for those with a BNP response (defined as a rise in BNP above 
5pg/ml) versus no BNP response at 5150 m were significantly different: 3.3+/-0.5 
vs. 0.75+/-0.5 (p=0.034) on day 10 and 3.3+/-0.4 vs. 0+/-0 (p=0.003) on day 11.  
The major difference in our study was that the research took place during a trek, 
with BNP samples taken on completion of that exercise stimulus, rather than a 
study where mechanized transport had been used to gain altitude. 
  
In 2011 we ran a second field study with 20 subjects repeating the same trek to 
Everest base camp.  This time blood samples were taken, centrifuged and frozen 
in addition to using a point of care monitor.  BNP and NT-proBNP (pg/ml, mean+/-
SEM) rose significantly from Katmandu (approximately 1300m) (9.2+/-2 and 
36.9+/-6.6 respectively) to arrival at 4270 m after exercise (16.6+/-4 and 152+/-
56.1, p=0.008 and p<0.001 respectively) and remained elevated the next morning 
at rest (28.9+/-9 and 207.4+/-65.1, p=0.004 and p<0.001 respectively). At 5150, 
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immediately following ascent to and descent from 5643 m BNP and NT-proBNP 
were 32.3+/-8.8 and 301.1+/-96.3 (p=0.003 and p<0.001 versus Kathmandu values 
respectively) and at rest the following morning were 33.3+/-9.7 and 258.9+/-89.5 
(p=0.008 and p=0.001 versus Kathmandu values respectively).  NT-proBNP and 
BNP correlated strongly at 5150 m (rho 0.905, p<0.001 and rho 0.914, p<0.001 for 
resting and post-exercise samples respectively (Woods, Begley et al. 2012).  At 
5150 m BNP levels were significantly higher among the four subjects with severe 
(LL score>6) AMS (58.4+/-18.7) compared to those without (BNP 22.7+/-8.6, 
p=0.048).  There were significant correlations between change in body water from 
baseline to 5150 m with both BNP and NT-proBNP (rho 0.77, p=0.001, rho 0.745, 
p=0.002 respectively).  This data suggests that exercise is important in provoking a 
BNP response and that the BNP response may in part be associated with fluid 
retention.  As BNP is a natriuretic peptide and would ordinarily stimulate a diuresis 
rather than causing fluid retention it seems likely that an additional mechanism, 
such as myocardial stretch, may have a role. 
 
1.5   Arginine Vasopressin Physiology 
1.5.1   At Sea Level 
Arginine vasopressin (AVP) is a hormone concerned with volume and osmolality 
maintenance.  It is also called antidiuretic hormone as it was originally thought that 
its actions were the result of two separate substances one vasopressor and one 
antidiuretic. 
 
AVP is synthesised in cells which have their cell bodies in the hypothalamus and 
axons projecting into the posterior pituitary, the magnocellular neurons.  The cell 
bodies in the hypothalamus are divided into supraoptic nuclei and paraventricular 
nuclei.  80-90% of the supraoptic nuclei secrete AVP.  The paraventricular nuclei 
have a more complex neuroendocrine function and a subgroup of these 
(parvocellular neurons) release AVP to the posterior pituitary via the pituitary portal 
system which acts on the adenohypophysis leading to an increase in 
adrenocorticotrophic hormone (ACTH) and subsequently cortisol.  This is an 
important part of the “stress response”.  Vasopressin is a nonapeptide with a 6 
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amino acid ring and a 3 amino acid tail.  It is synthesised as a precursor molecule 
consisting of the nonapeptide, hormone specific neurophysin and an additional 
glycopeptide (copeptin).  
 
There are two main stimuli to AVP secretion; changes in plasma osmolality and 
changes in blood pressure or plasma volume.  These stimuli act on the 
magnocellular body to generate an action potential which travels down the long 
axon to the posterior pituitary.  An increase in Ca2+ causes secretory granules to 
then fuse with the cell membrane and be extruded.  At physiological pH there is no 
binding of the AVP to its’ neurophysin so all AVP is free in the circulation.  
Synthesis and transport of AVP to the posterior pituitary are linked which increases 
transport in response to increased synthesis.  There is, however, asynchronicity in 
these events such that it takes a couple of days for a peak level of mRNA 
transcription which means that stores of AVP become depleted and may take a 
while to be replaced after a prolonged stimulus.  The main action of interest to fluid 
balance at HA is the action to facilitate the reabsorption of water by increasing the 
permeability of the distal collecting tubule mediated via V2 receptors.  When AVP 
binds to V2 receptors in the collecting duct cyclic AMP is activated which brings 
about the opening of water channels “aquaporins” which allow water to pass into 
the hypertonic renal medulla.  Dissociation of AVP then decreases cyclic AMP 
levels which causes internalisation of the aquaporins.  There is both an acute 
(minute by minute) response and a chronic increase in the number of channels in 
response to prolonged stimulation. 
 
Receptor Action 
V1 vasoconstriction 
V2 increase in permeability of collecting ducts and an 
increase in Von Willebrand Factor and Factor VIII 
V3 (or V1b) increase in ACTH secretion 
 
Table 1.2 Actions of AVP 
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AVP also has a role (along with angiotensin II) in regulating thirst.  Thirst is 
stimulated by changes in osmolality and plasma volume. 
 
There is a rapid, linear change in AVP in response to changes in osmolality 
whereas a 10% change in blood volume or blood pressure is required to make a 
difference.  Changes in volume amplify the response of AVP to a given change in 
osmolality.  Once blood volume has been lost and BP cannot be maintained there 
is a sudden and exponential increase in AVP. 
 
The primary function of AVP is in water homeostasis and maintaining osmolality.  
Sensors in the “osmostat”, an area of the organum vasculosum of the lamina 
terminalis (OVLT) and in the wall of the 3rd ventricle are sensitive to changes in 
osmolality.  These areas are outside the blood brain barrier.  Clinically, damage to 
OVLT e.g. in head injury leads to an inability to maintain osmolality.  Normal 
plasma osmolality is 280 – 295 mOsm/Kg H2O and is predominantly due to Na+.  
Basal levels of AVP are maintained at 0.5-2.0 pg/ml.  AVP release is very sensitive 
to changes in plasma osmolality with a 1% change in plasma osmolality leading to 
a change in AVP release, water reabsorption and increasing urine osmolality.  If 
there is no AVP urine volume is 18-20 l per day, with 0.5-1 pg/ml urine volume is 
reduced to 4 l per day. 
 
Of relevance to high altitude medicine are the facts that glucocorticoids inhibit AVP  
and dexamethasone is an important treatment for AMS and HACE (there is a rise 
in cortisol at extreme altitude) (Woods, Davison et al. 2012) and secondly, that 
nausea and vomiting are a potent stimulus for AVP secretion.  The latter are a 
feature of AMS and may amplify fluid retention and create a vicious spiral of 
worsening symptoms. 
 
1.5.2   Copeptin 
Copeptin is a 39 amino acid long glycopeptide first described by Holwerda in 1972 
(Holwerda 1972).  AVP is secreted as a 164 amino acid prohormone consisting of 
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a signal peptide, AVP, neurophysin II and copeptin.  Copeptin forms the C terminal 
part of pro AVP and can be referred to as CT-proAVP. 
 
As it is a prohormone it is much more stable in plasma than AVP and also stable at 
room temperature and far easier to assay than AVP.  Whereas AVP needs to be 
measured by radio-immunoassay over at least 3 days, copeptin has an automated 
assay taking 3 hours.  More importantly for field studies Morgenthaler showed only 
a 20% loss in recoverable copeptin after 7 days storage at room temperature 
(Morgenthaler, Struck et al. 2006). 
 
Copeptin levels in healthy volunteers are 1-12 pmol/l (median <5pmol/l) with men 
having consistently slightly higher values than women (by 1 pmol/l).  There is no 
correlation with age.  In the setting of exercise AVP has been shown to correlate 
with copeptin during endurance running events and in exercise tests on patients 
with cardiovascular disease (Maeder, Staub et al. 2010, Hew-Butler, Hoffman et al. 
2011).  Copeptin has not been measured at high altitude nor compared with AVP 
release at HA. 
 
In shock states the non-osmotic release of AVP is mirrored by increases in 
copeptin.  In a baboon model of haemorrhage copeptin increases from 7.5 pmol/l 
to peak at 269 pmol/l and closely follows AVP (Morgenthaler, Muller et al. 2007). 
Clinically copeptin rises quickly after a myocardial infarction and is higher in those 
who die.  Copeptin has also been shown to predict outcome in respiratory tract 
infections, strokes and head injury (Muller, Morgenthaler et al. 2007, Kleindienst, 
Brabant et al. 2010, Morgenthaler 2010).  AVP also increases after acute MI and it 
is unclear whether this is due to the stress response or as a result of cardiac 
dysfunction or relative under-filling.   
 
1.5.3   At High Altitude 
AVP is the key hormone involved in reducing free water excretion at the kidney and 
is crucial in determining fluid balance at SL.  Normally at SL a rise in osmolality or 
a marked decrease in plasma volume would lead to a rise in AVP secretion from 
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the posterior pituitary and a reduction in free water loss at the kidney thereby 
maintaining osmolality.  It seems intuitive that changes in this system will be 
important at high altitude where an initial diuresis is crucial in acclimatization.  
Plasma osmolality rises at HA, secondary to the diuresis (Blume, Boyer et al. 1984, 
Bestle, Olsen et al. 2002, Maresh, Kraemer et al. 2004).  However in spite of this 
most of the literature reports no accompanying rise in AVP in the normal process of 
acclimatisation.  In the presence of a documented rise in osmolality from 291 
mOsmol/kgH20 at SL to 299 mOsmol/kgH20 at 4300m (after two days) and 302 
(after 20 days) plasma AVP did not change (Maresh, Kraemer et al. 2004).  
Another report demonstrated a rise in osmolality from 290 mOsmol/kgH20 to 295 
mOsmol/kgH20 at 5400m and 302 at 6300m (with an average 26.5 days above 
5400m) with no accompanying rise in AVP (Blume, Boyer et al. 1984).  Such 
evidence suggests a reset osmotic threshold for AVP release that again facilitates 
the diuretic process at HA that allows a reduction in plasma volume and hence 
increase in oxygen carrying capacity of a given volume of blood.  Other studies 
support the notion that at HA a given vasopressin concentration requires a higher 
osmolality compared with SL.  Bestle and colleagues found that over eight days at 
4559m AVP was suppressed compared to SL despite an increase in plasma 
osmolality from 291 mOsmol/kgH20 to 296 mOsmol/kgH20.  This was associated 
with a reduced urine volume in the first two days.  These subjects were transported 
to this altitude and all had AMS on arrival.  Some studies have even found a 
reduction in AVP on acute exposure to moderate altitude (2000m) (Porchet, Contat 
et al. 1984).  Interestingly, high-altitude natives (2,600 m) have a greater resting 
AVP than sea-level natives (Ramirez, Pineda et al. 1998), again suggesting a 
dynamic hormonal response dependent on length of HA exposure.  One study has 
gone further and examined the AVP response to water deprivation (which would 
normally stimulate a rise in AVP) at HA.  The response to water deprivation 
appears to remain intact at HA.  A 24 hour water deprivation test (WDT) with acute 
altitude exposure (day 2 at 4300m) and prolonged altitude exposure (day 20 at 
4300m) still caused a rise in AVP in response to a rise in osmolality (Maresh, 
Noble et al. 1985).  Interestingly though the rise in AVP with acute altitude 
exposure peaked at 16 hours and then fell to baseline during WDT but persistently 
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rose throughout WDT after prolonged altitude exposure.  Further the increase in 
AVP to higher osmolalities (>300 mOsmol/kgH20) was greater after more 
prolonged exposure, demonstrating a change in the relationship between AVP and 
osmolality dependent on acclimatisation.  This may reflect the greater osmolality 
achieved in the latter WDT but could also reflect a dynamic change in AVP 
response to plasma osmolality according to acclimatisation.  In other words, 
despite the WDT inducing an acute rise in AVP, the AVP response is “capped” with 
acute altitude exposure to restrict water retention.  However, with further 
acclimatisation this effect is lost, presumably because the desperate need to 
reduce plasma volume to maintain oxygen delivery per given volume of blood has 
been overridden by other factors, such as a primary increase in red cell mass.  
Although it is suggested that plasma volume re-expands with chronic exposure to 
HA the osmolality in this study was 291 mOsmol/kgH20, 299 mOsmol/kgH20 and 
302 mOsmol/kgH20 at SL, day 2 and day 20 respectively. Rather than a re-
expansion of plasma volume with prolonged exposure there may simply be a 
levelling off once initial acclimatisation has occurred.  
 
AVP has been implicated in AMS (Hackett, Forsling et al. 1978, Blume, Boyer et al. 
1984, Bartsch, Maggiorini et al. 1991, Loeppky, Icenogle et al. 2005).  With acute 
(8-12 hour) exposure to a simulated 4880m altitude, subjects with high AMS scores 
(n=16) versus those with low AMS scores (n=16) demonstrated a rise in AVP at 
rest within 90 minutes of exposure.  This was followed by a reduced urine output 
within 3 hours and subsequent fluid retention.  In those subjects with AMS a 
positive fluid balance of 1.2 l was recorded versus a negative balance of 0.7 l in 
those without AMS.  The low AMS score subjects with the negative fluid balance 
appear likely to be due to the fall in AVP that was recorded in those subjects 
(Loeppky, Icenogle et al. 2005).  These findings are very supportive of the central 
role an early diuresis has in acclimatisation, albeit in a very acute setting, and the 
influence the AVP response has is critical to this.  Earlier evidence is supportive of 
this concept: a more pronounced AVP response in subjects with AMS symptoms 
after 3–4 hours of simulated HA has previously been recorded (Claybaugh, Wade 
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et al. 1982); and a tendency for higher AVP in HAPE sufferers versus controls has 
also been suggested (Cosby, Sophocles et al. 1988). 
 
1.6   Physiological Effects of Exercise 
In order to assess changes related to HA it is important to be able to review the 
results in terms of normal “sea level” responses to exercise.  In this way 
investigations can separate the HA specific changes to those related to exercise, 
exercise being an intrinsic part of many (if not all) recreational trips to HA.  
Exercise produces changes in cardiorespiratory parameters that are beyond the 
scope of this introduction.  The changes in specific hormones and factors that may 
be of interest in altitude illness will be considered at sea level and at HA. 
 
1.6.1   Effects of Exercise at Sea Level 
During exercise blood flow to the muscle is increased.  This is largely achieved by 
local factors and vasodilation but is augmented by neurohumoral mechanisms that 
drive an increase in cardiac output and alterations in blood flow (e.g. favouring 
muscle over gut). 
 
Key mechanisms that will be considered as relevant to altitude illness are: 
 Cortisol/ACTH “stress response” 
 Catecholamine response 
 AVP response 
 
Cortisol response 
The effects of cortisol are to increase gluconeogensis, free fatty acid mobilisation 
and glycogen storage.  The hormone also maintains circulatory function and is a 
key hormone involved in the adaptation to stress.  Cortisol can, therefore, be 
expected to rise with exercise.  One of the key features of the stress response is to 
retain salt and water, the converse adaptation required for successful 
acclimatisation to altitude. 
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The increase in cortisol with exercise depends upon both intensity and duration of 
exercise stimulus.  Bonen found that 10 to 30 minutes of gentle exercise at 3mph 
produced no change in cortisol (measured as urinary cortisol excretion) whereas 
the same duration of exercise at 7.5mph produced a significant elevation in cortisol 
excretion with 30 minutes (Bonen 1976).  Van Bruggen and colleagues found that 
cortisol responses increased significantly for both serum (40.4%; P = .001) and 
saliva (170.6%; P = .007) only in response to high-intensity exercise (VanBruggen, 
Hackney et al. 2011).  In a progressive exercise test to exhaustion cortisol 
significantly (p < 0.05) increased from 284 +/- 38 nmol/L at rest to 311 +/- 39 
nmol/L at exhaustion but was not significantly elevated at a workload equivalent to 
60% of VO2 max (Buono and Yeager 1991).  Salivary cortisol does not rise with 
low and moderate (at a workload equivalent to 44.5 and 62% VO2 max) effort, but 
does rise significantly with more strenuous (equivalent to 76% VO2 max) exercise 
(Jacks, Sowash et al. 2002). 
 
Cortisol exhibits diurnal variation and this has an influence on changes in relation 
to exercise.  Exercise related changes are blunted (i.e. not additive) to other diurnal 
variation.  Exercise after a midday meal, when cortisol levels rise produces a much 
reduced increase in cortisol when compared to morning exercise (Brandenberger 
and Follenius 1975).  The importance of taking into account diurnal variation is 
important. Hill and colleagues found a modest increase (5.7%) in cortisol at 40% 
VO2 max effort but when account was taken of diurnal variation they concluded 
that cortisol levels actually fell in response to exercise at that intensity (Hill, Zack et 
al. 2008).  
 
Catecholamine response to exercise 
Catecholamines increase heart rate, myocardial contractility, respiratory rate, 
mobilise energy sources and have a myriad of other effects beneficial when 
exercising.  It is therefore not surprising that catecholamine levels increase with 
exercise. 
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Even with very brief (but severe) exercise, catecholamine levels are raised.  
Brooks found that a 30 second stimulus at a high power output of 424.8 +/- 41.9 W 
(mean +/- SD) the plasma catecholamine concentrations increased from 2.2 +/- 0.6 
to 13.4 +/- 6.4 nmol.l-1 (p<0.001) and 0.2 +/- 0.2 to 1.4 +/- 0.6 nmol.l-1 (p<0.001) 
for norepinephrine and epinephrine respectively (Brooks, Burrin et al. 1988).  
Catecholamines start to increase at very low intensity exercise (with 
norepinephrine increasing before epinephrine) and this increase continues in line 
with exercise intensity to exhaustion.  Concentrations of norepinephrine can reach 
40x resting vbalues after a 400m race (Zouhal, Jacob et al. 2008). 
 
The timing of catecholamine measurement is also important as levels continue to 
increase after exercise with values increasing tenfold during the recovery period 
(Dimsdale, Hartley et al. 1984).  In a review of the literature Zouhal concluded that 
there is an enhanced catecholamine response in well trained individuals, a 
phenomena referred to as the “sports adrenal medulla”.  The same review also 
concluded that a variety of factors have a significant effect on catecholamine levels 
including posture, which muscle groups were involved in the exercise test,  
emotional state and familiarity with the test environment.  Gender has no 
significant effect on catecholamine levels in untrained subjects, at rest or with 
exercise (Zouhal, Jacob et al. 2008). 
  
AVP and sea level exercise 
AVP is the main hormone involved in maintainance of osmolality during exercise.   
Factors such as fluid restriction or avaliability of fluid during exercise will have a 
bearing on osmolality changes but it also appears that there are non-osmotic 
stimuli that affect AVP levels.  Hew-Butler in two studies showed a 3-4 fold rise in 
AVP during ultramarathon running despite no change in plasma sodium (Hew-
Butler, Jordaan et al. 2008, Hew-Butler, Hoffman et al. 2011).  A similar magnitude 
of change and evidence of non-osmotic stimuls to secretion has been found by 
other authors, Melin reported a 4.8 fold increase in AVP with exercise at a level 
equivalnet to 80% VO2 max (Melin, Eclache et al. 1980) whilst Inder et al found a 
higher rise in AVP during exercise to exhaustion despite no change in osmolality 
26 
 
as exhaustion was reached (Inder, Hellemans et al. 1998). 
 
1.6.2   Effects of Exercise at High Altitude 
Few studies have examined the endocrine response to exercise in hypoxia.   
Bouissou found that hypoxia provoked a two fold increase in adrenocorticotrophic 
hormone (ACTH) levels during exercise (breathing a gas mixture equivalent to 
3000m altitude) (Bouissou, Fiet et al. 1988).  Interestingly there was a lack of 
response, in terms of cortisol, which did not change.  This suggests a blunting of 
the cortisol response to ACTH at altitude.  In previous work, in a large number of 
trekkers at up to 5000m, we have shown a reduction in cortisol at 4270m before an 
increase at higher altitudes (5000m).  This is interesting in that a reduced cortisol 
response to ACTH would be beneficial and prevent a steroid induced retention of 
salt and water.  In this study there was also a weak inverse correlation between 
SpO2 and cortisol (rho=-0.451, p=0.004) at 5000m.  Although a lower SpO2 may be 
a stressor that increases cortisol, the correlation, albeit statistically significant, was 
not a particularly strong one and more subjects would be needed to confirm this 
finding (Woods, Davison et al. 2012). 
 
Catecholamines increase with exercise in hypoxia in both human (Clancy, Critchley 
et al. 1975, Strobel, Neureither et al. 1996) and animal experiments (Warner and 
Mitchell 1991).  Norepinephrine levels may contribute to the enhanced respiratory 
drive that is seen in hypoxia and this is supported by the fact that yohimbine (a pre 
synaptic alpha 2 blocker which enhances norepinephrine secretion) increases 
ventilatory response in humans (Clark, Galloway et al. 1997).  Acid base changes 
can affect catecholamine secretion with acidosis potentiating catecholamine 
release.  At altitude the usual acid base position is that of a compensated 
respiratory alkalosis so no net effect can be anticipated (Goldsmith, Iber et al. 
1990). 
 
Interestingly pre-existing anxiety traits may have an impact on catecholamine 
levels at higher exercise intensities (Peronnet, Blier et al. 1986).  This may be 
particularly relevant at HA, where anxiety is a common feature. 
27 
 
The AVP response to exercise may also be important.  AVP increases with 
exercise at altitude (Appenzeller and Wood 1992, Olsen, Kanstrup et al. 1992) and 
may contribute to water retention.  This effect may have pathological 
consequences: 30 minutes of exercise on arrival at HA (4559 m) induces a greater 
rise in AVP in those with AMS than those without (Appenzeller and Wood 1992, 
Olsen, Kanstrup et al. 1992).  This could lead to a “viscious cycle” of illness 
increasing stress and secretion of antidiuretic hormones, increasing salt and water 
retention and thus potentiating AMS. 
 
One interesting findng of relevance is that AVP levels are suppressed by 
dexamthasone, which is a highly effective treatment for AMS and HACE (Coiro, 
Volpi et al. 2011). 
In summary ANP and possibly BNP rise in hypoxia.  BNP also rises as a result of 
inflammatory processes.  Previous studies of BNP at high altitude have not 
produced a clear conclusion and exercise seems to be an important element in the 
BNP response.  NP changes may also be related to fluid retention with consequent 
atrial and ventricular distension.  AVP is a key hormone in the regulation of fluid 
balance and this appears to be suppressed (leading to a diuresis) at HA.  
Measuring AVP is difficult whereas the C terminal part of the proAV hormone 
(copeptin) can be measured by a simple assay and corrleates well with AVP in a 
variety of settings.  This has not been investigated at HA.  The effects of exercise 
complicate the endocrine response to hypoxia by creating an additive physiological 
stress.  AVP and cortisol both have dual roles in fluid balance and stress response, 
whilst catecholamine and BNP release are linked.   
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Chapter 2.   Diagnosis of High Altitude Illness; Why a Biomarker 
is Important 
 
2.1  Introduction  
2.2  Biomarkers for AMS 
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2.1  Introduction 
 
Incidence of AMS, HACE and HAPE. 
 
As can be seen in figure 2.1 the incidence of AMS varies substantially in different 
mountainous areas of the world.  This is related largely due to the altitude gained, 
ease of access and rapid transport to high altitude.  In Alaska where the ascent of 
Denali (6194m) requires a long slow ascent over a glacier from around 2500m the 
incidence is relatively low despite the high altitude eventually gained.  By contrast 
in Hawaii where rapid road transport can be used to access an observatory at 
4205m the incidence is 80% (Barry and Pollard 2003). 
 
On Kilimanjaro in Tanzania, Karinen studied 130 trekkers attempting to climb to the 
5895m summit.  Overall the incidence of AMS was 75% and the incidence of 
HACE was 18% (Karinen, Peltonen et al. 2008).  As 52,000 attempt to climb 
Killimanjaro annually the numbers at risk of potentially fatal HACE are very 
significant.  However, despite this very high risk of HACE the number of deaths on 
the mountain is reportedly around 10 climbers per year (various internet sources) 
suggesting Karinen over diagnosed the problem or that local factors such as 
heightened awareness or ease of descent mitigates the risk. 
 
In a previous study, conducted in Nepal by the DMS, out of 20 subjects, five had 
AMS at 3400m, and at 4300 m seven subjects had AMS, one of which was severe. 
At 5150m seven subjects had AMS, with four subjects developing severe AMS and 
two further subjects with mild AMS after a brief trek to Kalapathar (5600m)(Woods, 
Begley et al. 2012). 
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Figure 2.1  Incidence of AMS globally (Barry and Pollard 2003) 
 
AMS is not only a problem at extreme altitude with 25% of conference attendees at 
a medical conference in the Rocky Mountains at elevations of around 2000m 
(Montgomery, Mills et al. 1989) reporting symptoms attributable to AMS, half of 
these took medication.  With more than 120 million people visiting the European 
Alps each year at similar altitudes (source - 
http://wiki.answers.com/Q/How_many_people_go_to_the_alps_each_year?#slide=
2 accessed Jan 2014) this is a significant public health problem. 
Potential cost implications 
The British Mountaineering Council has recently investigated helicopter rescue in 
Nepal and found (in terms of diagnosis of significant illness) : 
“The picture becomes even more confused when the evacuated trekker reaches 
Kathmandu. A well-regarded doctor working at Kathmandu clinic that sees many 
evacuated trekkers splits patients arriving by helicopter into three categories: 20 
per cent definitely required evacuation (usually because of HAPE or HACE); 60 per 
cent fell into a range of uncertainty (diagnosing altitude conditions is very difficult 
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once the patient is back in oxygen-rich air); and 20 per cent didn’t require 
evacuation at all. 
The numbers are striking. The doctor, who requested anonymity, reports seeing up 
to 15 patients evacuated by helicopter every day in the peak season. That means 
at least three have been flown unnecessarily at a cost of around $5,000 each. And 
that’s just one clinic.” (https://www.thebmc.co.uk/helicopter-rescue-nepal accessed 
Jan 2014). 
A test that excluded high altitude related illness would be as useful as a test to 
diagnose the condition in reducing this cost burden as well as reducing the risk to 
rescuers. 
Military Importance 
Since the end of the cold war there has been a shift in conflict from large organised 
Armies to smaller “asymmetric” threats from ideologically motivated groups rather 
than nation States.  It stands to reason that these groups will seek shelter in 
inhospitable regions, away from easy surveillance and communication and 
mountains provide just such a haven.  During the initial war in Afghanistan US 
forces fought at HA to displace the Taliban.  An important battle during this phase 
was Op Anaconda, fought in the Shahi-Kot valley, where 2700 US and Afghan 
soldiers faced 1000 Taliban fighters at altitudes of 2500 – 3500m.  During this 
phase of the conflict 8% of casualties evacuated by the US were as a result of 
altitude illness (Peoples, Gerlinger et al. 2005). 
The problem of identifying when troops are ready to deploy at HA is exacerbated 
by the fact that the only diagnostic criteria for AMS is the self-reported Lake Louise 
Score (Hackett and Oelz 1992).  A self-reported score may not be useful with a 
cadre of highly motivated and committed soldiers and the score also shares many 
features with anxiety questionnaires.  A biochemical test or predictor for altitude 
illness, or acclimatisation would be useful.  The  NATO Review of high altitude 
medicine in the Military (NATO RTM 146, Review of Military Mountain Medicine 
Technology and Research Barriers, Sep 2011, accessed on line 20 Dec 2014 
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http://natorto.cbw.pl/uploads/2011/9/$$TR-HFM-146-ALL.pdf) identifies the need 
for a capability for the “early detection and diagnosis of altitude illness prior to 
onset of severe symptoms that is independent of the victim reporting their 
symptoms” and this “ will reduce altitude illness impact on mission and medical 
support and evacuation requirements”. 
Diagnosis of Acute Mountain Sickness 
In order to conduct research into AMS the problem must be able to be defined in 
terms of specific symptoms, signs and clinical tests.   
 
Figure 2.2 Defining the problem (with thanks to Prof Hugh Montgomery) 
 
With AMS the major difficulty is the lack of a defining “gold standard” for diagnosis, 
with largely subjective symptoms, no hard signs and variable data from easily 
performed tests (eg SpO2).     
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Lake Louise Score 
The most frequently used standard for the diagnosis of AMS at the present time is 
the Lake Louise Acute Mountain Sickness Scoring System (Roach, Bartsch et al. 
1993). This is widely used for both clinical diagnosis and research.  The score was 
devised by expert opinion of a committee during the Eighth International Hypoxia 
Symposium in Lake Louise in 1993 (LLS) (Roach, Bartsch et al. 1993), and it was 
based in part on a previous discussion of criteria for AMS during the Seventh 
International  Hypoxia Symposium in 1991 (Hackett and Oelz 1992). 
 
The consensus statement states the following;  
A diagnosis of AMS is based on a recent gain in altitude, at least several hours at 
the new altitude, and the presence of headache and at least one of the following 
symptoms: gastrointestinal upset (anorexia, nausea, or vomiting), fatigue or 
weakness, dizziness or light-headedness and difficulty sleeping (table 1.1).  A 
score of three points or greater on the AMS self-report questionnaire alone, or in 
combination with the Clinical Assessment score, constitutes AMS.  The Clinical 
Assessment score is made by an examiner who examines for changes in mental 
status, ataxia, and peripheral edema.  Finally, there is a Functional Score, which 
can be self-reported or elicited by the examiner.  The question asked is this: 
“Overall, if you had any symptoms, how did they affect your activity?” This is 
graded 0 through 3. 
 
Most research papers only report the self-reported score values. 
 
One weakness of using the LLS is that it is self-reported and therefore likely to be 
altered by a subjects’ expectation or aspiration.  Bartsch has noted that only 61% 
of the mountaineers reporting a LLS>5 actually said they felt ill (Bartsch, Bailey et 
al. 2004).    
 
The mechanism behind high altitude headache and sleep disturbance may be 
distinct and the scoring system may be flawed in considering these two variables 
together.  Macinnis has recently reported LLS in a large group of Nepalese pilgrims 
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(n=491).  He found the sleep quality item of the LLS was weakly related to the 
other items of the LLS and that removing the sleep component of the score 
improved the internal  consistency of the test (Macinnis, Lanting et al. 2013).  
Recent work using clustering methodology to identify symptom patterns in AMS 
has found that there is poor association between sleep pattern and other 
symptoms (Hall, Maccormick et al. 2014). 
 
Headache is a predominant feature of AMS (Roach, Kayser et al. 2011) and using 
the LLS a diagnosis of AMS cannot be diagnosed without it.  Other scores do not 
require the presence of a headache and altitude related illness can occur in the 
absence of a headache (West 2011).  Perhaps the best justification for including 
headache is that it reduces the background noise from self-reporting, for example 
without headache a trekker who was sleeping badly and anorexic as a result of a 
gastrointestinal upset could very easily be diagnosed as having severe AMS.  
 
Another scoring system, which was introduced earlier, is the Environmental 
Symptoms Questionnaire (ESQ) (Sampson, Cymerman et al. 1983).  This has 67 
items and is therefore more cumbersome to complete.  For this reason a shortened 
form has been developed which uses 11 items of the ESQIII questionnaire for the 
calculation of the acute mountain sickness – cerebral (AMS-C) score.  Each item is 
graded 0-5 (not present to extremely severe).  Each item then has a factorial 
weight given in parentheses: 
light-headed (0.489) 
headache (0.465) 
dizziness (0.446) 
feeling faint (0.346) 
dim vision(0.501) 
off-coordination (0.519)  
feeling weak (0.387) 
sick to stomach (0.347) 
loss of appetite (0.413) 
feeling sick (0.692) 
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feeling hung over (0.584) 
 
To obtain the AMS-C score, the sum of all item scores multiplied by the respective 
factorial weight is multiplied by 5 and divided by 25.95.  An AMS-C score of 0.7 
and above is used to identify subjects suffering from AMS. 
 
Dellasanta found that diagnosis of AMS by the AMS-C score was similar to that 
diagnosed as severe AMS by the LLS (Dellasanta, Gaillard et al. 2007).   However 
there was some difference in a significant number of cases, 14% of cases 
diagnosed by LLS were not diagnosed by AMS-C and 6% diagnosed by AMS-C 
were not considered AMS by the LLS.  One probable confounder in this study is 
that he used the entire ESQIII with 67 questions and some trekkers were non-
English speakers. 
 
Maggiorini found that at 4559 m the prevalence of AMS was 40% and 39%, when 
measured by the AMS-C and LLS respectively. (Maggiorini, Muller et al. 1998) 
 
2.2   Biomarkers for AMS 
An ideal biomarker would have certain characteristics; 
 Detection of the key features of the disease 
 Differentiation between diseases presenting in a similar way 
 The ability to stratify severity of the disease 
 Reliable, reproducible, simple and inexpensive methodology 
 The biological samples used should be easily accessible 
There is some evidence that AMS is an inflammatory process (Richalet, Hornych et 
al. 1991, Kleger, Bartsch et al. 1996, Grissom, Zimmerman et al. 1997, Klausen, 
Olsen et al. 1997, Hartmann, Tschop et al. 2000, Roggla, Moser et al. 2000, Harris, 
Wenzel et al. 2003, Bailey, Kleger et al. 2004, Tissot van Patot, Leadbetter et al. 
2005, Behn, Araneda et al. 2007, Gertsch, Lipman et al. 2010, Julian, Subudhi et 
al. 2011, Eide and Asplund 2012, Gertsch, Corbett et al. 2012, Lipman, Kanaan et 
al. 2012, Nussbaumer-Ochsner, Schuepfer et al. 2012, Zafren 2012, Gertsch, 
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Holck et al. 2013, Lipman and Kanaan 2013) and as such inflammatory markers 
may be useful as biomarkers. 
CRP, Troponin, NGAL, NT Pro-BNP, BNP (and potentially, in the near future, 
copeptin) can all be measured by point of care testing and so are attractive 
possible biomarkers for altitude illness.  This will be developed in the subsequent 
chapters. 
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Summary 
This study was undertaken in a remote and high altitude environment in the 
Cordillera Real region of Bolivia and provided the bulk of the data for this thesis.  
The study involved 50 subjects over a period of 5 weeks and the collection of over 
2000 blood samples and 300 cardiac echocardiogram studies. 
This chapter develops the rationale for performing studies in such an environment, 
the difficulties and the factors (such as subject selection) pertinent to the data used 
in subsequent chapters. 
 
3.1 Introduction 
The specific details of assays used and data collection will be covered in detail in 
the relevant chapter.  The purpose of this chapter is to act as an overview, 
highlighting the difficulties of research of this nature and the scope of the 
investigations undertaken.  
 
History of the association of science and mountaineering.   
Anecdotal accounts of medical problems at high altitude go back to the ancient 
Chinese around 2000 years ago and mountain exploration and scientific enquiry 
have always gone hand in hand.  First ascensionists of Mont Blanc, the physician 
Michel Gabriel Paccard (1757–1827) and local crystal hunter Jacques Balmat, 
(1762–1834) were motivated by the ambition to make scientific observations on the 
summit, including barometric pressure, when they climbed the mountain in 1786.  
The first scientific work on altitude related physiology was published by Paul Bert in 
Paris in 1878, “La Pression Barometrique” (Bert 1878).  Bert’s work was primarily 
done in hypobaric chambers and he demonstrated that hypoxia was the prime 
danger of hypobaric conditions.  High altitude observatories and laboratories were 
built on the two highest mountains in the Alps (Mont Blanc and Mont Rosa) during 
the late 1800’s (Richalet 2001).  Significant events occurred at these laboratories 
including work on the ventilatory response to hypoxia and what is probably the first 
recorded case of HAPE.  Expeditions with a significant medical aim (rather than 
science as a secondary aim of the expedition) began with a Pike’s Peak Expedition 
in 1911.  This expedition was led by J.S. Haldane (the famous Scottish 
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physiologist) and was the first to measure the fall in alveolar carbon dioxide during 
two weeks at altitude (West JB 2007).  The landmark field study was the “silver 
hut” study in 1960-1.  A laboratory was built at 5800m in the Everest area and 
inhabited for 6 months and data collected up to 7440m on Makalu (Milledge 2010).  
This project led on to the American Medical Research Everest Expedition in 1981 
(led by Professor John B West), where barometric pressure was measured on the 
summit of Everest for the first time and alveolar gas samples taken (West 2010).  
In the recent past the Caudwell Xtreme Everest expedition took 208 trekkers to 
Everest base camp, 15 climbers onto Everest and 8 to the summit in a 21/2 month 
long expedition (Grocott, Martin et al. 2010).   Data was collected on energetics, 
exercise tests and microcirculatory function.  Arterial blood gases were taken at 
8400m showing profound hypoxia and hypocarbia (mean (range) KPa  PaO2 3.28 
(2.55 – 3.93) and PaCO2 1.77 (1.37-2.1) (Grocott, Martin et al. 2009). 
 
Association with military mountaineering  
The Joint Services Expeditions Trust was set up in September 1969 to encourage 
Joint Service adventurous expeditions which have a significant scientific element. 
The Trust give grants to support scientific research of all kinds (not exclusively 
medical) during adventurous training expeditions.  The purpose of the grants are 
“to further the efficiency of Her Majesty’s Armed Forces through the development 
of personal and leadership qualities by supporting adventurous and arduous 
expeditions for the purpose of carrying out research of a scientific nature (including 
social sciences), and disseminating the knowledge gained as a result thereof” (DIN 
2007-06-09 The Joint Services Expedition Trust published July 2007).  Military 
expeditions have had a history of including medical research including performing 
some valuable field studies, notably the first measurement of ANP at altitude and 
early work on the hypoxic ventilatory response (Milledge, Broome et al. 1988, 
Milledge, Thomas et al. 1988, Milledge, Beeley et al. 1989).  Indeed Griffith Pugh’s 
knowledge of exercise in hypoxia and in extreme environments, gained during 
military service in World War 2 and beyond, has been credited as the difference 
that made the ascent of Everest in 1953 possible (Tuckey 2013).  
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Mountains are natural borders between countries and therefore potentially areas of 
conflict.  During the early 1960’s the Chinese and Indian armies faced each other 
across the Himalayas (China invaded in 1964).  The Indians realised that their 
troops were at a great disadvantage when compared to the Chinese who were 
resident at high altitude on the Tibetan plateau.  During the conflict the Indian 
troops suffered greatly with high altitude illness and much work was published 
during that period by the Indians (Singh, Kapila et al. 1965, Singh, Khanna et al. 
1969).  Other potential high altitude flash points exist, India and Pakistan have high 
altitude military posts on the Siachen Glacier in the Karakorum Himalayas and a 
significant proportion of Afghanistan and northern Pakistan is over 3000 m.  Future 
conflicts are likely to be fuelled by a lack of resources (e.g. oil and gas) and 
climatic changes (MoD Strategic Trends Programme.  4th Edition.  Global Trends 
out to 2040. Published 2010).  This is likely to result in conflict in high altitude 
regions as populations migrate and exploit currently untapped resources. 
 
Shock and hypoxia is a part of all critical illness. Even with good pre-hospital 
airway care and ventilation trauma patients frequently present to the Emergency 
Department in the hospital in Camp Bastion with a profound base deficit indicating 
tissue hypoxia (22 major ballistic injuries, median base deficit 7, median SpO2 
99.5%) (Mellor and Woods 2012).  Inducing physiological shock in healthy subjects 
is ethically difficult, however enabling individuals to take part in an expedition 
during which they will inevitably become profoundly hypoxaemic may provide an 
acceptable approach for both investigators and subject.  As an alternative chamber 
studies have been used to replicate the altitude profiles of Everest ascents.  These 
studies are immensely costly and ethically challenging.  To run a hypobaric 
chamber requires a team of two operators and medical cover around the clock, a 
typical Everest ascent takes 8 weeks.  The ethics of subjecting individuals to 8 
weeks of enforced captivity during which they are very likely to become unwell is 
questionable.  Chamber studies can only replicate the hypobaric elements of 
mountaineering and not the relationship of hypoxia to exercise, dehydration or 
dietary changes.  Contrast this with expeditions where those taking part do so of 
their own free will and would often undertake the trek with or without the science 
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element.  There are far fewer ethical conflicts.  Furthermore through combining a 
few days of research (as planned days throughout the expedition) and still being 
able to achieve other aims, in terms of trekking or climbing, individuals taking part 
in expeditions can achieve research aims.  In many ways the military is ideally 
placed to lead scientific expeditions and as stated above has a long history of 
doing so.  The Joint Services Adventurous Training scheme supports adventurous 
training financially (typically split equally with contributions from public funds, non-
public funds and personal contributions) and further grants are available to 
expeditions fulfilling suitable scientific aims through the Joint Services Expeditions 
Trust.   
  
Challenges of high altitude field research.   
Mountainous regions of the world are generally poorly developed in terms of road, 
rail, telephone and power supplies.  This lack of resource produces significant 
challenges to the planning and execution of field research. 
 
Temperature falls in a predictable way with altitude; this is referred to as the lapse 
rate.  Typically in clear skies the rate is 1°C per 100m, with very cold temperatures 
at high altitude.  However due to the thinner atmosphere the radiated solar energy 
is very high leading to a huge difference in temperature between that in direct 
sunlight and shade, with almost inevitable sub-zero temperatures after dark.  The 
consequence of this is that maintaining samples or equipment within a reasonable 
temperature range is difficult.  This large temperature range has implications for 
power supplies.  Cold batteries rapidly loose charge or do not generate sufficient 
power for operating equipment, batteries need to be kept warm (usually in a pocket 
by day or sleeping bag overnight) if they are to have the predicted output.  Even in 
use equipment can cool rapidly and thought given to maintaining temperature for 
example, placing equipment on a hot water bottle or inside a down jacket. 
 
Despite the small size and relative portability of modern medical equipment power 
remains a real issue.  Even in well-travelled areas such as the Khumbu valley on 
the Everest Base Camp trail, there is relatively little reliable electricity.  Most tea 
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houses allow trekkers to recharge from a solar panel or their domestic system 
(usually solar charged battery rather than generator) for a fee.  This supply may not 
be adequate to charge medical equipment.  Solar panel technology has improved 
dramatically over the last few years but the supply may still be of inadequate output 
to power a lap-top computer, additionally solar panels are most effective when left 
stationary but on many expeditions most of the day-light hours are spent trekking.  
Compact generators can be used but are heavy (usually at least 25Kg, a full porter 
load where they have to be carried on foot) and sufficient clean fuel may be difficult 
to obtain. 
 
Disposal of waste (e.g. sharps, contaminated clinical waste) will be difficult in 
remote areas and at least require carrying in and out. 
   
Carrying out research is often not seen by all the expedition members as the most 
important aspect on an expedition.  During the DMS expedition to Vellicitos and 
Aconcagua in 2007, few subjects felt able to perform a step test at 0400 in the 
morning, when it was -5 ºC and oxygen saturations were in the low 80’s, however 
all the team managed to find motivation to climb to the summit of Vellicitos later 
that morning!  Careful planning of the expedition itinerary is required in order to 
ensure that individual expectation is matched to the scientific aims.  Scheduling 
days for investigation allows work to be carried out in sun light, with functioning 
batteries or solar power, rather than trying to perform measurements at the end of 
a long days trekking, in the dark when it’s well below freezing.  Caudwell Extreme 
Everest (CXE) overcame this problem by having 4 fixed “laboratories” carrying out 
investigation along the trek to base camp.  This provides an ideal solution but can 
only be used by large scale expeditions (CXE had 208 trekkers and was the largest 
project of its’ kind ever undertaken)(Grocott, Richardson et al. 2007).  
 
Whilst the leap from high altitude research in healthy subjects to critically ill 
octogenarians on an intensive care unit is not immediately apparent, high altitude 
research can help to investigate areas relevant to critical illness. This informs at 
both the basic science a clinical level.  Richard Feynman eloquently observed that 
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“nature uses only the longest threads to weave her patterns, so that each small 
piece of her fabric reveals the organization of the entire tapestry” (Fennymann 
1967).  High altitude research adds strands to the tapestry, and therefore the whole 
picture is more likely to emerge 
 
3.2   Study Overview 
This field study took place in the Cordillera Real region of Bolivia.  This was chosen 
to give a provocative but ethically acceptable ascent profile in terms of the risk of 
developing AMS, relatively easy access and transport, attractive climbing 
objectives and most importantly, a range of altitude for study that were comparable 
with altitudes used on previous studies. 
 
The expedition was planned to use the trek into the mountains as the exercise 
component.  Whilst this was not a standardised exercise challenge it provided the 
“real world” stimulus that is of interest. 
 
3.2.1   Ethics 
Ethical approval for the field study, including all aspects of data collection, was 
obtained from MoD Research Ethics Committee in April 2012 (68/Gen/09 3rd 
amendment dated 05/04/2012). 
 
3.2.2   Subjects 
Subjects were all Service personnel and the expedition was organised as military 
Adventurous Training allowing subjects to be partially funded and have time for the 
expedition.  Subjects were recruited by advertising within the military using 
Defence Instructions, word of mouth, newsletters within the Defence Medical 
Services etc. 
 
Fifty subjects were recruited, one subject was unable to take part in the study at 
very short notice and one subject was withdrawn at the first study altitude due to 
difficulty taking blood.  
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Previously published data from field studies in Nepal suggested an observed rate 
of severe AMS at similar altitudes of around 20% (4 subjects of 20) (Woods, 
Begley et al. 2012).  It was therefore anticipated that an n=50 would lead to a high 
enough incidence of AMS to be able to identify any differences between a cohort 
with severe AMS and those without.   
 
All subjects were medically fit and in date for their annual military fitness test 
(which comprises a 1.5 mile run).  Demographic data are presented in Table 3.1 
below. 
  
3.2.3   Baseline data collection 
Baseline physiological data (height, weight, total body water (TBW), 1.5 mile run 
time, SpO2, blood pressure, respiratory rate) were collected on all subjects prior to 
leaving the UK. 
 
A sub-group of 20 subjects took part in a trek in Snowdonia (6 hours with 600m 
ascent) during which baseline data was collected including phlebotomy and cardiac 
echocardiograms using the field study protocol.  The demographics for this sub 
group are presented below; 
 
 Sea level  
Control group 
High Altitude  
group  
P value  
Age (SD) 
Range 
35.1 ± 11.1 
21-54 
35.0 ± 9.0 
 22-54 
0.98 
Height (cm) 172.2 ± 8.1 175.6 ± 9.50 0.14 
Weight (Kg) 77.14 ± 15.2 77.8± 14.0 0.87 
1.5mile run time 
(minutes) 
10.19 ± 1.5 9.85 ± 1.2 0.42 
Smoking history     
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- current  
- non smokers 
1 
19 
3 
45 
 
0.52 
Sex  
- males 
- females 
 
13  
7  
 
34  
14  
 
 
0.71 
Data is expressed as mean (standard deviation) P values is expressed for 
comparison of sea level versus high altitude group 
Table 3.1   Subject demographics 
 
3.2.4   Field Study 
La Paz is the highest capital city in the world, the airport is at around 3800m.   This 
was one of the main factors in choosing this region in which to conduct the study.   
Research was conducted following a trek and then again at rest the following day 
in accordance with the schedule below. 
 
Day 1 Arrive La Paz airport 4061m, hotel 3681m  
Day 2 Lake Titicaca1 3833m following 6 hour trek with 600m height gain 
Day 3 Lake Titicaca rest 3833m 
Day 4 Prep La Paz 3681m 
Day 5 Road head2 4450m following 4 hours trek and 200m height gain 
Day 6 Road head 4450m - research (rest) 
Day 7 BC 4710m 
Day 8 BC 4710m 
Day 9 Research camp3 5129m following 4 hour trek with 400m height 
gain 
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Day 10 Rest at research camp 5129m (rest) 
1. Lake Titicaca (Hotel Esmeralda) 
Altitude 3833m 
Location 16 deg 09 mins 56.92 s  69 deg 05 mins 23.88 s 
 
2.  Road Head Camp  
Altitude 4,450m (research hut), 4,430 (camp spot) 
Location: 16° 4'8.03"S  68°27'9.45"W 
  
3.  High Camp 
Altitude 5,129m 
Location: 16° 0'35.17"S  68°23'53.36"W 
 
Summarised graphically the acclimatisation profile is shown in figure 2.1; 
 
 
Figure 3.1 Field study altitude profile 
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3.3   Field Study Protocols 
The investigations carried out are outlined in the table below and will be discussed 
in more detail in the relevant chapters of this thesis. 
 
Basic physiological data and scoring systems for altitude illness (LLS and AMS-C) 
where carried out each morning and evening by the subjects.  The LLS and AMS-C 
are discussed elsewhere in more detail (Chapter 2). 
 
The subjects rating of perceived exertion (RPE) was recorded according to the 
score developed by Borg (Borg 1970).  This was recorded retrospectively at the 
end of each exercise study day (day 2,5,9).  Subjects were asked to record how 
much they felt they had exerted themselves according to the scale below; 
 
Score Effort Perception 
6 20%  
7 30% Very,very light (rest) 
8 40%  
9 50% Very light (walking) 
10 55%  
11 60% Fairly light 
12 65%  
13 70% Somewhat hard – steady pace 
14 75%  
15 80% Hard 
16 85%  
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17 90% Very hard 
18 95%  
19 100% Very very hard 
20 Exhaustion  
 
Table 3.2  15 point Borg RPE scale (Borg 1970) 
 
The scale starts at 6 as the scale is related to heart rate (approximately HR = RPE 
x 10).  This scale has not been validated at high altitude however at sea level  it 
has been found that there is a correlation between RPE and heart rate, lactate 
levels, %VO2 max and breathing rate (Noble, Borg et al. 1983).  Correlation with 
heart rate was reported to be good in over 2000 cardiopulmonary exercise tests 
(rho 0.72) (Scherr, Wolfarth et al. 2013). A Borg score of 15 represents “hard effort” 
and is above the recommended level for exercise in non-trained athletes (Graham, 
Atar et al. 2007).   For this reason data was divided into two cohorts low Borg (<15) 
and high Borg (>15).  
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 Day 0 1 2 3 4 5 6 7 8 9 10 
Altitude Baseline 3681 3833 3833 3681 4450 4450 4710 4710 5129 5129 
Comment   Post 
exercise 
Rest  Post 
exercise 
Rest   Post 
exercise 
Rest 
Venous Blood – 
Serum and plasma 
separated Point of 
care BNP & NGAL 
           
Vital signs (HR, RR, 
BP, SpO2)(post trek 
& following morning) 
           
LLS (post trek and 
following morning) 
           
Total body water 
(after rehydration) 
           
Body weight            
Haematocrit            
24 hour urine volume            
 = test performed 
Table 3.3   Subject testing schedule for Bolivia field study 
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At each post-exercise and rest study altitude (days 2,3,5,6,9,10) approximately 25 
mls of venous blood was taken.  This was allowed to clot where appropriate, 
immediately centrifuged and frozen for unstable hormones (such as AVP and 
catecholamines) and frozen within 3 hours in the case of serum for osmolality, 
[Na+] e.t.c.  BNP and NGAL were measured on a point of care monitor (Biosite 
Triage Pro, Alere, Cheshire).  Overall at each study point 9 cryovials were collected 
as follows: 
 
Lithium heparin blood tube – plasma decanted into 2 cryovials for AVP assay. 
EDTA blood tube – plasma decanted into 4 cryovials for catecholamines (x2), 
copeptin and plasma rennin 
 
Serum Separator tube – 3 cryovials for cortisol, osmolality and urea and 
electrolytes. 
 
Echocardiography was performed by a trained technician on a Vivid I machine (GE 
HealthcareTM Vivid I) post-trek and at rest at the main study altitudes.  PASP was 
estimated from the maximum velocity of the trans-tricuspid gradient using continuous 
wave Doppler imaging added to a fixed value of 5 mmHg (Yock and Popp 1984), in 
the UK, by a Consultant Cardiologist (Dr Chris Boos, Poole and Bournemouth NHS 
Trust) blinded to other data. 
 
Total body water (TBW) was measured using both single frequency (SF) and 
multiple frequency (MF) devices.  SF-BIA was undertaken using The Non Invasive 
Cardiac System (NICaS®, Israel) which calculates TBW and non-invasive cardiac 
output (CO).  MF-BIA was performed using a tetrapolar technique with a 
QuadScan® 4000 (Bodystat, Douglas, United Kingdom) (Castillo Martinez, Colin 
Ramirez et al. 2007).  This is considered in more detail in chapter 4. 
 
The cold chain was maintained by the use of two Engel 35l freezers.  These ran 
from a generator by day and on a 12v battery overnight at a monitored temperature 
51 
 
of -20ºc throughout the study.  In transit the freezer was carried, connected to a 
battery by a team of two porters. 
 
3.4   Conclusion 
This was a logistically challenging study but one which investigated hormonal 
changes during the “real world” physiological challenge of a high altitude trek.  This 
study formed the main piece of work for this thesis.  Forty-eight subjects were 
studied on six research days collecting a total of 2600 cryovials of plasma, almost 
300 cardiac echos and around 6000 physiological observations.  
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Chapter 4 -  Fluid Balance At High Altitude 
  
4.1    Introduction 
4.2 Measuring Fluid Balance at HA 
4.3 Experimental methods 
4.4 Results  
  4.4.1  Comparison of methods of measuring total body water with BIA 
4.4.2  Fluid balance measurements 
  4.4.3  Thirst VAS 
4.5 Discussion 
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Summary 
Fluid retention is a key feature of altitude illness and a diuresis is an important part 
of the process of acclimatisation.  Measuring total body water at high altitude is 
difficult and many techniques cannot be used for practical reasons.  Bioimpedance 
(BIA) techniques, either multifrequency or single frequency, are attractive to use on 
field studies as they are non-invasive, straightforward and require lightweight 
portable equipment.  Recording body mass and fluid balance are also simple 
techniques.  In this study single and multifrequency BIA was compared and data 
collected on fluid balance and body mass.  A simple visual analogue score for thirst 
was included to investigate the utility of this as a surrogate for other measures of 
hydration. 
 
Hypotheses 
  Altitude illness would be associated with an increase in TBW and a rise in 
AVP (and copeptin)  
 There would be no difference between TBW measured by single or 
multifrequency BIA. 
 
4.1   Introduction 
The most commonly appreciated response to HA exposure is the increase in 
concentration of haemoglobin mediated by a hypoxia-driven increase in 
erythropoietin.  However, whilst the rise in erythropoietin takes place within a few 
hours, changes in red cell mass take several weeks and lag behind the crucial 
early changes in fluid homeostasis.  In the acute stages of HA exposure, changes 
in fluid balance with a marked natriuresis and diuresis are key to initial 
acclimatization (Zaccaria, Rocco et al. 1998, Hildebrandt, Ottenbacher et al. 2000).  
This process reduces total body water by up to 3 litres and leads to a reduction in 
plasma volume which increases the concentration of haemoglobin per volume of 
blood.  The effect is to increase the oxygen carrying capacity of a given volume of 
blood compared to sea-level and partially compensates for the reduced partial 
pressure of oxygen that occurs at HA.  A frequently reported feature of altitude 
illness reported in the literature is a failure of this diuresis to occur (Singh, Khanna 
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et al. 1969, Hackett, Rennie et al. 1982, Hamilton, Cymmerman et al. 1986, 
Ramirez, Bittle et al. 1988, Milledge, Beeley et al. 1989) highlighting the central 
importance of fluid balance and the endocrine response to HA in both 
acclimatisation and the pathogenesis of altitude illness.  The maintenance of salt 
and water homeostasis is regulated by a number of hormones with a complex 
relationship between those hormones, catecholamines and other stimuli such as 
exercise.  Arginine vasopressin (AVP) has a predominant action to retain free 
water through altering the permeability of the distal collecting tubule.  As already 
discussed a diuresis is an essential component of altitude adaptation and it seems 
likely that AVP is an important hormone in acclimatisation.   Normally at SL a rise 
in osmolality or a marked decrease in plasma volume would lead to a rise in AVP 
secretion from the posterior pituitary and a reduction in free water loss at the 
kidney thereby maintaining osmolality.  
 
Our groups previous work in Nepal (using single frequency bioimpedance 
spectroscopy (BIS)) showed a significant (p = 0.001) reduction in percentage total 
body water (TBW) between 1,300 and 5,150 m (57.6 ± 1.3; 56.24 ± 0.97; 55.88 ± 
0.86 and 54.8 ± 0.97 at 1,300, 3,400, 4,300 and 5,150 m, respectively). In those 
with AMS as judged by the LL score at 5,150 m, TBW was 56.1% in AMS cases 
and 52.9% in those without AMS but this was non-significant (p = 0.089) (Woods, 
Hooper et al. 2011).  For those with severe AMS, although numbers were small (4 
subjects), the difference in TBW was significant (p=0.047) (figure 4.1). 
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Figure 4.1  Change in TBW at altitudes up to 5150m 
  
Changes in catecholamines, cortisol, AVP and exercise intensity can all have 
effects on TBW.  It is therefore important to understand fluid shifts to understand 
the mechanisms behind changes in these hormones.  In a practical, clinical sense, 
a simple reliable measure of TBW may have clinical utility in making a diagnosis of 
AMS as fluid retention is key in this process.  Our previous data in 2009 and 2011 
showed significant changes as a group but the intra-individual variation was too 
great to use single frequency BIS for individual assessment. 
 
4.2  Measuring Fluid Balance At High Altitude 
In a comprehensive review of techniques for measuring TBW Armstrong 
(Armstrong 2007) makes the point that any assessment technique provides a 
singular measure of what is a complex and dynamic process.  He states that “total 
body water approximates “euhydration” when morning body weight is near the 
normal baseline, fluid intake is adequate, urine colour is pale and urine volume is 
normal”.  For the reasons we have seen above this state my never be reached 
during a trek at HA.  Table 4.1, taken from this review, outlines 13 methods of 
measuring hydration status. 
Change in total body water (litres) from Baseline to 
3400m (change 1); 4300m (change 2); 5150m 
(change 3) according to presence (n=4) or absence 
(n=11) of Severe AMS at 5150m (p=0.047 for TBW 
change 3) 
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Hydration assessment 
technique 
Body fluids 
involved 
Cost Time  Technical 
expertise required 
Portability Likelihood of 
adverse event 
Stable isotope dilution All (ECF and 
ICF) 
3 3 3 3 2 or 3 b 
Neutron activation 
analysis 
All 3 3 3 3 2 
Bioelectrical 
Impedance 
spectroscopy 
Uncertain 2 3 2 2 1 
Body mass change c All 1 1 1 1 1 
Plasma osmolality d ECF 3 2 3 3 2 
% plasma volume 
change 
blood 2 2 3 3 2 
Urine osmolality Excreted urine 3 2 3 3 1 
Urine specific gravity Excreted urine 1 2 2 1 1 
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Urine conductivity Excreted urine 2 2 2 3e 1 
Urine colour Excreted urine 1 1 1 1 1 
24 hr urine volume Excreted urine 1 1 1 1 1 
Salivary flow rate, 
osmolality, protein 
Whole, mixed 
saliva 
2-3 2 3 2-3 1 
Rating of thirst Hypothalamus 1 1 1 1 1 
Key to rating  1=little 
2=moderate 
3=great 
1=little 
2=moderate 
3=great 
1=little 
2=moderate 
3= great 
1=portable 
2=moderate 
3=not 
portable 
1=low 
2=moderate 
3=high 
b depending on type of isotope (i.e. radioactive, stable, non-radioactive) 
c using a floor scale 
d freezing point depression method 
e portable hand held meters are available 
 
Table 4.1 13 methods of measuring hydration status (Armstrong 2007) 
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Of these methods above body mass will change on a prolonged trekking 
sojourn due to anorexia and/or a relative lack of calorie intake.  Osmolality may 
change as a result of the hormonal changes at HA, independent of hydration 
status which would also affect percentage plasma change and urine 
measurements.  Neutron activation analysis involves the use of highly 
specialized equipment and is not appropriate for a field setting.  Collection of 24 
hour urine would, at the very least, prove logistically challenging to carry the 
extra weight and volume for a large number of subjects! 
 
Of the methods available, practical solutions to the measurement of TBW at HA 
are BIS, use of stable isotope dilution (such as deuterated water) or the rating of 
thirst.    
 
Isotope dilution is generally considered to be the gold standard for 
measurement of TBW (Armstrong 2007) and has been used previously to 
assess TBW in subjects exposed to simulated high altitude (Loeppky, Icenogle 
et al. 2005).  However, equilibration of the radioisotope takes several hours and 
this technique assumes that volume of body fluid compartments remains stable 
during equilibration.  It can also only be performed once over a two week 
period.  These conditions are impossible to generate in remote field 
environments at HA.  Isotope dilution techniques are also expensive (£250 per 
test) and laborious with a relative long learning curve and the time taken for 
isotopes to equilibrate prevents frequent, serial measurements of TBW.  BIS 
overcomes several of these shortcomings and has the distinct advantage of 
being a non-invasive, portable and very quick and easy to perform.  This 
creates several opportunities for HA research where changes in TBW and its 
associated compartments may be linked to the pathogenesis of AMS and 
possibly HAPE (Woods, Begley et al. 2012).  Estimation of TBW using both 
single and multi-frequency (SF and MF) BIS has been shown a very high 
correlation with isotope dilution methods though differences in absolute values 
of TBW may be observed (Lukaski, Johnson et al. 1985, O'Brien, Baker-Fulco 
et al. 1999, Carlsson, Bosaeus et al. 2004, Powers, Choi et al. 2009, Haas, 
Schutz et al. 2012).  Furthermore TBW using SF-BIA has strongly correlated 
with that from MF-BIS (Donadio, Consani et al. 2005).  It was on this basis that 
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we chose to directly compare these two BIS devices that had potential for 
increased use at HA. 
 
The Non Invasive Cardiac System (NICaS) (NICaS®, Israel) system has 
adapted the principles of SF-BIA to also measure key cardiac performance (eg 
cardiac index) and haemodynamic measures (eg systemic vascular resistance 
index) with ECG monitoring creating further options for cardiac (eg in heart 
failure) and HA research not available from the Quadscan device (Paredes, 
Shite et al. 2006, Tanino, Shite et al. 2009).  However, the device only 
measures TBW and does not provide information on compartmental extra 
cellular water (ECW) or intracellular water (ICW) which is of value in 
assessment of hydration which is also important to HA research. The 
QuadScan® 4000 (Bodystat, Douglas, United Kingdom) (QuadScan) utilises the 
concept of MF-BIS.  The principle of BIS is dependent on the current frequency 
applied.  At low frequencies, the current cannot bridge the cellular membrane 
and will pass predominantly through the extracellular space.  At higher 
frequencies penetration of the cell membrane occurs and the current is 
conducted by both the ECW and ICW (Kyle, Bosaeus et al. 2004). Using MF-
BIS technology to measure the varying impedance at higher and lower 
frequencies and by applying predictive equations, it is possible to estimate 
TBW, ECW and ICW (Donadio, Consani et al. 2005). 
 
BIS is based on the fundamental principle that resistance or impedance (Z) to 
the flow of an electrical current through the body is dependent on the length of 
the conductive path, the volume of the conductive material, and the resistivity of 
the conductive material (Kyle, Bosaeus et al. 2004).  The actual parameter 
measured with BIS is the voltage (V ) that is produced between two electrodes 
located most often at sites near to, but different from, the sites where a small 
clinically undetectable electrical current (I) is introduced.  Impedance is 
calculated from the ratio V/I.  In humans, only body water, with its dissolved 
electrolytes, will conduct a current.  Hence, using the assumption that the 
resistivity of the conductive material is constant, and using height (H) to 
estimate the path length water TBW can be estimated by measuring impedance 
to the flow of a small current.  Specific prediction equations have been 
developed to evaluate body TBW from height and height and impedance and 
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variable regression equations have evolved to include weight and sex amongst 
other factors (Kyle, Bosaeus et al. 2004).  
 
4.3 Experimental method 
Participants were studied in the supine position on a non-conductive surface, 
with arms and legs abducted at a 30°-45° angle from the trunk to avoid medial 
body contact by upper and lower extremities.  Electrode positions were carefully 
cleaned prior to use (Powers, Choi et al. 2009). 
  
SF-BIS was undertaken using NICaS which calculates TBW and non-invasive 
CO.  For TBW calculation an electrical current of 1.4 mA with a 32 kHz 
frequency wave is passed through the patient via two pairs of tetrapolar 
electrodes with one pair placed at left wrist above the radial artery, and the 
other pair placed on the contralateral side above the posterior tibialis artery 
(Paredes, Shite et al. 2006, Tanino, Shite et al. 2009).  TBW was calculated by 
adopting the Kushner formula to the NICaS as follows (Kushner, Schoeller et al. 
1992:   
 
TBW in litres= 0.42 x Height2 / Bessel Resistance + 4.96 for women 
TBW = 0.42 x Height2 / Bessel Resistance + 8.30 for men).  
 
MF-BIS was performed using a tetrapolar technique with a QuadScan® 4000 
(Bodystat, Douglas, United Kingdom) (Castillo Martinez, Colin Ramirez et al. 
2007).  Two electrodes were placed on the left wrist with one just proximal to 
the third metacarpophalangeal joint (positive) and one on the wrist next to the 
ulnar head (negative) on the left hand side.  Two electrodes were placed on the 
ipsilateral ankle with one just proximal to the third metatarsophalangeal joint 
(positive) and one between the medial and lateral malleoli (negative).  Total 
body electrical impedance to an alternate current (0.2mA) was assessed at four 
different frequencies (5, 50, 100, and 200 kHz) (Donadio, Consani et al. 2005).  
At the 50 kHz frequency TBW (and Fat-Free Mass) can be predicted using the 
manufacturer's software after entering the subjects age, sex, height and weight.  
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Statistical Analysis (BIS)  
The Kolmogorov-Smirnov test was undertaken to assess normality of all 
continuous data. The results were presented as mean ± standard deviation 
(SD). As TBW was normally distributed paired comparisons of TBW measures 
were performed with a paired T test and correlations were quantified using the 
Pearson correlation coefficient ± 95% confidence interval (CI).  Comparisons of 
continuous data from >3 groups were performed using ordinary or repeated 
measures ANOVA as appropriate with a Tukey post-test.  A p value of <0.05 
was considered significant for all comparisons. 
 
Agreements between NICaS (SF-BIA) and QuadScan 4000 (MF-BIA) for TBW 
measurement were assessed using Bland-Altman plots (Bland and Altman 
1986) in which the difference between the two values were compared with the 
average values from the comparative two readings.  The bias was defined as 
the mean ± SD of the difference between the readings.  Reasonable agreement 
was defined as <5% of readings being within 1.96SD (95% CI) from the mean. 
 
Fluid Balance Recordings 
During the 24 hours post exercise subjects recorded their fluid balance in terms 
of input and output.  Subjects recorded the volumes (mls) of all liquids 
consumed and measured urine output in a measuring jug.  This enabled a 
measure of overall fluid balance during resting conditions and free access to 
food and water.  The intention was to collect this data to examine the correlation 
between fluid balance and the development of AMS and changes in AVP and 
copeptin.  TBW was only measured on the rest day as the predominant 
changes following a trek would be related to exercise and dehydration rather 
than to adaptive mechanisms relating to acclimatization.  For this reason we 
could not directly relate TBW directly to fluid balance.  This is also the reason 
why the numbers and incidence of AMS reported differ to those reported in 
other chapters. 
 
Thirst Visual Analogue Score 
Thirst perception can be measured on a visual analogue score (VAS) or a 
categorical rating.  Rolls has published the use of a 10 cm scale (Rolls, Wood et 
al. 1980).  Subjects responded to the statement “how thirsty are you now” with a 
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mark on the horizontal line.  “Not at all” was a mark at the 0cm end of the scale 
whilst “very thirsty” anchored the 10 cm end.  This scale was found to track 
changes in plasma osmolality.  For the field study this VAS was slightly modified 
for the rating from “no thirst” to “worse thirst ever”, this was to reflect the fact 
that subjects were asked the question “how severe was your thirst at the 
thirstiest part of the day”.  On initial investigation it was clear that there was a 
great deal of variability in the subjects’ response to the question, with some 
subjects consistently recording high levels of thirst whilst others were seldom 
reporting any thirst.  For this reason the change in thirst was modified by 
subtracting the day 4 score from other scores recorded.  Day 4 was a rest day 
in La Paz with free access to water and no physical exertion.   
 
4.4  Results 
4.4.1   Comparison of methods of measuring total body water with BIA 
The average age was 34.5 ± 9.3 years with an age range of 21-54 years (70.2% 
male).  Body weight was 77.0 ± 14.6 kg at sea level, 77.6 ± 13.9 kg at 3833m 
post exercise, 77.5 ± 14.0 kg at 3833 at rest, 76.9 ± 13.80 at 4450m and 76.1 ± 
13.4 kg at 5129m (figure 4.2).  On repeated measures ANOVA this difference 
was significant between all altitudes and 5129m (p<0.0001).  The comparative 
sequential changes in TBW for the NICaS and QuadScan at sea level and 
increasing HA are shown in figure 4.3.  At sea level there was no paired 
difference between TBW measurement with NICaS (SF-BIA) compared with the 
QuadScan 4000 (MF-BIA) device respectively (40.5 vs 40.7l; p=0.76) (fig 4.4).  
At 3833m at both exercise (40.2 vs 41.8l; p<0.0001) and rest (39.3 vs 41.3; 
p<0.0001) NICaS readings were lower than that for the QuadScan device 
respectively (figure 4.4).  The resting TBW readings at 4450m (38.7 vs 40.9; 
p<0.0001) and 5129m (39.7 vs 41.2l; p=0.004) were again lower with NICaS 
than with the QuadScan respectively (fig 4.4).  There was an overall significant 
difference in TBW measurements between NICaS (39.8 ± 8.5) and QuadScan 
(41.5 ± 7.7; mean difference -1.7l: p<0.0001).  
 
There were strong correlations between the QuadScan and the NICaS systems 
for TBW assessment at sea level (r=0.90; 95% CI 0.78 – 0.95: p<0.0001) and at 
HA (r=0.92; 0.89 - 0.94: p<0.0001).  There was also a strong overall correlation 
between the two methods (r=0.91; 0.88 - 0.93: p<0.0001) (fig 4.5). There was a 
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stronger correlation between TBW and total body weight with the QuadScan 
(r=0.91, 95% CI: 0.89 - 0.93:p<0.001) than with the NICaS system (r=0.83; 95% 
CI: 0.79 - 0.87: p<0.0001) (figures 4.6 and 4.7). 
 
On Bland-Altman comparisons of the two methods of TBW assessment the 
values for TBW at sea level were higher with QuadScan than with NICaS 
measurements (mean difference [bias] 0.2l; 95% limit of agreement -6.6 to 6.7l) 
(figure 4.8).  This difference was greater at HA (mean difference 1.91; 95% limit 
of agreement -3.7 to 7.5l) (fig 4.8).  
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Figure 4.2 Changes in body weight at sea level and at exercise (Ex) and rest at 
increasing altitudes 
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Figure 4.3 Comparative changes in total body water for the NICaS versus 
QuadScan at sea level and at exercise (Ex) and rest at increasing altitudes 
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Figure 4.4: Paired changes in data for quantification of total body water at sea 
level and successive altitudes (* significant on paired testing) 
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Figure 4.5 Correlation between total body water measurements using NiCAS 
and BodyStat at sea level and at exercise (Ex) and rest at increasing altitudes 
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Figure 4.6: Correlations between total body water using the QuadScan and 
total body weight across all study points 
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Figure 4.7 Correlations between total body water using the NICaS system and 
total body weight across all study points 
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Figure 4.8 Bland-Altman plots comparing total body water measurements with 
the NICaS versus the QuadScan system at sea level  
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Figure 4.9 Bland-Altman plots comparing total body water measurements with 
the NICaS versus the QuadScan system high altitude 
 
4.4.2   Fluid balance measurements 
 
Altitude 3833m 4450m 5129m 
N 48 48 45 
Balance 675 (785)  
-2150 - +1800 
767 (731) 
-1025 - +2730 
817 (748) 
-800 - +2700 
 
Table 4.2  Fluid balance recorded at each study altitude.  Data presented as 
mean(SD) range, mls. 
 
 
Although there was a trend towards a more positive fluid balance with 
increasing altitude there was no statistical significance (38 vs. 44 p= 0.555, 38 
vs. 51 p=0.343, 44 vs. 51 p=0.88) 
 
 
Figure 4.10 Relationship of copeptin to fluid balance 
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There appeared to be no correlation between fluid balance and copeptin (rho 
0.090 p=0.296) 
 
 
Figure 4.11 Relationship of AVP to fluid balance 
 
Likewise there was no relationship between AVP and fluid balance recorded 
(rho -0.061 p=0.8) 
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Figure 4.12  Relationship of TBW to copeptin and AVP when recorded on 
Quadscan device 
Total body water as recorded on the Quadscan device showed no relationship 
to AVP or copeptin (rho -0.022, p=0.8 and rho -0.039, p=0.66 respectively). 
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Serum sodium measured at rest at each altitude showed no correlation with 
AVP or copeptin (rho -0.029 p=0.75 and rho 0.037, p=0.67 respectively).  
 
There was no difference in mean fluid balance between those with AMS (n=37) 
and those without (n=100) (mean +748 mls v’s 761 p=0.925). 
 
 
Figure 4.13 Fluid balance in groups with AMS (LLS>3) or no AMS 
 
There was no difference in fluid balance for those with severe AMS (n=11) v’s 
those without (n=126) (mean +771 v’s +608 mls p= 0.494). 
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Figure 4.14 Fluid balance in groups with severe AMS (LLS>6) or no AMS 
 
 
4.4.3   Thirst VAS 
The VAS for thirst was completed on 279 out of 288 study points. 
 
These showed great variability between individuals.  In an effort to see if the 
VAS score was meaningful within individuals the score was modified by 
subtracting the value recorded on day 4.  Day 4 of the field study was a day of 
preparing equipment in La Paz, involved no physical exertion and was in close 
proximity to free fluids, therefore subjects should have been fully hydrated and 
not unduly thirsty on this day. 
 
The unmodified mean thirst recorded was 35.52mm SD 18.5 and a range of 
80mm.  When modified by subtracting day 4 result the mean VAS recorded was 
5.4 with an SD of 16.5 a range from -70 to +53 mm. 
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Thirst did not correlate with osmolality either with or without the modification to 
the score (Pearson’s rho 0.106 p=0.08 and rho 0.076 p=0.21) 
 
 
Figure 4.15   Distribution of thirst score when modified with osmolality 
(Pearson’s rho =0.106). 
 
There was no correlation with AVP or copeptin with either modified thirst rating 
(rho -0.068, p=0.279 and -0.073, p = 0.23 respectively) or the unmodified thirst 
score (rho 0.125, p = 0.045 and 0.1009 p = 0.072) 
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Figure 4.16   AVP correlation with unmodified thirst (Pearson’s rho 0.125) 
 
 
 
Figure 4.17   Log AVP plotted against unmodified thirst. 
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4.5  Discussion 
There have been very few published studies comparing TBW assessment using 
SF-BIS and MF-BIS (Donadio, Consani et al. 2005) and this study focussed on 
the individual BIS methodologies relative to isotope dilution methods and 
anthropometric estimations rather than direct comparisons of the two BIS 
techniques.  In a previous study of 52 healthy subjects (26 men and 26 women) 
without known disease SF-BIS agreed well with deuterated water though TBW 
values were 0.7l higher with deuterium dilution (Haas, Schutz et al. 2012). 
Interestingly, as in our study, there were relatively wide limits of agreement 
(mean ± SD) which was greater in men than women (-5.9 to 4.2 vs -3.5 to 2.3). 
Nevertheless, the methods were highly correlated in both men and women 
respectively (r2=0.90 and 0.76). 
 
The small mean difference of 0.2l between the NICaS and the Quadscan 4000 
at sea level, observed in our current study, is in keeping with the work of Haas 
and Donadio cited above. For example, Donadio et al (Donadio, Consani et al. 
2005) noted (n=19) higher post-dialysis TBW readings (+0.45l: 95% CI -0.71 to 
1.61l) with the BodyStat QuadScan 4000 than that with another SF-BIS 
analyser (STA-BIA, Akern, Florence) among a group of haemodialysis patients, 
with a very high linear correlation between the methods (r=0.967). In our study, 
there was a further increase (overall difference 1.9 l, <5%) in TBW at HA but the 
strong correlation between the two methods remained the same.  There are a 
number of factors that may explain the observed differences in TBW and it is 
not possible to know necessarily whether the QuadScan over-estimated TBW or 
the NICaS underestimated it as comparisons were not made to a reference 
isotope dilution measure of TBW for the reasons explained earlier.  However, 
we did reference TBW to body mass which is a validated surrogate index for the 
changes in TBW (Baker, Lang et al. 2009).  The QuadScan 4000 appeared to 
more strongly correlate with body weight than NICAS and more closely reflected 
the changes in TBW throughout the study.  The increased difference in TBW 
measures between the two devices at HA may relate to the differences in their 
prediction equations and frequencies used and the impact of changing 
environmental and physiological conditions on the TBW values obtained (Kyle, 
Bosaeus et al. 2004).  The small differences in electrode placements between 
the two devices could have influenced the findings but we used the electrode 
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placements as recommended by the manufacturers and according to previously 
published work (Paredes, Shite et al. 2006, Tanino, Shite et al. 2009).  The 
NICaS SF-BIA utilises an adapted Kushner equation for TBW quantification 
(Kushner, Schoeller et al. 1992).  The Kushner equation has shown a very 
strong agreement with that quantified by the gold standard of deuterium dilution 
(r = 0.996, SEE = 1.47 kg) across a number of differing subject groups.  
However, it was observed in the validation cohort that the differences increased 
at higher body weights and underestimated TBW by 7% and no information was 
provided in this paper on the examination altitude.  During the Bolivian field 
study there was reduction in weight at the highest altitude of 5129m which could 
have influenced the findings but this would not explain the observed differences 
in at the two lower altitudes of 3833m and 4450m.  Of importance there was no 
further difference in TBW measures on the post exercise sample at 3833m.  
 
This study had a large sample size performed in a very difficult HA environment 
and at multiple altitudes (sea level, 3833m, 4450m and 5129m) and the 
assessment of exercise (at 3833m).  There are also a number of limitations of 
this study that should be acknowledged.  In this study SF-BIS was compared 
with MF-BIA and not to gold standard measures of TBW.  As stated earlier, 
measurement of deuterated water would not have been possible given the 
environmental conditions of this study.  It has been observed that BIS 
measurement can be influenced by diet and environmental conditions such as 
ambient and skin temperature and humidity which could not be controlled for in 
this field study (Lukaski, Johnson et al. 1985, Ellis, Bell et al. 1999).  However, 
these factors would have been equally applicable to both methods which were 
performed at similar time points.  It would have been attractive to have 
assessed the comparative values of other biometric assessments such as ICW 
and ECW however these are not available on the NICAs system.  The two 
methods of TBW assessment do use differing frequencies and TBW prediction 
equations which would apply equally across all the study altitudes.    
 
The fluid balance data did not support a failure of diuresis in those developing 
AMS.  Again this may have been for a number of reasons, fluid intake may not 
have been accurately recorded, some subjects may have taken more oral 
rehydration during the trek or have been less inclined to drink during the night 
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and there may have been a variation in fluid taken in food.  This demonstrates 
the difficulty of performing this sort of study in field conditions rather than in the 
controlled conditions of a lab. 
 
The fact that copeptin and AVP showed no correlation with fluid balance or 
TBW is supportive of the discussion later in this thesis that the main stimulus to 
secretion is through non-osmotic stimuli.  Further evidence for this is provided 
by the lack of correlation between plasma sodium and AVP or copeptin. 
 
The use of the VAS score as a surrogate for hydration status was not 
successful.  This may be for a number of reasons.  Firstly our modification of 
the scale and asking for a rating at the end of the day differs from previous 
methodology used.  Whilst in Rolls study this VAS did track osmolality the time 
course was much more acute with 11 recording of the VAS score over 1 hour 
(Rolls, Wood et al. 1980).  A 37 point categorical Likert (in the form of 
responding to questions as to how strongly one agrees or disagrees) rating has 
been used for thirst sensations but this would be impractical to use in the field 
(Engell, Maller et al. 1987).  A more useful modified Likert rating has been used 
as a research tool for pre-gastroscopy fasting and may prove useful in future 
field studies (no thirst/mild thirst/moderate to severe thirst) (Greenfield, Webster 
et al. 1996) to at least group subjects. 
 
As a conclusion to this study, we found there was good overall agreement 
between TBW assessments using the SF-BIA NICaS system compared with the 
MF-BIA BodyStat Quadscan 4000, although the 9% confidence intervals around 
these agreements were quite wide. Whilst the agreements between the two 
methods remained unchanged with HA the absolute difference in TBW 
measurements was greater at both rest and exercise at HA.  As the MF-BIA 
Bodystat Quadscan 400 tracked changes in body mass with more accuracy 
than the SF device this device seems to be the device of choice for future 
investigations.  The VAS scale proved to be useless in this setting and further 
work should evaluate the modified Likert score used by Greenfield 
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Summary 
BNP has many effects that may make it a beneficial adaptive hormone involved 
in acclimatisation.  It also has been shown to rise in a variety of pathological 
conditions associated with increased right heart pressures or inflammation and 
may therefore rise as a marker of high altitude illness.  During the field study in 
Bolivia the BNP and NTPro-BNP levels of trekkers ascending to altitude were 
measured and compared to PASP and AMS scores.  Data was analysed to 
produce RoC curves for the utility of BNP or NTPro-BNP in predicting AMS or 
high PASP.  RoC analysis for the NPs in severe AMS revealed an AUC for BNP 
of 0.675 (95% CI 0.553-0.797, p=0.013) and for NT-proBNP an AUC of 0.686 
(95%CI 0.56-0.813, p=0.008). An NT-proBNP of 80.5pg/ml had a sensitivity of 
61% and a specificity of 69% for detecting severe AMS.  For detecting a PASP 
>40mmHg showed an AUC of 0.645 (95% CI 0.557-0.732, p=0.001) for BNP 
with an AUC of 0.648 (95% CI 0.566-0.730, p=0.001) for NT-proBNP.  These 
figures are similar to the utility of BNP for detecting heart failure in healthy 
populations and must be seen in the context of a relatively low pre-test 
probability of any subject having AMS.  Both BNP and NTPro-BNP show 
potential to aide in the diagnosis of high altitude illness.  
Hypothesis 
That BNP would rise with HA illness and could be used as a diagnostic test. 
 
5.1   Introduction 
As stated earlier in this thesis (chapter 1) there are a number of reasons to 
suppose that brain natriuretic peptide (BNP) may change with altitude and be a 
marker for high altitude diseases.  To recap briefly these are;  
 Effects that induce a natriuresis, diuresis and reduce secretion of renin 
and aldosterone – all of which would help acclimatisation to high altitude 
(Hall 2005). 
 Has pulmonary vasodilator effects which would reduce any pathological 
rise in PAP at HA and therefore prevent the formation of HAPE.   BNP 
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levels are related to PAP in a number of diseases (Nagaya, Nishikimi et 
al. 2000, Elstein, Nir et al. 2005, Corte, Wort et al. 2010).  
 The related peptide, atrial natriuretic peptide, is known to rise at HA 
(Rock, Kraemer et al. 1993, De Angelis, Ferri et al. 1996).   
 Prolonged endurance exercise induces a rise in BNP (Elstein, Nir et al. 
2005, Scharhag, Herrmann et al. 2005, Hew-Butler, Noakes et al. 2008, 
Scharhag, Meyer et al. 2008).  
 BNP increases in a variety of inflammatory states, correlates with other 
inflammatory markers (Chiurchiu, Izzi et al. 2008, Inoue, Kawai et al. 
2010, Dimitroulas, Giannakoulas et al. 2012) and is a powerful predictor 
of death and morbidity following surgery and other illness (Christ-Crain, 
Breidthardt et al. 2008, Eliasdottir, Klemenzson et al. 2008).   
 BNP is also elevated after acute brain injury (Sviri, Soustiel et al. 2006). 
 
Previous studies in humans at high altitude have not shown a consistent picture 
(table 5.1).  
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Reference- N Altitude BNP/NtPro Exercise PASP Change in BNP conclusion 
(Due-
Andersen, 
Pedersen-
Bjergaard et 
al. 2008) 
20 
Not 
stated 
PaO2 
5.8+/-0.5 
KPa 
NTPro-
BNP 
No No ↑ 
Hypoxaemia stimulates BNP 
rise 
(Cargill, 
McFarlane et 
al. 1996) 
10 
Not 
stated 
SpO2 75-
80% 
BNP No No No change  
(Gao, Wang et 
al. 2013) 
46 >3000m NTpro 
Not 
stated 
No 
↑ HA or HAPE, 
↓ with rx 
NTPro may be a biomarker 
(Toshner, 
Thompson et 
al. 2008) 
10 5200m NTPro No Yes 
None despite 
inc PASP 
NTpro BNP does not rise 
(Feddersen, 
Ausserer et al. 
2009) 
14 5050m BNP Yes (trek) No ↑ 
Correlated with severity of 
AMS but not diuresis 
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(Woods, 
Hooper et al. 
2011) 
32 5150m BNP Yes (trek) No ↑  
A rise in BNP was associated 
with AMS 
(Woods, 
Begley et al. 
2012) 
20 5150m BNP & NT 
Pro 
Yes (trek) No ↑ BNP associated with AMS 
(Woods, 
Mellor et al. 
2013) 
20 5150m BNP & NT 
Pro 
Yes(trek) Yes ↑ High NT pro BNP identified 
those with PASP>40 
(Boos, 
Holdsworth et 
al. 2013) 
1 
(case 
report) 
3833m BNP Yes Yes ↑↑↑ ↓with treatment, useful 
clinical marker 
 
Table 5.1 Previous human studies measuring BNP in hypoxia
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Six of the eight studies have found a rising BNP with altitude and studies 
looking at specific pathologies (such as HAPE) have generally found a rise in 
NTPro-BNP with rises in PASP (Woods, Hooper et al. 2011, Woods, Begley et 
al. 2012, Boos, Holdsworth et al. 2013, Gao, Wang et al. 2013, Woods, Mellor 
et al. 2013).  The one exception is the study by Toshner (Toshner, Thompson et 
al. 2008) and the Apex 2 study group at 5200m in Bolivia.  In this study a cohort 
of 10 individuals were studied at sea level and then 5200m, whilst their mean 
NTPro-BNP dropped with ascent (despite increasing mean PASP) only means 
were compared and their data shows several outliers with either high NTPro-
BNP or high PASP.  Only 2 subjects reported a score consistent with severe 
AMS, 2 subjects showed a dramatic rise in NTPro-BNP and 3 subjects 
developed a PASP above 40mmHg.   It is impossible to know whether these are 
the same subjects and demonstrates the importance of investigating outliers in 
these studies rather than comparing means. 
A recent study in Chinese moving from lowland areas to the Tibetan plateau 
has found a rise in NTPro-BNP in subjects with HAPE (Gao, Wang et al. 2013) 
and significantly, this is reduced with treatment. 
Overall this suggests a mechanism behind the disease (i.e. raised PASP in 
HAPE), a marker that rises with the mechanism identified (BNP) and one which 
can readily be measured.  
 
5.2   Methods 
The study methods are described elsewhere (Chapter 3).  
BNP was analysed in the field on a Biosite Triage point of care monitor (Alere 
Ltd, Stockport, UK) using a Triage cardiorenal test kit.   The Triage® cardiorenal 
test is a point-of-care, fluorescence-based immunoassay used which gives a 
rapid (15 minutes) quantitative measurement of BNP in the range 5-5000 pg/ml 
and NGAL in a range from 60 to 1,300 ng/ml.  This technology was used as it is 
very suitable for a point of care system to be used in areas with limited power, 
access to cold storage and calibration equipment.  Similar technology does exist 
for the measurement of NTPro-BNP but we chose to measure this using a lab 
based test on a serum sample that had been frozen at -20°C.  The NTPro-BNP 
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assay was performed using the Roche NT-proBNP assay (Roche Diagnostics, 
Mannheim, Germany) with a range from 5 to 35000 pg/mL and a coefficient of 
variation at a mean NT-proBNP of 474 pg/mL of 5.8%. 
As the maximal PASP response in healthy subjects to hypoxia is thought to be 
40 mm Hg and as non-HAPE susceptible individuals have a mean rise of PASP 
to 37+/-4 mmHg during exercise in hypoxia (Grunig, Mereles et al. 2000) data 
were also analysed according to a PASP cut-off of 40mmHg. A ROC (receiver 
operating characteristic) analysis was done to investigate the utility of the NPs in 
identifying AMS/severe AMS and a PASP >40 mmHg. 
For statistical calculations the software package SPSS 21.0 was used. Subjects 
were excluded who took drugs to aid acclimatization (n=3). Parametric or non-
parametric statistical tests were applied after performing the Shapiro-Wilks 
statistic. Changes in dependent variables between altitudes were initially tested 
by Student’s paired t test or Wilcoxon signed ranks test. For independent 
variables an independent-samples t test or Mann Whitney test was used. Either 
a within subjects ANOVA or a Friedman test was performed to investigate any 
serial changes in measures (eg PASP or BNP) with ascent. A correlation analysis 
between BNP and NT-proBNP was performed using Spearman’s rank 
correlation.  
 
5.3   Results  
All data presented as mean, SD (+/- range where appropriate) pg/mL. The 
subjects were 35.2±9.1 years old, 175.5±9.5 cm in height and 77.5±13.9 kg in 
weight. 45 subjects reached the highest study altitude (5129 m).  
LL scores 
Repeated measure (RM) ANOVA revealed a significant change in LL score with 
ascent (p<0.001).  Over the six study time points at HA 65 LL scores (24.4%) 
were consistent with AMS (LL score≥3) and 18 (6.8%) consistent with severe 
AMS (LL score≥6). 
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 Altitude (m) Sea Level 3833 4450 5129 
      
SpO2 Rest 98 (1.34, 94-99) 88 (4.2, 75–93) 86 (4.96, 62-93) 81 (4.4, 66-90) 
 Exercise 97 (1.53, 94-99) 84 (4.95, 71-94) 81 (6.28, 53-90) 79 (4.4, 68-88) 
PASP 
(mmHg) 
Rest 20.2 (7.0, 10-34.4) 27.2 (10.8, 12-54) 32.5 (8.5, 17-56) 33.2 (9.1, 17-54) 
Exercise 23.1 (6.4, 13.1-38) 29.8 (11.6, 12-58) 31.5 (9.8, 16.7-
63) 
33.9 (11.6, 17-63) 
NT-ProBNP 
(pg/mL) 
Rest 43 (29, 10-116) 137 (175, 16-
1195) 
50 (47, 7-270) 85 (92, 8-479) 
Exercise 62 (43, 14-174) 102 (64, 13-289) 36 (29, 5-134) 75 (121, 6-730) 
BNP (pg/mL) Rest 8.9 (7, 5-34.7) 13.4 (16.6, 5-111) 6.5, (3.8, 5-24.1) 11.6 (9.7, 5-40.9) 
Exercise 8.9 (5.9, 5.2-27.7) 12.3 (11.1, 5-8.3) 6.3 (4.2, 5-29.6) 8.0 (5.9, 5-33.8) 
Data presented as mean (SD, range) 
Table 5.2  BNP, NT-proBNP and PASP at each altitude.   
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5.3.1   BNP and NT-proBNP  
BNP and NT-proBNP values for each study point are detailed in Table 5.2. NT-
proBNP and BNP significantly correlated (rho 0.763, p<0.001)  
 
Figure 5.1 Correlation between BNP and NT-ProBNP across all time points 
 
NT-proBNP (p<0.001), but not BNP, rose modestly following exercise at near-SL 
in the UK.  Repeated measures analysis demonstrated a significant change in 
BNP and NT-proBNP with ascent (P<0.001 for both).  Peak BNP and NT-proBNP 
levels were seen at 3833 m. There was no significant difference in BNP at rest or 
post-exercise between SL and 5129 m.  NT-proBNP was significantly higher at 
rest at 5129 m vs SL (p=0.008) but not following exercise.  
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Figure 5.2  NTPro-BNP changes at each altitude 
 
5.3.2   AMS scores and BNP/NT-proBNP 
At altitude there were 266 simultaneous recordings of a LL score at HA with a 
simultaneous BNP and NT-proBNP.  NT-proBNP and BNP were significantly 
higher on those occasions when LL score was consistent with AMS (n=65, 
24.4%) vs. those without (NT-proBNP: 113±164 vs 72±78, p=0.034; BNP 
13.1±16 vs 8.7±7, p=0.008).  On those occasions when LL scores were 
consistent with severe AMS (n=18, 6.8%) NT-proBNP and BNP were also 
significantly higher than those without (NT-proBNP: 161.2±264 vs 76.4±82.5, 
p=0.008; BNP 17.1±25 vs 9.2±8, p=0.007). 
 
ROC analysis (to investigate the utility of BNP and NT-proBNP in detecting AMS 
and severe AMS) revealed an AUC of 0.601 (95% CI 0.519-0.682, p=0.015) for 
BNP with an AUC of 0.588 (95% CI 0.506-0.67, p=0.034) for NT-proBNP in AMS. 
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ROC analysis for the NPs in severe AMS revealed an AUC for BNP of 0.675 
(95% CI 0.553-0.797, p=0.013) and for NT-proBNP an AUC of 0.686 (95%CI 
0.56-0.813, p=0.008).  An NT-proBNP of 80.5 had a sensitivity of 61% and a 
specificity of 69% for detecting severe AMS.   
 
Fig 5.3  Roc Curve for NT-proBNP as a marker in severe AMS (AUC 0.686) 
 
5.3.3   PASP and BNP/NT-proBNP  
At altitude there were 245 echocardiographic assessments of PASP with 
simultaneous BNP or NT-proBNP values.  Of these 52 (21%) had a PASP≥40 
mm Hg.  Both NT-proBNP and BNP were significantly higher in those with a high 
PASP vs those without (NT-proBNP: 137±195 vs 71.8±68, p=0.001; BNP 
15.3±18.1 vs 8.7±6.6, p=0.001).  
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ROC analysis (to investigate the utility of BNP and NT-proBNP in detecting a 
PASP≥40 mm Hg) revealed an AUC of 0.645 (95% CI 0.557-0.732, p=0.001) for 
BNP with an AUC of 0.648 (95% CI 0.566-0.730, p=0.001) for NT-proBNP.  
 
Peak BNP and NT-proBNP occurred at 3833 m at rest.  At that point there were 
6 subjects with a PASP≥40 mm Hg.  Their NT-proBNP and BNP were higher than 
those with a lower PASP (NT-proBNP: 370+/-413 vs 101+/-72, p=0.003; BNP: 
37.5+/-38 vs 10+/-6.7, p=0.003).  
 
5.4   Discussion 
There was good correlation between NT-proBNP and BNP suggesting that (as in 
other conditions) these markers can be used with equal confidence. 
 
There was a peak rise in NT-ProBNP and BNP at 3833m, this was associated 
with peak LLS at 3833m post exercise where mean LLS recorded was 
approximately twice that at 4450m or 5129m after exercise (2.9 vs. 1.4 p= 0.001 
vs 4450m and 0.002 vs. 5129m).  While it could be argued that the diagnostic 
ability of the NPs in detecting AMS or a high PASP is not at present clinically 
robust it must be noted that the test was applied in all subjects, irrespective of 
symptoms, at HA. As such the pre-test probability of detecting either condition 
will naturally be low.  The clinical utility of the NPs in detecting asymptomatic left 
ventricular systolic dysfunction in apparently healthy populations is also highly 
variable with BNP values between 45-50 pg/ml giving 95% specificity but very 
low sensitivity (13-27%)(Vasan, Benjamin et al. 2002).  The AUC for BNP in 
detecting mild systolic dysfunction is around 0.60 in women and 0.72 in men 
(Goetze, Mogelvang et al. 2006).  For an NT Pro-BNP this study found an AUC 
of 0.686, with a value of 80.5 pg/ml providing a sensitivity of 61% and specificity 
of 69% for severe AMS.  One reason our data was not stronger is that the pre-
test probability of an individual having the disease was low.   For the diagnosis of 
cardiac failure NPs have an AUC of between 0.804 and 0.883 (Boldanova, 
Noveanu et al. 2010) if breathless patients presenting to the emergency room are 
tested.  One of the major problems with this line of investigation is the lack of a 
gold standard against which to assess the test.   The Lake Louise Consensus 
score is quoted as having a sensitivity of 78% and a specificity of 93% for a LLS 
>4 being consistent with a diagnosis of acute altitude illness when compared to 
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AMS-C and AMS clinical score (Maggiorini, Muller et al. 1998).  Of note it is 
interesting that Maggiorini uses a LLS >4 rather than the usual score of >3 to 
diagnose AMS. 
 
Figure 5.2 shows that NT-ProBNP rose with exercise at sea level yet rises at rest 
at HA.  This is explained by the time course of the measurements.  For the control 
group rest samples were taken, there was an ascent followed by descent over 
several hours.  There was therefore a delay from peak exercise stress to 
sampling.  The DMS hypoxia study group has previously shown that brief, 
profound hypoxia does not produce a BNP result if tested at 3 hours post hypoxia 
(Woods, Hooper et al. 2011).  More importantly the rest samples in Bolivia were 
taken the following day so a period of exercise took place followed by overnight 
rest and prolonged exposure to the hypoxic environment.  This has implications 
for optimum timing of any sample for either clinical or research purposes. 
 
Diagnosing HAPE in the field can be a significant clinical challenge and although 
a high PASP is a key feature of HAPE (Maggiorini, Melot et al. 2001, Bartsch, 
Mairbaurl et al. 2005) echocardiography is not typically available. A surrogate 
biochemical marker could therefore be extremely useful and facilitate both early 
detection and diagnosis.  
 
NT-proBNP has also recently been found to fall with treatment of HAPE in 
Chinese subjects (Gao, Wang et al. 2013) suggesting the possibility that the NPs 
may have a role in monitoring the response to treatment similar to that in CCF.  
 
Prolonged endurance exercise leads to increases in NT-proBNP (Scharhag, 
Herrmann et al. 2005, Hew-Butler, Noakes et al. 2008, Scharhag, Meyer et al. 
2008).  It has previously been reported (Toshner, Thompson et al. 2008) that 
following arrival by vehicle at 5200 m (after 5 days acclimatization at 3600 m) no 
rise in NT-proBNP occurred despite a rise in PASP.  This emphasizes the 
importance of prolonged exercise at HA in the release of NPs.  It would seem 
likely that exercise at HA will increase the myocardial oxygen gradient, potentiate 
myocardial hypoxaemia, and be a greater stimulus to NP release.  However this 
hypothesis does not explain the lag to BNP rise - brief hypoxia to a nadir of an 
SPO2 of 62% does not increase BNP within 3 hours (Woods, Hooper et al. 2011). 
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NT Pro-BNP would appear to be the best biomarker for further investigation.   NT-
proBNP is more stable in plasma and has a longer half-life therefore values 
measured are higher and a change more likely to be recognized.  The challenge 
for future studies evaluating biomarkers at HA is to further delineate the 
pathological from the physiological by investigating those who are symptomatic 
and where the differential diagnosis may lie between respiratory infection or 
HAPE.  A biomarker that could detect an abnormally high PASP or HAPE at HA 
could significantly improve diagnosis, management and outcome, similar to that 
seen with the use of biomarkers in CCF and acute coronary syndromes.  
 
5.5   Clinical relevance - Case Report Subject 42(Boos, Holdsworth et al. 
2013) 
The potential clinical utility of measuring natriuretic peptides at HA is illustrated 
by the case of subject 42, a 39 year-old-male participant on the research study.  
He presented with headache, fatigue and nausea, following a six hour trek from 
3,200m to 3,833m.  He had flown into La Paz, Bolivia at 3,650m from the UK 48 
hours earlier.  He subsequently developed orthopnea and significant nocturnal 
breathlessness leading to insomnia and the onset of central chest tightness by 
the morning of day three.  He was an experienced mountaineer.  In 2003 he had 
suffered a right central retinal vein occlusion at 7,000m on Everest, descending 
immediately, with spontaneous resolution after four weeks at sea-level.  He had 
subsequently climbed to >4,000m on multiple occasions over the ensuing nine 
years. He was an athlete and had completed the Marathon des Sables and 
several mountain marathon events.  He has no other past medical history and 
was on no medicine to aid acclimatisation or other medication.  
On examination, he was obviously breathless and tachypnoeic with a SpO2 of 
76% and had bilateral inspiratory crepitations with severe AMS (LLS 9).  He 
underwent a portable transthoracic echocardiogram (Vivid I, GE Healthcare™, 
Amersham, Bucks, UK).  This revealed significant pulmonary hypertension and 
right ventricular dilatation with a peak PASP of 54.0 mmHg (Table 7.3). Brain 
natriuretic peptide (BNP) levels, measured on point-of-care testing (Alere 
Triage® BNP, Alere Ltd, Cheshire, UK) were significantly raised at 111 pg/ml 
(normal 5-30pg/ml).  Subsequently laboratory investigation showed his NT-
proBNP to be 1195 pg/mL at the same time.  He was diagnosed with HAPE.  
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Descent would have been extremely difficult requiring an initial ascent of 300m, 
furthermore the location he was in required a ferry crossing to return to the 
mainland – an option that was not available in the evening when the diagnosis 
was made.  Hence, he was kept at altitude and treated with stat oral nifedipine 
10mg bid and monitored regularly.  Within four hours he had started to improve 
and slept better that night with resolution of his chest pain by the following 
morning.   
 
On day four he improved further and continued by vehicle to 4,450m.  His 
PASP, pulmonary vascular resistance, and right ventricular diameter fell (Table 
5.3), with normalization of his BNP measurements by day five.  He went on to 
climb to 6,000m just ten days later.  Two months later, following his return to 
sea-level, his stored serum, taken at presentation, was analysed for high-
sensitivity cTnT (hs-cTnT) levels (Roche Diagnostics, Burgess Hill, UK; (Table 
5.3).  His levels were significantly elevated at 43.7 ng/l (normal <14.0ng/l). He 
also had a repeat echocardiography and a cardiopulmonary exercise test 
including full 12-lead ECG analysis (Medical Graphics®, Ultima O2, MN, USA). 
This showed normal PASP, right ventricular size and supra-normal functional 
exercise capacity (peak VO2 130% predicted) with no evidence of dynamic ECG 
changes.  At that time he also had a hs-cTnT within the normal range. 
This case reports the first case of HAPE where simultaneous echocardiography 
and testing for BNP and cTnT were obtained at HA during the actual clinical 
event in a known healthy individual.  The patient fulfilled the diagnostic criteria 
for HAPE which requires the presence of at least two typical symptoms 
(dyspnoea, cough, decreased exercise and chest tightness) and two recognised 
clinical features (chest crepitations or audible wheeze, central cyanosis) 
(Roach, Bartsch et al. 1993).  
 
Our patient presented with HAPE and an associated pathological rise in both 
point-of-care BNP and latterly available NT-proBNP and hs-cTnT levels.  It has 
been shown that HAPE-susceptible subjects generate higher PASP compared 
with control subjects, at equivalent HA owing to enhanced hypoxia-driven 
pulmonary vasoreactivity, which might explain their rapid response to oral 
Nifedipine (Sartori, Vollenweider et al. 1999, Schoene 2008).  
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The significant increases in PASP, BNP and hs-cTnT, in this case occurred, 
despite normal cardiac output and normal estimated left ventricular filling 
pressures.  The rise in BNP and hs-cTnT were not dissimilar to that observed in 
genuine clinical heart failure and myocardial infarction respectively.  The cause 
for this rise is uncertain and may relate to the degree of PASP increase, right 
ventricular overload or severity of AMS (Nagaya, Nishikimi et al. 1998, Schoene 
2008, Woods, Begley et al. 2012).  The availability of echocardiography and 
simple point-of-care testing for BNP in this case supported the diagnosis and 
allowed the patient to be safely managed without the need for descent.  
His BNP has returned to normal levels in 24 hours yet his PASP remained 
elevated.  At the same time his NTpro-BNP was still elevated (in the highest 5% 
of the cohort).  Whilst his PASP remained high his RV dimensions and 
calculated pulmonary vascular resistance had both started to fall.  This may 
reflect the complexity of measuring resistance in the pulmonary vasculature 
(with PASP being a crude measure) and the fact that BNP has a shorter half-life 
than NT-proBNP, hence NT-proBNP values would have reflected the events of 
the last 24 hours.  
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  Altitude 
 Sea 
Level 
3800m Sea 
level 
Variables Baseline At 
presentati
on 
24 hours 
later 
Two 
month
s later 
Respiratory rate (minute-1) 14 28 18 14 
Heart rate (minute-1) 44 88 78 43 
Blood pressure (mmHg) 135/65 111/73 119/73 122/70 
SpO2 (%) 98 76 89 100 
Lake Louise AMS score 0 9 1 0 
Right ventricular end diastolic 
diameter (cm) 
4·1 5.2 4.7 4.4 
Pulmonary artery systolic pressure 
(mmHg) 
16.1 54.0 50.4 21.6 
Pulmonary artery resistance 
(dyn.s/cm-5) 
37 226 142 96 
Cardiac output (L minute-1) 4.4 6·1 7·1 5.4 
Estimated left ventricular filling 
pressure  
6.9 4.7 5.1 7.2 
BNP level pg/ml  - 111 <5 <5 
NT-ProBNP pg/ml  1195 192.3  
Hs-cTnT level, ng/l  - 43.7 36.7 <14 
Table 5.3. Time-dependent changes in clinical, echocardiographic and 
hormonal values with presentation  
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Summary 
As previously described fluid balance is a key part of adaptation to high altitude.  
Arginine vasopressin (AVP, also known as anti-diuretic hormone) may play a 
key role in this.  The assay of AVP is a complex and time consuming 
radioimmuno assay and therefore has practical difficulties.  Copeptin is C 
terminal proAVP and can be assayed in an inexpensive, automated way.  
Confirmation that copeptin values over the duration of a high altitude field study 
relate to AVP is therefore an important question. 
 
Hypothesis; 
Copeptin and AVP would increase together with rising osmolality at HA and be 
associated with AMS. 
 
6.1  Introduction 
As discussed in the introduction an early diuresis is a key part of acclimatisation 
to altitude.    
 
Anti-diuretic hormone was the name given to the hormone involved in salt and 
water regulation at the kidney.  More recently this hormone has been 
discovered to have a wider range of properties and has been renamed arginine 
vasopressin (AVP).  Its’ release is stimulated by osmoreceptors in the 
“osmostat”, an area of the organum vasculosum of the lamina terminalis and in 
the wall of the 3rd ventricle that are sensitive to changes in osmolality.  Normal 
plasma osmolality is 280 – 295 mOsm/Kg H2O, the greatest contribution to this 
is plasma sodium, along with glucose, urea and potassium.  Basal levels of AVP 
are 1.15 – 2.4 pmol/l when osmolality is below 285mOsmol/Kg 
(Knoepfelmacher, Pradal et al. 1997).  A 1% change in osmolality leads to a 
change in AVP release.  AVP increases with increasing plasma osmolality and 
acts to facilitate the reabsorption of water by increasing the permeability of the 
distal collecting tubule.  Non-osmotically stimulated secretion also occurs as 
part of the stress response, with high levels in critical illness and multiple 
trauma patients (Westermann, Dunser et al. 2007).   There is evidence that 
there is an alteration of the osmotic stimulus to AVP release (with relatively 
suppressed AVP at HA) and also that elevated AVP is associated with HA 
illness (more fully described in other chapters).  Furthermore newly developed 
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competitive AVP antagonists (such as Tolvaptan) offer a potential therapeutic 
option for treatment or prophylaxis of altitude illness, if a pivotal role for AVP 
can be proven.  These reasons make AVP an extremely interesting hormone in 
terms of HA physiology.  
 
The major problem with studying AVP is that the assay is complex, costly and 
time consuming.  Additionally AVP is an unstable nonapeptide with a short (5-
15 minutes) half-life in plasma.  It is also highly bound to platelets and present 
in small amounts in the circulation.  It can only be assayed by 
radioimmunoassay, a process which takes 3 days and is available in very few 
centres.  This makes AVP a difficult peptide to study, especially in samples 
collected in the field. 
 
Over the past decade an assay has been developed for copeptin, the C terminal 
part of pro AVP. 
 
 
Figure 6.1   The processing of preproAVP (adapted from Elshafi.  Annual 
Review and Research in Biology 2013) 
 
Copeptin has the advantage of being more stable both in vivo and ex vivo.  It 
can be measured by an automated process (see below) which takes less than 
one hour.  Copeptin can be stored in a variety of media (EDTA, heparin, citrate 
or serum separator tubes).  Analysis of 5 patients samples in serum, citrate, 
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heparin – plasma and EDTA showed mean values between 90 and 110% of the 
original after 7 days storage at room temperature (Morgenthaler, Struck et al. 
2006), with a similar range of 93 – 110 % after two weeks at 4 ºC.  The same 
authors found that samples could be subjected to 4 cycles of freezing and 
thawing with no change in the copeptin level measured.  This is obviously a 
major advantage over AVP assays for use in a field setting. 
 
Copeptin has been looked at in a number of studies and shown to correlate with 
AVP (table 6.1). 
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Author Correlation 
(rho) 
P value N Sample group 
Morgenthaler 
(Morgenthaler, 
Struck et al. 
2006) 
0.74 <0.0001 39 Patients with 
sepsis 
0.31 0.008 71 Healthy 
controls 
0.78 <0.0001 110 Both groups 
combined- 
Balenescu 
(Balanescu, Kopp 
et al. 2011) 
0.8 <0.0001 20 Healthy 
subjects 
during water 
and salt 
loading study 
Hew-Butler (Hew-
Butler, Hoffman et 
al. 2011) 
0.55 <0.0001 74 Ultra marathon 
runners 
Jochberger 
(Jochberger, 
Morgenthaler et 
al. 2006) 
0.282 0.017 70 Healthy 
controls 
0.73 <0.001 25 Critically ill, 
septic patients 
0.518 <0.001 36 SIRS patients 
0.725 <0.001 96 Post cardiac 
surgical 
patients 
Jochberger 
(Jochberger, 
Dorler et al. 2009) 
0.614 <0.001 60 ICU patients 
   
Table 6.1.  Previously published relationship between AVP and copeptin 
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The field study carried out in Bolivia was the first time that copeptin 
measurement at HA had been reported and was in a relatively large cohort 
(potentially 340 data points).   The aim of this study was to support the fact that 
samples could be handled in an appropriate way for the copeptin assay and to 
provide evidence for AVP being a surrogate of AVP thus enabling the simpler 
and easier assay to be used in future studies. 
 
There is a suggestion that copeptin (being more stable in the plasma) may 
reflect more long term changes in plasma volume whereas acute dehydration or 
stress, nausea etc. (non-osmotic stimuli to AVP) may cause a greater change in 
AVP secretion (Hew-Butler, Hoffman et al. 2011).  This would be reflected in an 
increase in AVP relative to copeptin and an increase in the AVP:Copeptin ratio.    
 
Importantly Jochberger found a significant but weak correlation (rho=0.33) in 
healthy controls with a stronger correlation in the septic patients where copeptin 
and AVP values were higher (rho=0.8) in septic patients (Jochberger, 
Morgenthaler et al. 2006).  This suggests that the correlation is stronger in the 
stimulated state – healthy controls had a copeptin of 6+/-3 pmol/l whereas in 
critically ill patients the copeptin was 87 +/- 77 pmol/l.  Following endurance 
exercise there is a good correlation between copeptin and AVP (rho=0.55) 
(Hew-Butler, Hoffman et al. 2011).  One problem with studying these hormones 
at HA is that levels of AVP are thought to be suppressed (see discussion below) 
from already low resting levels in the un-stimulated state.  
 
This was the first study to investigate the relationship between copeptin and 
AVP at high altitude in a large cohort of participants and to assess the utility of 
the copeptin assay as a surrogate for AVP at HA.    
 
6.2   Methods  
The study design and subject demographics are outlined in Chapter 3.   To 
briefly review 20 subjects studied on a near sea level trek formed the control 
group.   Fifty subjects were studied at 6 time points, at 3833 m, 4450m and 
5129m  (following a trek and at rest). 
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Data was collected for plasma osmolality, AVP, copeptin at each study point 
(and at near sea level in 20 subjects).   
 
Plasma osmolality – samples were collected by venesection form an antecubital 
fossa vein in a serum separator tube (SST).   This tube was allowed to clot and 
then centrifuged within 3 hours.   Serum was pipette into a cryovial and 
immediately frozen to -20ºC. 
 
AVP – samples were collected as above into a Lithium Heparin collection tube.   
These samples were immediately centrifuged, pipetted and frozen at -20ºC.   
1ml of plasma was required for each assay. 
 
Copeptin – samples were collected as above into an EDTA tube.  These 
samples  were centrifuged, pipetted and frozen within 30 minutes.  Fifty µl was 
required for each assay. 
 
Subjects recorded daily physiological variables and perceived exertion during 
the treks as part of the study.  The Borg perception of exertion was recorded 
(Borg 1970) at the end of each day to record the hardest perceived exertion 
experienced during the day. 
 
6.2.1  AVP Assay 
 
Arginine Vasopressin Assay method 
Assay of plasma AVP is difficult due to its’ low concentrations (this is specifically 
a problem at HA where AVP secretion is suppressed) and short half-life in 
plasma.  Newcastle University/RVI Hospital has developed a solid phase 
radioimmunoassay (RIA) for AVP based on reaction with antibodies raised in a 
rabbit model (Burd, Weightman et al. 1984).  As part of this MD I personally 
analysed the majority of the AVP samples from the field study in the laboratory 
at the RVI.  The plasma samples require extraction by reversed phase solid 
phase extraction method before incubating with AVP antibody and then a 
further incubation with 125I-AVP complex. 
 
Principles of solid phase extraction 
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Sample preparation - The sample is prepared from a lithium heparin blood 
sample centrifuged and the plasma frozen within 30 mins.   This is a crucial step 
due to the short half-life of AVP.   One ml of plasma is required and is initially 
acidified to reduce any protein binding of the AVP.   The solid phase extraction 
uses a Sep-Pak® C18 non polar sorbent with the samples drawn through via a 
vacuum eluting system. 
 
Cartridge Conditioning – For reversed phase sorbents the cartridge must be 
preconditioned and 5ml of methanol is used for the AVP assay.   This is 
preceded and followed by 10 mls de-ionised water.   This step is necessary to 
allow the solvent to penetrate the hydrophobic surface and wet the sorbent and 
increase the surface area of sorbent available. 
 
Cartridge Loading – The acidified plasma sample is then applied to the 
extraction column.   It is important at this stage to monitor the rate of flow 
through the column as too high a rate leads to sample breakthrough and poor 
reproducibility. 
 
Wash step – The cartridge is then washed with 4% acetic acid.   This removes 
unwanted material on the matrix whilst leaving the AVP bound to the sorbent. 
 
Elution step – The AVP bound to the cartridge is eluted with methanol into a 
receiving tube. This produces a sample of approximately 4 mls which must be 
taken down to complete dryness.   Once dry, the samples can be stored in a 
freezer until sufficient numbers have been accumulated to run an assay. 
 
Principles of RIA  
Radioimmunoassay is a technique first described by Yalow and Bersen to 
assay plasma insulin (Yalow and Berson 1959).  In short this technique involves 
introducing a known concentration of radiolabelled antigen and antibody to a 
sample.  The labeled antigen then competes with the antigen in the sample to 
form complexes.  When the excess radiolabelled antigen is removed the 
remaining radioactivity is related to the concentration of antigen in the sample.  
By creating known standards a binding curve can be generated which allows 
the value of antigen in the patient sample to be calculated. 
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AVP RIA Technique 
The dried samples must first be resuspended in buffer 800µl of assay buffer.   
The buffer is made by dissolving 3.028g TRIS(hydroxymethyl)methylamine and 
0.1g sodium azide in 400mls distilled water in a beaker.  To this 1.75g Bovine 
serum Albumin fractition V (Sigma A9647) is dissolved.  This is then adjusted to 
be pH 7.4 by adding 5M HCl and made up to a volume of 500mls in a 
volumetric flask.   The tubes are then centrifuged to remove sediments at 
1500RPM at 4ºC for 15 mins.  200µl of this is then taken off into another tube 
(and duplicates created) and incubated with the “first antibody” (AVP-Ab) at 4 
ºC for 24 hours.   This antibody has been generated in rabbits by a method 
described by Burd in 1984 (Burd, Weightman et al. 1984).   During this 
incubation period the rabbit antibody forms complexes with the AVP (antigen) in 
resuspended sample.  After 24 hours 100 µl 125I-AVP is added to the mixture.   
Radiolabelled iodine is chosen as this readily binds with the tyrosine residues in 
proteins.   This 125I-AVP will then form complexes with any rabbit AVP-Ab in a 
competitive fashion with the sample AVP.  The labeled AVP is supplied as (3-
[125I}iodotyrosyl)Vassopressin[Arg 8] (Perkin Elmer cat no NEX128010UC).  
This is allowed to incubate at 4ºC  for 18 hours.  The final step is to add 100µl 
anti rabbit Sac Cel (anti rabbit anti-IgG serum) to the tubes.  This precipitates 
the Ab-Ag complex.  The tubes then have 1ml of de-ionised water added to 
dilute the supernatant and are centrifuged for 15 minutes (3000 rpm 4ºC).  The 
final complexes then appear as a white precipitate in the tubes with a clear 
supernatant.  These tubes are then inverted to pour off the supernatant and left 
briefly to dry.  These samples are then counted on a gamma counter (Cobra 
gamma counter programme 13).  This programme initially generates a 
calibration curve from 10 standards (see below) and calculates AVP from a 
position on that curve.  Background count is also measured and taken into 
account.  Results are reported in pmol/l. 
 
QC samples 
QC samples are prepared from commercially available sources (Bio Rad 
Hypertension marker 1 and 2) and prepared at 3 dilutions. 
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Preparation of standards 
The standards are prepared from 0.5mg AVP standard (Ferring AB, Malmo, 
Sweden).  This is made into Stock AVP standard (1280pg/ml) and is stored at -
20 ºC in 0.5ml aliquots.  The Stock standard is initially made up to 2 mls to give 
a concentration of 320pg/ml.  A series of 10 tubes are prepared labeled S1 to 
10 to which 800µl of assay buffer is added.  Tube S10 then has a further 400µl 
of buffer and 400µl diluted stock standard to make up 1600µl volume.  Serial 
dilution is now performed adding 800µl from each tube in tern i.e. 800µl from 
S10 to S9, 800µl from S9 to S8. 
 
Potential errors 
This is an old assay still using antibody generated in a rabbit over 10 years ago.  
It involves multiple complex steps during extraction and the RIA process and 
additionally AVP has a very short half-life in plasma.  The method has an intra 
assay co-efficient of variation of 4% and a functional sensitivity of 0.3 pmol/l 
(laboratory data, RVI, Newcastle,UK). 
 
 
6.2.2   Copeptin assay 
The measurement is automated and carried out on a B·R·A·H·M·S KRYPTOR 
compact PLUS.  The technology used is based on TRACE™ Technology 
(Time-Resolved Amplified Cryptate Emission), which measures the signal that 
is emitted from an immunocomplex with time delay.  As this is a trademarked 
process the description in the following two paragraphs is taken from the 
product data sheet supplied by the company.  The basis of the TRACE™ 
Technology is non-radiative energy transfer from a donor (a cage-like structure 
with a terbium ion in the centre) to an acceptor, which is part of a chemical 
protein.  The proximity of donor (cryptate) and acceptor when they are part of 
an immunocomplex and the spectral overlap between donor emission and 
acceptor absorption spectra intensify the fluorescent signal of the cryptate and 
extend the life span of the acceptor signal, permitting the measurement of 
temporally delayed fluorescence. 
 
When the sample is excited with a nitrogen laser at 337 nm, the donor 
(cryptate) emits a long-life fluorescent signal in the millisecond range at 620 nm, 
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while the acceptor generates a short-life signal in the nanosecond-range at 707 
nm.  When the two components are bound in an immunocomplex, both the 
signal amplification and the prolongation of the life span of the acceptor signal 
occur at 707 nm, so that it can be measured over µ-seconds.  This long-life 
signal is proportional to the concentration of the analyte to be measured. Non-
specific signals, e.g. the signals of the short-life and unbound acceptor and the 
medium-specific interference signals conditional upon the natural fluorescence 
of the sample, are eliminated by temporal delay of the fluorescence 
measurement.  The signal generated by the cryptate at 620 nm serves as an 
internal reference and is measured simultaneously with the long-life acceptor 
signal at 707 nm which is the specific signal.  Interfering influences, e.g. from 
turbid sera, are automatically corrected by means of the internally calculated 
ratio of the intensities at these wavelengths. 
 
Technical data: 
Sample volume................................................ 50 µl 
Incubation time................................................ 14 min  
Results are given in......................................... pmol/l 
 Direct measuring range................................... 0.9…500 pmol/l  
Measuring range with automatic dilution......... 0.9…2 000 pmol/l  
Sample type.................................................... serum, plasma (EDTA, heparin)  
Kit stability on board........................................ 15 days  
Assay principle................................................ sandwich 
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6.3   Results 
Samples were available for 308 samples for AVP and 321 for Copeptin.   This is 
from a potential maximum of 328 samples.  The missing samples were a result 
of difficulties with venesection in some cases and the fact that a higher sample 
rate was achieved for copeptin is reflective of the fact that whilst 2 ml of blood is 
required for AVP assay (to give 1ml of plasma) only around 100 µl is required 
for copeptin. 
 
When this initial data was analysed there were some significant outliers (being 
more than 3 SD from the mean).  For this reason values greater than 22.36 for 
AVP and 68.72 for copeptin were excluded.  Values excluded are listed below 
(table 1) and were checked for the AVP/Copeptin ratio (mean 0.77 across all 
samples) and any other features that might identify that case as a clinical 
outlier.  Only one case had a high AVP, which was lower than a (high) copeptin, 
however this subject showed no other signs of being a clinical outlier so the 
data was excluded. 
    
Sample no. AVP (pmol/l) Copeptin (pmol/l) Action 
SL Ex 07 45.4 5.2 AVP excluded 
5200 R 10 35.4 2 AVP excluded 
5200 Ex 33 63 2.3 AVP excluded 
5200 Ex 31 27.8 13.9 AVP excluded 
4200 R  46 35.9 1.7 AVP excluded 
3500 Ex 33 31.3 87.7 AVP and 
copeptin  
excluded 
3500 Ex 23 1.7 353.1 Copeptin 
excluded 
Table 6.2:  AVP and copeptin outliers 
 
107 
 
The revised data for AVP and copeptin was distributed as shown in the table 
below (values pmol/l)  
      Kolmogorov-
Smirnov 
 n Mean Median SD Range Statistic P 
value 
AVP 301 1.87 1.40 2.29 0.1 – 
21.50 
0.260 <0.001 
Copeptin 319 5.46 3.80 5.42 0.9 – 
53.3 
0.212 <0.001 
Table 6.3:  Revised AVP and copeptin distribution data 
 
 
Both AVP and copeptin had values clustered around low levels with significant 
outliers as illustrated below.  The data for both was not normally distributed . 
 
 
Figure 6.2.   AVP value distribution (AVP in pmol/l) 
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Figure 6.3.   Copeptin (cop) value distribution (Copeptin in pmol/l) 
 
There were no significant differences between AVP and copeptin between 
males and females. 
 Male Female P Value  
AVP  
-N  
-value 
 
210 
1.4 (1.8, 0.1 – 
2.6) 
 
91 
1.8 (2.4, 0.2 – 
17.7) 
 
 
0.155 
Copeptin 
-N 
-value 
 
222 
3.9 (4.68, 0.9 – 
28.7) 
 
97 
3.1 (0.9 – 
53.3) 
 
 
0.155 
Independent samples Mann Whitney U test 
 
Table 6.4:   Distribution of AVP and copeptin by gender 
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Across all time points AVP correlated with copeptin with a Spearman’s rho 
=0.621 (p<0.0001). 
 
 
Figure 6.4   Distribution of AVP and copeptin plotted as log values for clarity. 
 
This correlation held true across the altitudes with the exception of at rest at 
4500m (3833m exercise Spearman’s rho 0.459 p=0.002, rest rho0.414 p=0.004, 
4500m exercise rho 0.812, p<0.0001, rest rho 0.295 p=0.064, 5129m exercise 
rho 0.834 p<0.0001, rest rho 0.663, p<0.0001).  
 
The relationship with exercise of copeptin was maintained at all altitudes with an 
increase from resting levels.   AVP showed a significant increase with exercise 
only at SL and 5129m.   Whilst copeptin levels increased with exercise overall 
values were significantly reduced compared to sea level values at 4500m at rest 
and exercise and at 3833m following exercise.   Copeptin showed a significant 
increase with exercise at 5129m. 
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 Sea Level  3833m 4450m 5129m P value  
Copeptin (pmol/l) 
-rest  3.5 (0.9-
13.7) 
3.3  (0.9-
13.4) 
3.2 (0.9-12.9) 3.4 (0.9-15.0) 0.48 
-exercise 5.5 (2.6-
28.4) 
4.2 (1.2-
53.3) 
3.7 (1.0-
8.7)** 
6.6 (1.0-24.5) 0.007 
AVP (pmol/l) 
-rest  0.9 (0.1-
3.3) 
0.9 (0.3-
5.9)  
1.5 (0.8-9.4) 
** 
1.5 (0.2-11.0) <0.001 
-exercise 1.9 (0.1-
21.6) 
1.1 (0.3-
17.7)* 
1.1  (0.3-
13.0) 
2.0 (0.2-13.7) 
## 
0.002 
Plasma Osmolality (mOsmol/Kg H2O) 
 -rest  286 (281- 
293) 
291(279– 
299) 
286 (276 –
298)# 
286 (281 – 
298)## 
0.002 
 
-exercise 296 (284 - 
304) 
293(281 – 
300)* 
292 (283 – 
305)** 
286 (274 – 
303)*** 
<0.001 
Data presented as median and range. P value for Kruskal-Wallis (non-parametric 
ANOVA) shown with post-test for significance: * 3833m vs SL, ** 4450m vs SL, 
***5129m vs SL; # 3833m vs. 4450m, ## 3833m vs. 5129m 
 
Table 6.5 Copeptin, AVP and Osmolality changes with rest and exercise at the 
study altitudes 
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Figure 6.5 Changes in Copetin levels (median, interquartile range) during 
exercise and rest across increase high altitude. * refers to significant difference 
(p<0.05) on paired sampling,** (P<0.001) 
 
 
 
Figure 6.6 Changes in AVP levels (median, interquartile range) during exercise 
and rest across increase high altitude. * refers to significant (p<0.05) difference 
on paired sampling ** (P<0.001) 
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Altitude (m) Sea Level 3833 4450 5129 
 N  N  N  N  
Rest 18 3.7 (2.25-
31.0) 
46 3.78 (0.75-
17.2) 
40 1.9 (0.41 
– 5.83) 
44 2.89 
(0.29 -
6.7) 
Exercise 18 4.14 (0.4-
26) 
44 4.16 (0.31 
– 31) 
42 2.98 (0.94 
– 7.6) 
42 3.45 
(1.08 – 
10.74) 
Table 6.6   Copeptin/AVP ratios 
    
There is no difference in copeptin or AVP values in the subjects developing 
AMS  or severe AMS group (table 6.7). 
 
 No AMS AMS Severe 
AMS 
P Value  
AVP  
-N  
-value 
 
192 
1.4 (0.2 – 13.7) 
 
46 
1.4 (0.2 – 
11.0) 
 
17  
1.4 (0.6 – 
17.7) 
 
 
0.55 
Copeptin 
-N 
-value 
 
206 
3.7 (0.9 – 24.5) 
 
48 
3.1 (0.9 – 
24.8) 
 
17 
5.0 (0.9-53.3) 
 
 
0.44 
 
Table 6.7 AVP and copeptin levels (pmol/L) in subjects with acute mountain 
sickness (AMS)  
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If the headache component of the LLS is examined in more detail there is no 
difference in copeptin between those with or without headache, either at all time 
points (p=0.31) or at 5129m where the copeptin is highest (p=0.556). 
 
Altitude 
(m) 
3833 4450 5129 
 
None Mod Sev None Mod Sev None Mod Sev 
Rest 23 25 0 36 11 1 19 15 9 
Exercise 18 28 2 29 17 0 31 15 1 
Table 6.8 Frequency of headache (number of observations, none = 0, moderate 
= 1, severe > 2 ) 
 
Only 3 subjects reported nausea at 5129m (copeptin values 1.3, 11.50, 13.6 v’s 
median 6.6.   These numbers are too small to interpret meaningfully. 
 
Oxygen saturations fell with ascent to altitude and were lower after exercise 
than at rest.  Mean oxygen saturations at 3833m  were 84% post exercise, 88% 
at rest (p value v’s rest value p<0.001), 4450m 82 % post exercise, 86% at rest 
(p<0.001) and at 5129m 79% after exercise and 81% at rest (p=0.014).   There 
was no correlation between SpO2 and copeptin (rho -0.073), or  AVP (rho -
0.114). 
 
Body weight was 77.0 ± 14.6 kg at sea level, 77.6 ± 13.9 kg at 3833m post 
exercise, 77.5 ± 14.0 kg at 3833 at rest, 76.9  ± 13.80 at 4450m and 76.1 ± 13.4 
kg at 5129m (figure 1). On repeated measures ANOVA this difference was 
significant between all altitudes and 5129m (p<0.0001).   This represents weight 
lost during the expedition as opposed to fluid lost during the day as osmolality 
did not change at 5129m. 
 
Cortisol values are reported in chapter 8 of this thesis.   Cortisol correlated with 
copeptin at 5129m (rho 0.358 p=0.014). 
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The mean Borg score for the trek to 3833m was 13.15 (SD 1.92), for the trek to 
4500m it was 12 (SD 1.8) and for the trek to 5129m it was 14.98 (SD 1.98).   
The trek to 5129m was perceived as significantly harder than either of the lower 
treks (p<0.0001 v’s both).   The trek to 3833 m was perceived as harder than 
the trek at 4500m (p<0.0001). 
 
 
Fig 6.7 Copeptin in the groups with Borg < 15 vs. >15 
 
If a cut off of 15 on the Borg score, a rating of “hard effort 80%” is taken then 
the median copeptin in the high group is 7.9 (n = 38 range 1.1 – 24.8) v’s 3.7 
(n=94 range 1 -24.2) p<0.0001 independent samples Mann Whitney U test) 
There is a weak but statistically significant correlation between the Borg RPE 
score at each time point and the copeptin (rho 0.245 p=0.005). 
 
If post exercise osmolality is divided according to Borg RPE category then those 
reporting a Borg > 15 have a mean osmolality of 288 vs. 291 if Borg < 15 
P=0.011 (fig 6.8). 
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Fig 6.8  Plasma osmolality (mOsmols/L) in the groups with Borg < 15 vs. >15 
 
7.4   Discussion 
The main findings of this study were that: AVP and copeptin correlate at HA; the 
AVP and copeptin response to exercise is subdued at altitude until extreme 
altitude (>5000 m) is reached; AVP and copeptin are not associated with AMS 
as assessed by LLS; AVP and copeptin secretion at HA are stimulated by non-
osmotic rather than osmotic stimuli.  The stability of copeptin would favour its 
use as a surrogate for AVP secretion in future HA field studies. 
 
The median quoted normal value for copeptin in healthy individuals is 4.2 pmol/l 
(median range 1-13.8 pmol/l).   Jochberger found values of 5.9 pmol/l (+/-2.9) in 
a population of healthy controls (although much higher values in septic patients) 
(Jochberger, Morgenthaler et al. 2006). This compares well with the data 
presented ranging from 3.2 to 6.6 pmol/l, with a sea level median value of 3.5 
pmol/l.   This data is unique in that it demonstrates equal copeptin values in 
males and females.   Other data shows a difference in values between males 
and females (Morgenthaler, Struck et al. 2006, Bhandari, Loke et al. 2009).   
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Bhandari found that males had a higher value than females [median (range): 
4.3 (0.4-44.3) compared with 3.2 (1.0-14.8) pmol/l; P<0.001].   His study 
population were from a heart failure screening project although cardiac disease 
was excluded.   Morgenthaler published figures of 5.2 pmol/l for males and 3.7 
pmol/l for females, the age of his subjects is not clear.  The population in this 
study is young and fit and that may explain the difference. 
 
Across all time points AVP and copeptin correlated strongly.   This is in keeping 
with the correlations quoted in other papers (Jochberger, Morgenthaler et al. 
2006, Morgenthaler, Struck et al. 2006, Jochberger, Velik-Salchner et al. 2009, 
Balanescu, Kopp et al. 2011, Hew-Butler, Hoffman et al. 2011) and shows that 
copeptin is a useful surrogate for AVP in the challenging environment of a HA 
field study.   In other studies copeptin and AVP have correlated more highly in 
sepsis rather than at rest (Jochberger, Morgenthaler et al. 2006) i.e. when there 
was more stimulus to AVP release. The strongest correlation we found was at 
5129m after exercise, when copeptin was at its’ highest value and the weakest 
when copeptin was at its’ lowest value (4450m rest). 
  
A significant finding is that copeptin did not rise outside the normal range 
despite very significant physiological stress.   Copeptin levels in patients with 
systemic inflammatory response syndrome are reported at a mean (sd) of 88 
(+/- 89) pmol/l (Jochberger, Morgenthaler et al. 2006).  In fact the median 
copeptin at rest was lower than that at sea level (statistically significant at 
4450m) and lower than sea level following exercise at 3833m and 4450m.  This 
damping down of the copeptin/AVP response most probably represents an 
adaptive neurohumoral response to HA given the detrimental effects of an 
antidiuresis during acclimatisation to altitude.    At higher altitudes (5129m) 
copeptin rises to above the equivalent value at sea level.  Our hypothesis is that 
this is due to the extreme physiological stress of a perceived hard trek over-
riding this damping down of the copeptin response resulting in a normal post 
exercise rise in copeptin, similar to that seen at sea level.  This is similar to the 
change that is seen in cortisol with suppression of release at rest and post 
exercise at 4270m but a significant rise at 5150m (Woods, Davison et al. 2012) 
and the suppression in aldosterone secretion at similar altitudes (Bouissou, Fiet 
et al. 1988).   We did see a large rise in post exercise cortisol at 5129m at a 
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time of day when we would have expected a dip due to diurnal variation.   It is 
significant that this occurred in tandem with a rise in copeptin (link copep and 
cortisol or AVP and cortisol) and was more marked with those subjects who had 
exerted themselves hard.    This shows a pronounced stress response to hard 
exertion at extreme altitude.  
 
The fact that we did not observe a rise in osmolality over time at altitude 
conflicts with other published data.  In a series of 7 subjects osmolality 
increased to 299.6 +/- 2.2 mOsmol/l over 2 days exposure to 4300m.   Despite 
this AVP did not change, suggesting suppression of the AVP response (Maresh, 
Kraemer et al. 2004).  Bestle found that 8 days at 4559m increased plasma 
osmolality (+5.3 +/- 1.4 mOsmol/kgH2O) and decreased AVP from 1.14 +/- 0.16 
to 0.38 +/- 0.06 pg/ml (Bestle, Olsen et al. 2002).  This study was a small 
number of subjects (n=8) and transport to the Magherita hut where the research 
was conducted took place by helicopter.  As long ago as 1984 Porchet showed 
a marked decrease in AVP in 15 male workers ascending 2000m by cable car.  
AVP went from 3.8 (+/_0.4) pg/ml to 0.9 (+/-0.1) pg/ml within 2 hours of 
reaching altitude (Porchet, Contat et al. 1984).  Despite this osmolality did not 
change.  This ascent required no physical exertion and the workers were 
presumably well acclimatised to the altitude which may explain the pronounced 
fall in AVP which was not offset by any stress response.   Our study is the 
largest study of its’ kind involving the real world stimulus of trekking exercise 
and allowing subjects access to fluids ad libitum.   The data shows that exercise 
stimulates a rise in osmolality and copeptin at 3833m and at 4500m.  The trek 
to 5129m was perceived to be much more strenuous although the horizontal 
distance covered was only 1.59km.  Why osmolality didn’t rise on the ascent to 
5129m compared with that to 4500m is interesting.   One possible explanation 
is that the trek to 3833m and 4500m was preceded by a 3 hour coach journey 
and took place during the heat of the day at lower altitude whereas the trek to 
5129m took place in cooler conditions from a basecamp with all subjects well 
hydrated.  In fact the finding was that osmolality was reduced in those reporting 
a high Borg RPE whereas copeptin increased.  This seems counterintuitive but 
may be because those exercising at a higher intensity may have taken on-board 
more fluids during the trek.   Although body mass fell at 5129m this was not due 
to dehydration as osmolality was not increased.  This was most likely due to 
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progressive weight loss caused by anorexia at high altitude.  The significant rise 
in AVP and copeptin at 5129 m following exercise was the greatest rise seen at 
any altitude yet was clearly due to non-osmotic stimulation.  This was perceived 
by the subjects as the hardest trek during the study period.  Possible non 
osmotic causes behind the copeptin and AVP rise may include exertional 
headache or nausea, anxiety or the stress of a steep climb to a new altitude.  
Whilst there was no relationship between copeptin or AVP and AMS, nausea or 
headache as recorded at the end of the day, the effect of transient exercise 
effects (in terms of nausea etc) cannot be entirely discounted.   
 
The change in the neuroendocrine response above 5000m is of interest.   It is 
widely acknowledged that whilst most people can acclimatise to altitudes up to 
5000m not everyone can acclimatise beyond that. It is unlikely to be pure 
coincidence that 5000 m is also the altitude of the highest permanent human 
habitation.   Anand reports a clinical picture of congestive cardiac failure 
occurring in otherwise fit Indian Army soldiers deployed at extreme altitudes for 
long periods (Anand, Chandrashekhar et al. 1993).  These soldiers 
demonstrated fluid retention and increases in cortisol levels.  His conclusion 
was that the neuroendocrine response to the stress of cold, hypoxia and 
exertion was important in the development of this “subacute mountain 
sickness”.   Our findings support this hypothesis with the rise in copeptin not 
occurring as a result of changes in osmolality and presumably reflecting 
neuroendocrine stress.  Furthermore the rise in cortisol (and associated AVP 
rise) would create an anti-diuresis which may be the mechanism behind 
Anand’s observations.   Many studies are conducted at altitudes below 5000m 
with or without exercise which may explain inconsistencies in the published 
data.  In chamber studies involving a 2 hour ascent to and 2 hour stay at 6000m 
equivalent altitude (without an exercise stimulus) Okazaki found a fourfold 
increase in AVP associated with a rise in cortisol and osmolality (Okazaki, 
Tamura et al. 1984).   In contrast Blume (Blume, Boyer et al. 1984) found no 
change in AVP during a prolonged period at 6300m on a mountaineering 
expedition to the Everest region. However, these samples were taken in the 
morning, after a nights rest and in well acclimatised individuals.  In fact Blume’s 
data suggest a suppression of AVP response (as osmolality increased to 302 
mOsmol/KgH2O) even at extreme altitude.   
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In this dataset oxygen saturation is only very weakly correlated with LLS (n=273 
rho = -0.135 p=0.026) and not at all with copeptin or cortisol.  This fits the 
published evidence that oxygen saturations are not predictive of AMS as 
discussed in Chapter 8.1.    
 
It appears that the main stressor is that of exercise and the exercise intensity.   
There was a highly significant difference between the median values of copeptin 
dependant on the Borg RPE rating.   This data suggests that with increased 
exercise in hypoxia there is a significant stress response which leads to an 
increase in AVP and copeptin (regardless of plasma osmolality).  This overrides 
the suppression of antidiuretic hormones seen at lower altitudes.  Studies which 
demonstrated a rise in osmolality and decrease in AVP had no significant 
exercise stress (Porchet, Contat et al. 1984, Bestle, Olsen et al. 2002).  Fluid 
retention is a recognised part of AMS and it may be that this stress response is 
key in leading to fluid retention and AMS. 
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Summary 
Other markers may be of use in diagnosing acute mountain illness based on 
knowledge of the mechanism behind the illness.  Cardiac troponin (hs CTnT) 
rises with exercise, at HA and with increased PA pressures due to an increase in 
myocardial stress.  Neutrophil gelatinase associated lipocalin (NGAL) is a protein 
which is expressed by lung, renal tissue and gut during hypoxia. Earlier work by 
the DMS has shown a rise in NGAL with HA.  Highly selective C reactive protein 
(hs-CRP) is an acute phase protein which rises to reflect inflammation which may 
be an integral part of the disease process in altitude illness.  During the field study 
in Bolivia assays were carried out for troponin (hs-cTnT), NGAL and hs-CRP.  
After exertion at sea level, 3833m and 5129m a significant number of subjects 
had a hs-cTnT above the upper limit of normal (6, 14, 11 respectively).  cTnT was 
significantly higher in those with a PASP >40 mm Hg than those without: (cTnT: 
13.8+/-21 vs 7.8+/-6.5, p=0.018).  ROC analysis (to investigate the utility of cTnT 
in detecting a high PASP) revealed an AUC of 0.607 (95% CI 0.520-0.693, 
p=0.018).  There was a statistically significant increase in hs-CRP with increasing 
altitude but no correlation with AMS.  NGAL did not change at any altitude, 
possibly due to changes in the assay compared to the previous investigation at 
altitude.  Of these the three biomarkers investigated hs-cTnT shows most 
promise as a biomarker for altitude illness. 
 
7.1   Introduction 
Key processes involved in the development of high altitude illness are a high PA 
pressure (HAPE) and inflammation (AMS).  Troponin rises with exercise both of 
long duration and shorter more intense activity.  O’Hanlon found that 11 of 17 
athletes completing a marathon run had a rise in troponin above the cut off for 
myocardial infarction at 6 hours post-race (O'Hanlon, Wilson et al. 2010), whilst 
other published data show a rise with 30 mins of high intensity exercise (Shave, 
Ross et al. 2010).  This is significant as AMS is thought to occur in association 
with strenuous exercise.  There is little work showing the cTnT response to 
exercise in hypoxia when PASP will be raised.  Recent work has shown a rise in 
cardiac troponin with maximal exercise (symptom limited) in patients with 
pulmonary hypertension (Volkers, Rohde et al. 2013).  In a different study in 
patients with raised PASP, hs-cTnT correlated with right ventricular systolic 
strain and was raised in 90.9% of patients with a PA pressure above 45mmHG 
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(n=55) (Filusch, Giannitsis et al. 2010).  This evidence suggests that hs-cTnT 
may be useful as a marker for raised PASP (a key mechanism in developing 
HAPE) and may reflect poor tissue oxygenation warranting further investigation 
as a biomarker for altitude illness.    
 
NGAL is a 25 kDa peptide, part of the lipocalin family of small soluble proteins.  
It is produced in a number of human tissues, notably the distal nephron but also 
in the lung (Cowland and Borregaard 1997, Borregaard N 2006).  NGAL rises 
rapidly in the nephron in response to a renal insult and an NGAL ≥ 150 ng/ml 
following acute kidney injury (AKI) is predictive of acute renal failure (ARF) well 
before creatinine has risen (Haase, Bellomo et al. 2010). NGAL is also an acute 
phase protein (Liu and Nilsen-Hamilton 1995), has a role in inflammation 
(Borregaard N 2006, Roudkenar, Halabian et al. 2009) and is up-regulated in 
the lung during inflammation (Cowland and Borregaard 1997, Cowland, 
Sorensen et al. 2003, Chan, Liu et al. 2009). NGAL is also known to rise in 
conditions associated with oxidative stress (Roudkenar, Halabian et al. 2011) 
(Bolignano, Coppolino et al. 2010) and oxidative stress has been implicated in 
AMS (Bailey, Davies et al. 2001, Bailey, Evans et al. 2009). NGAL may 
therefore be a useful biomarker increasing at HA secondary to these various 
stimuli and that the magnitude of any increase might relate to the presence of 
AMS.  
 
During previous studies we have investigated a cohort of trekkers from 2 
expeditions to HA (Mellor, Boos et al. 2013).  In order to clarify the relative 
contribution of AMS, hypoxia or exercise to NGAL levels we also studied a 
cohort pre- and post-exercise at near sea-level and a further cohort exposed to 
acute normobaric hypoxia. 
 
The treks involved a total of 52 subjects (32 on the first trek, 20 on the second) 
in the Khumbu region of Nepal.  Blood samples were taken at 3 study altitudes: 
on day 2 at 3400 m, day 6 at 4270 m and day 10 at 5150 m (following ascent to 
Everest Base Camp at 5364 m trek 1 and Kala Patthar 5643m trek 2).  As in 
Bolivia samples in this study were collected immediately following a day 
trekking (“post-exercise”) to the study altitude. 
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In a separate hypoxic chamber study 14 subjects underwent a 3 hour exposure 
to normobaric hypoxia (FiO2 11.6%, equivalent to 4800 m altitude). This exposure 
included a 5 minute step-test (step height of 25cm, 1 complete step every 2 
seconds) at 95 minutes. NGAL was assayed at baseline and after 180 minutes 
of hypoxic exposure. 
 
As a control a group of 22 subjects performed a trek at near SL with an ascent 
from sea-level to 1085m over 6 hours (an equivalent gain in altitude and duration 
of exercise as to that experienced on a trekking day in Nepal).  
The results of these studies can be summarized as follows: 
 
 A near sea level ascent produced no significant (p=0.084) rise in NGAL.  
SL NGAL was 63.9+/-10.6 (ng/ml, mean+/-sd, range 60-104) and post-
exercise NGAL was 71.2+/-13.8 (ng/ml, mean+/-sd, range 60-100).  
 Ascent to 5150m was made by 46 out of the 52 subjects.  SpO2 (%, 
mean+/-sem) dropped from 96.7+/-1.6 at 1300 m to 84.4+/-5.4 and 79.2+/-
7.3 at 4270 and 5150 m respectively (p<0.001). There was a moderate 
inverse correlation between NGAL and SpO2 at 5150 m (r=-0.477, 
p=0.001) with a weaker inverse correlation between NGAL and SpO2 at 
4270 m (r=-0.340, p=0.019).  
 There was a significant change in NGAL (RM ANOVA) with ascent both at 
rest (p=0.007) and post-exercise (p=0.001) (figure 7.1).  
 Although normobaric hypoxia led to a significant fall in oxygen saturations 
SpO2, (%, mean+/-sem) from 98.8+/-0.4 at baseline to a nadir of 79.3+/-
5.2 (p<0.001), however, NGAL (ng/ml, mean+/-sd, range) showed no 
change between baseline and 180 minutes: 62.8+/-26 (29-80) vs 66.7+/-
25 (27-84), p=0.538. 
 There was a significant difference between NGAL depending on the 
presence or absence of AMS at 5150 m; no AMS (n=23) (NGAL: 123.6+/-
11.6); mild AMS (n=16) (NGAL: 171.4+/-18.5, p=0.026 for NGAL versus 
no AMS); severe AMS (n=7) (NGAL: 200.7+/-33.5, p=0.009 for NGAL 
versus no AMS).  
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Figure 7.1  NGAL changes with ascent in Nepal (taken from Mellor et al 
Neutrophil Gelatinase Associated Lipocalin: It’s response to Hypoxia and 
Association with Acute Mountain Sickness; Disease Markers. 35(2013), (5) 537-
542.) 
 
NGAL also rises with oxidative stress which is increased by exercise (Bakonyi 
and Radak 2004) and HA-induced oxidative stress (Huang, Han et al. 2008) has 
been implicated in AMS (Bailey, Davies et al. 2001). As such it is interesting to 
note that we found a higher NGAL following exercise and in those with AMS at 
the highest altitude.  
 
C reactive protein (CRP) is an annular (ring-shaped), pentameric protein found 
in the blood plasma, the levels of which rise in response to inflammation (i.e., is 
an acute-phase protein).  Acute mountain sickness is more likely to occur in the 
presence of infection and in itself, may be an inflammatory process (Bailey, 
Kleger et al. 2004).  Unsurprisingly CRP has been shown to increase with 
altitude, Hartmann found an increase at 3458m and 4559m (with no associated 
HAPE) (Hartmann, Tschop et al. 2000).  Highly selective CRP (hs-CRP) is a 
more recently developed assay which is more sensitive to show a change within 
the normal range of values.  hs-CRP has shown an association with the risk of a 
future cardiovascular event in large epidemiological studies (Ridker 2001).  
There is limited data to suggest hs-CRP may be associated with AMS from a 
study of 32 climbers ascending to 2900m from sea level  (Shintaro, Yuji et al. 
NGAL with ascent at rest and post-exercise
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2006).  The authors found plasma levels of hs-CRP in AMS were significantly 
higher than those in healthy climbers after climbing (2.433 +/- 0.831 mg/L vs 
0.914+/- 0.272 mg/L, P<0.05).   
 
Hypothesis 
Inflammation and/or rises in PASP occur with the development of high altitude 
illness and would lead to a detectable rise in hs-cTnT, NGAL or hs-CRP. 
 
7.2   Methods 
The study methodology has been previously explained.  Venous blood was 
sampled from the study group on reaching a new altitude after a trek (exercise) 
or the following day (rest).  All assays were stored at -20 ºC until they could be 
transferred back to the UK and stored at -80 ºC until assayed. 
 
7.2.1   Assays 
 Highly sensitive cardiac troponin T (hs-cTnT) assay was performed using an 
electro-chemiluminescence immunoassay (ECLIA) on a Cobas Analyser (Roche 
Diagnostics, Mannheim, Germany). This assay has a range from 3-10000 ng/L. 
The upper reference limit (99th percentile) for this assay in healthy volunteers is 
14 ng/L (pg/mL). 
 
NGAL was analysed in the field on a Biosite Triage point of care monitor (Alere 
Ltd, Stockport, UK) using a Triage cardiorenal test kit.   The Triage® cardiorenal 
test is a point-of-care, fluorescence-based immunoassay used which gives a 
rapid (15 minutes) quantitative measurement of NGAL in a range from 15 to 1,300 
ng/ml. 
 
Hs-CRP was assayed using a commercially available, highly-sensitive, 
immunoturbidimetric assay (Roche diagnostics) was used to measure CRP on 
samples taken at the same time-points as the NPs.  This assay has a measuring 
range of 0.1-300 mg/L and a between run coefficient of variation between 2.5 and 
5.7%. 
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7.2.2   Statistical analysis 
For statistical calculations the software package SPSS 21.0 was used. Subjects 
were excluded who took drugs to aid acclimatization (n=3). Parametric or non-
parametric statistical tests were applied after performing the Shapiro-Wilks 
statistic. 
 
Changes in dependent variables between altitudes were initially tested by 
Student’s paired t test or Wilcoxon signed ranks test.  For independent variables 
an independent-samples t test or Mann Whitney test was used.  Either a within 
subjects ANOVA or a Friedman test was performed to investigate any serial 
changes in measures (eg PASP or cTnT) with ascent.  A correlation analysis 
between NGAL and SpO2 was performed using Spearman’s rank correlation. 
 As with the BNP/PASP investigation described in the preceding chapter data 
were analysed according to a PASP cut-off of 40mmHg.  As hs cTnT may rise 
with cardiac strain a ROC (receiver operating characteristic) analysis was done 
to investigate the utility of hs-cTnT in identifying a PASP >40 mmHg and 
AMS/severe AMS. 
 
A p value <0.05 was considered significant throughout. 
 
7.3 Results 
All data presented as mean (sd, +/- range where appropriate). The subjects were 
35.2±9.1 years old, 175.5±9.5 cm in height and 77.5±13.9 kg in weight. 45 
subjects reached the highest study altitude (5129 m).  
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Table 7.1  Biomarkers at each altitude 
 Altitude (m) Sea Level 3833 4450 5129 
SpO2 Rest 98 (1.34, 94-99) 88 (4.2, 75–93) 86 (4.96, 62-93) 81 (4.4, 66-90) 
 Exercise 97 (1.53, 94-99) 84 (4.95, 71-94) 81 (6.28, 53-90) 79 (4.4, 68-88) 
PASP (mmHg) Rest 20.2 (7.0, 10-34.4) 27.2 (10.8, 12-54) 32.5 (8.5, 17-56) 33.2 (9.1, 17-54) 
Exercise 23.1 (6.4, 13.1-38) 29.8 (11.6, 12-58) 31.5 (9.8, 16.7-
63) 
33.9 (11.6, 17-63) 
hs-cTnT (ng/l)  
 
Rest 5.0 (2, 3-10.3) 7.3 (5.5, 3-37) 6.1 (3.3, 3-20) 8.2 (7.0, 3-44) 
Exercise 14.4 (17.0, 4-69) 11.7 (8.5, 3-44) 6.9 (3.7, 3-20) 13.7 (22.0 3-120) 
NGAL (ng/ml) Rest 42.9 (13.6,  (29-80) 27.0 ( 6.9, 15 – 56) 29.2 (13.6, 15 –
77) 
48.7 (30.4, 15 – 147) 
Exercise 46.8 (13.6, 27-84) 34.2 (9.7, 21.2 – 
71) 
31.0 (10.2, 17– 
65) 
28 (12.4, 15 – 61) 
hsCRP (mg/l)  Rest 1.43 (1.7, 0.28-7.29) 3.75 (3.6, 0.57-
6.47) 
9.1 (15.9, 0.39-
62.28) 
7.46 (21.3, 0.34-124.02) 
Exercise 1.36 (1.6, 0.26-7.04) 1.71 (2.6, 0.29-
17.53) 
6.1 (10.6, 0.46-
47.62) 
7.35 (18.3, 0.28-93.68) 
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7.3.1   hs-cTnT 
Repeated measures analysis showed a significant change in cTnT at HA (p<0.001, 
table 7.1).  Peak values were seen after exercise at SL and after trekking at 5129 m.  
Subjects with a cTnT above the upper limit of normal (ULN, 14 ng/l): SL rest: 0; SL 
post-exercise: 6; 3833 m post-trek: 14; 3833 m rest: 4; 4450 m post-trek: 2; 4450 m 
rest: 2; 5129 m post-trek: 11; 5129 m rest: 7.  cTnT was significantly higher in those 
with a PASP >40 mm Hg than those without: (cTnT: 13.8+/-21 vs 7.8+/-6.5, 
p=0.018).  ROC analysis (to investigate the utility of cTnT in detecting a high PASP) 
revealed an AUC of 0.607 (95% CI 0.520-0.693, p=0.018), a troponin of 7.13 ng/l 
had a sensitivity of 60% and a sensitivity of 63.7% of detecting a high PASP.  ROC 
analysis to investigate the utility of cTnT in detecting AMS showed that cTnT was of 
no value with an AUC of 0.466 (95% CI 0.382 – 0.55). 
 
7.3.2   NGAL 
Repeated measure analysis showed a significant rise with NGAL with altitude 
(p<0.001), pairwise comparison showed this to be a rise from 4450m to 5129m 
(mean 30.5ng/mL vs. 37.9 ng/mL).  Across all time points there was no correlation 
between NGAL and oxygenation (as measured as SpO2) Spearman rho -0.032 p = 
0.604. In the group with AMS (n=65 LLS>3) median NGAL was 28 (15-147) whereas 
in the group with no AMS (n=201) median NGAL was 30 (15-98) (p=0.899).   In those 
with severe AMS (n= 28) median NGAL was 29 (15 – 60) v’s 29 (15 – 147) (p=0.814). 
 
7.3.3   hs-CRP 
Repeated measures analysis showed a significant change in hs-CRP at HA 
(p<0.001), table 6.1.  Overall there was a weak correlation between hs-CRP and NT-
proBNP (rho=0.367, p<0.001) and BNP (rho=0.263, p<0.001).  However, there was 
no difference in hs-CRP according to presence or absence of AMS (6.3+/-19 vs. 
5.6+/-12 respectively) or severe AMS (6.3+/-15 vs. 5.7+/-14 respectively). 
 
There was correlation between hs cTnT and NTPro-BNP (rho 0.389 p<0.001), no 
correlation between hs-CRP and cTnT but a weak correlation between hs-CRP and 
NT-proBNP (rho 0.195 p=0.001). 
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7.4   Discussion 
This significant cohort at HA demonstrates cTnT are higher in those with a high 
PASP and exercise, even of short duration at HA, was a significant stimulus to cTnT 
release.  
 
It has previously been reported that at SL exercise stimulates hs-cTnT release 
(Shave, Ross et al. 2010, Legaz-Arrese, George et al. 2011, Duttaroy, Thorell et al. 
2012, Eijsvogels, Veltmeijer et al. 2012).  We also found an exercise-induced rise at 
SL, 3833 m and 5129 m. We did not see a rise in hs-cTnT at 4450 m but the exercise 
stimulus was perceived to be mild.  Although the trek to 5129 m was shorter than 
that to 4450 m it was of a greater intensity and physically more strenuous.  It would 
seem that exercise intensity, whether over long (30-50 km walking) (Eijsvogels, 
Veltmeijer et al. 2012) or short duration, (high intensity over 30-60 mins) (Shave, 
Ross et al. 2010, Duttaroy, Thorell et al. 2012) is key to the stimulation of cTnT 
release.  We also found significantly higher cTnT in those with a high PASP. Similar 
to the relation between NPs and PASP further work is needed in symptomatic 
subjects at HA to evaluate the use of cTnT in identifying those with an abnormally 
high PASP.  Whether the cTnT release we have seen is secondary to increased 
membrane permeability or true myocardial necrosis remains to be elucidated but it 
is noteworthy that several participants demonstrated a cTnT in the range normally 
associated with myocardial infarction (ULN 14ng/L) (Thygesen, Alpert et al. 2012). 
 
The hs-CRP results found on this study were consistent with those found at lower 
altitude by Shintaro.  What this data shows is an increase in hs-CRP with increasing 
altitude and increasing physiological stress.  The difficulty is in elucidating what is a 
normal response and what is pathological.    
To use the parallel of hs-CRP in cardiology multiple large epidemiological studies 
have been used to compile risk based on stratification of hs-CRP results in 
apparently normal individuals (table 7.2 and figure 7.2). 
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Quintile Range hsCRP (mg/dl) Risk estimate 
1 0.01–0.07 Low 
2 0.07–0.11 Mild 
3 0.12–0.19 Moderate 
4 0.20–0.38 High 
5 0.38–1.50 Highest 
 
 
Table and figure 7.2.  Relative risk of cardiovascular event depending on quintile of 
hs-CRP (from Ridker, Circulation 2001). 
This data is compiled on large population studies of between five and 22 thousand 
individuals (Ridker 2001).  Clearly performing such studies on populations at HA is 
practically impossible. 
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One disappointment with this data was the lack of NGAL response to HA.  Although 
there was a statistically significant difference at 5150m this was a very small 
increase.  Our previous data in 2011 had shown a strong rise in NGAL with AMS at 
5150m and NGAL values above 100ng/ml with exercise at all altitudes above 1400m.  
There are good theoretical reasons why NGAL may be an attractive biomarker to 
use.  Investigation with Alere, who make the point of care assay we used showed 
that they had changed the assay from a competitive assay to a sandwich assay.  
This has been refined from the first generation to a mammalian (rather than bacterial) 
antibody system.  The new test employs two antibodies that have been selected not 
to recognize or bind to NGAL complexes (NGAL-MMP-9 heterodimer and NGAL 
homodimer forms) and is more specific for renally expressed NGAL.  As renal failure 
is not a feature of high altitude illness it is not surprising we saw no change in NGAL.  
NGAL is also released from lung tissue but this would not be detected with the newer 
assay.  A range of other NGAL antibodies are commercially available and this may 
be a future route of investigation. 
It seems likely that the main benefit of point of care testing of this nature may be to 
rule out severe illness.  As more systems become available a panel of markers may 
provide greater specificity and sensitivity than one alone and is worthy of future 
investigation.  One finding of interest is that there was correlation between hs cTnT 
and NTPro-BNP (rho 0.389 p<0.001) this suggests a common mechanism leading 
to increases in both these markers (i.e. increasing myocardial stress).  There was 
no correlation between hs-CRP and cTnT but a weak correlation (rho 0.195 p=0.001) 
with NTPro-BNP (as discussed previously there is increasing evidence that BNP 
rises in inflammatory conditions).  This suggests that there may be value in 
combining both hs-CRP and either NTPro-BNP or hs-cTnT.  
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Summary 
Exercise at sea level brings about increases in AVP, cortisol and catecholamines 
(Melin, Eclache et al. 1980, Zouhal, Jacob et al. 2008).  This is an adaptation to 
improve cardiovascular performance and retain salt and water during prolonged 
exercise.  At high altitude there is an initial excretion of salt and water related to a 
decrease in aldosterone (Bartsch, Shaw et al. 1988) stimulated by hypoxia.  As 
fluid retention is a key feature of AMS and related to the severity of AMS (Loeppky, 
Icenogle et al. 2005) it follows that there may be significant interaction between 
exercise, fluid retention and AMS. 
 
This chapter investigates the changes recorded in physiological variables, 
catecholamines and cortisol during the field study in Bolivia. 
 
Hypothesis 
Changes in stress hormones associated with exercise are key in the pathogenesis 
of altitude illness 
 
8.1   Basic Physiological data  
8.1.1   Methods 
Data was collected on a daily basis throughout the first 10 days of the trek.  This 
daily data included heart rate, SpO2, respiratory rate, blood pressure, LLS, AMSc. 
Blood pressure was monitored on an automated blood pressure cuff (Omron M2 
basic, Omron Healthcare, Kyoto, Japan).  This had not been validated prior to the 
expedition although data collected on an earlier expedition using a manual aneroid 
sphygmomanometer was comparable and the cuff had been used successful on 2 
previous expeditions.  Recent data has been published validating a very similar 
automated cuff Omron HEM-7201 (Cho, Tian et al. 2013).  Pulse oximetry is a non-
invasive measure of arterial oxygen saturation.  The device uses the fact that 
oxygenated and reduced blood absorb different amounts of light at wavelengths 
between 650 and 950 nm.  By switching on and off rapidly the proportion of the 
signal which changes due to the pulsatile flow of arterial blood can be analysed.  
The precision of pulse oximeters is within + 2-3% when the SaO2 is 90% or more; 
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the precision is thus + 4- 6% if a 95% confidence interval (+ 2 SD) is desired. For 
example, if the SpO2 is 94%, then the true SaO2 may be as low as 88% or as high 
as 100% for 95% of the measurements.  Pulse oximeters are also only calibrated 
to be accurate in the clinical range (70-100%) and at extreme altitude values may 
fall outside this range giving a greater discrepancy between SpO2 and arterial 
oxygen content (SaO2).  The device used for the field study was a Nellcor N-20P 
pulse oximeter (Nellcor Puritan Bennett Ltd, Coventry.UK), this is designed to 
operate over the range of saturation 70-100% (+/- 2%) and heart rate range 20-250 
bpm.  The design specification is to function up to 6300m.  In a trial of similar 
oximeters a mean SpO2 of 86.7+/- 8.6% compares with a SaO2 of 87.2% +/- 11% 
at 2240m (Torre-Bouscoulet, Chavez-Plascencia et al. 2006).  SpO2 decreases 
with altitude, this has been shown many times before.  This is expected as 
available inspired oxygen partial pressure (PiO2) decreases with barometric 
pressure.  The Silver Hut experiments performed in the early 1960’s demonstrated 
that SpO2 fell from 67% at rest to 63% and 56% with work rates of 300 Kg-m/min 
and 900 Kg-m/min respectively at 5800m (West, Lahiri et al. 1962).  Previous work 
by the DMS)conducted on Mt Aconcagua in Argentina showed an SpO2 of 84% at 
4250m falling to 77% following a very brief (1 minute) step test (Hooper, Levett et 
al. 2010).   Respiratory rate was observed by one of the other research subjects 
and measured over a 30 second period (multiplied by 2 to give a rate per minute).  
LLS and AMSc scores were recorded as reported elsewhere in this thesis.
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 Altitude (m) Sea Level 3833 4450 5129 P (change with 
altitude) 
SPO2 Rest 98 (1.34, 94-99) 88 (4.2, 75–93) 86 (4.96, 62-
93) 
81 (4.4, 66-90) <0.001 
 Exercise 97 (1.53, 94-99) 84 (4.95, 71-94) 81 (6.28, 53-
90) 
79 (4.4, 68-88) <0.001 
Heart rate 
(bpm)  
Rest 60 (6.10, 50-71) 76 (11.57, 51-
102) 
82 (12.41, 45-
120) 
88 (12.74, 65-120) <0.001 
Exercise 68 (12.75, 43-98) 83 (12.43, (56-
120) 
88 (13.25, 58-
110) 
95 (15.27, 66-129) <0.001 
Systolic 
blood 
pressure 
(mmHg) 
Rest 135 (11.10, 109-
150) 
136 (11.16, 111-
161) 
134 (11.43, 
117-159) 
139 (13.02, 110-
168) 
0.12 
Exercise 133 (12.84, 107-
164) 
134 (13.59, 110-
174) 
135 (14.3, 
103-171) 
131 (12.66, 88-159) 0.651 
Diastolic BP 
(mmHg) 
Rest 73 (8.04, 56-90) 83 (9.13, 64-
109) 
86 (9.11, 69-
111) 
86 (11.20, 58-113) <0.001 
Exercise 72 (6.59, 62-83) 83 (8.26, 67-
104) 
88 (10.26, 71-
112) 
83 (8.82, 52-109) <0.001 
Respiratory 
rate (bpm) 
Rest 15 (2.44, 12-20) 17 (3.40, 12-28) 17 (3.12, 12-
28) 
19 (3.64, 12-28) 0.001 
Exercise 15 (2.62, 12-20) 18 (3.21, 12-26) 18 (3.03, 14-
30) 
21 (5.45, 12-40) <0.001 
Table 8.1:  Physiological changes at rest and post exercise with altitude (Bolivia field study)
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8.1.2   Results 
The changes in basic physiological variables are presented in table 8.1. 
The change in SpO2 with altitude was significant (p <0.001 across all altitudes at 
rest and after exercise Kruskal-Wallis).  When tested between levels (Rest, 
Exercise 3833 v 4450 p=0.001 and p= 0.005 4450 v’s 5129 p<0.001 and p=0.001) 
and significant for the change with exercise 3833m p<0.001, 4450m p<0.001 and 
5129m p=0.011. 
 
The change of heart rate with altitude was significant with altitude at all times and 
between rest values and exercise values with increasing altitude (p<0.001 for all). 
Systolic blood pressure did not change significantly whereas diastolic blood 
pressure changed significantly with altitude in both the resting and post exercise 
states (p<0.001).   
 
The changes in respiratory rate increased significantly with altitude p<0.001 in all 
conditions and for rest values p=0.001 and exercise values p<0.001.   
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Figure 8.1  Changes in SpO2 with changes in altitude. 
Overall in the data recorded in Bolivia there was a very weak, although statistically 
significant correlation between SpO2 and LLS recorded at all time points (n=273 
rho = -0.135 p=0.026).  The same very weak correlation was evident between the 
SpO2 after the exercise stimulus with LLS at rest the following day (n=135 
Spearman’s rho = -0.176 p=0.041) and between the LLS and SpO2 at rest the 
following day (n=139, Spearman’s rho -0.187 p = 0.027).   
 
8.1.3   Discussion 
An increase in minute ventilation is an early response to hypoxia and a failure to 
increase ventilation has been implicated in AMS (King and Robinson 1972, 
Hackett, Rennie et al. 1982).  Measuring respiration was performed by observation 
post exercise or at rest and so extremes of ventilatory effort with exertion would 
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have been missed.  The limited observations within a narrow range of results may 
explain the lack of statistical significance.     
 
It is worth noting that the heart rate and SpO2 recorded for exercise was actually 
taken at the end exercise so the nadir of saturation and peak heart rate would have 
been quite different.  The rest values were taken the following day after a night at 
the new altitude so improvement will be in part recovery from the exercise of the 
ascent the previous day and in part related to adaptation to the new altitude. 
 
The data on whether or not a low oxygen saturation correlates with AMS or success 
on a climb is mixed with a number of authors finding a predictive value (Roeggla, 
Roeggla et al. 1996, Roach, Greene et al. 1998, Basnyat, Lemaster et al. 1999, 
Burtscher, Flatz et al. 2004, Koehle, Guenette et al. 2009, Karinen, Peltonen et al. 
2010, Lazio, Van Roo et al. 2010, Major, Hogan et al 2012) and some finding no 
relationship between a low SpO2 and altitude illness (Roach, Houston et al. 1995, 
O'Connor, Dubowitz et al. 2004, Davies, Kalson et al. 2009).  This is not surprising 
given the potential differences between SpO2 and SaO2 (see above) and the fact 
that most of these studies have been observational and not blinded.  If a low SpO2 
reading is regarded as dangerous and subjects advised to rest or turn back then the 
result becomes self-fulfilling.  Interestingly, at the extreme, Grocott reported a 
climber returning from Everest summit with an SaO2 of 34.4% who felt well and was 
not suffering from altitude illness (Grocott, Martin et al. 2009).  Those with better 
oxygenation the following morning could be assumed to be adapting better and 
therefore not suffering AMS. 
 
8.2   Catecholamines 
8.2.1   Normal physiology  
The adrenal glands produce hormones involved in the body’s “stress response”.   
Catecholamines (epinephrine and norepinephrine) are secreted by the medulla, 
whilst the cortex secretes cortisol.  Catecholamines act rapidly to alter heart rate, 
blood pressure and respiration, whilst cortisol has more prolonged actions on 
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metabolism (glucose metabolism and fluid balance).  The actions of these 
hormones as part of the body’s response to stress and fluid balance suggests that 
they are likely to be important in understanding the response to the dual stresses 
of hypoxia and exercise during mountaineering activities.    
 
Metanephrines are the 3-methoxy metabolites of epinephrine and norepinephrine, 
respectively.  The metanephrines are stable metabolites and are co-secreted 
directly with catecholamines from the adrenal medulla and the sympathetic chain.  
Due to their stability, assay of these metabolites is preferable to direct assay of 
epinephrine and norepinephrine, which are unstable and have short plasma half-
lives.  Metanephrine and normetanephrine are both further metabolized to 
conjugated metanephrines and vanillylmandelic acid.    
 
Sea level normal values are;  Normetanephrine: 120 – 1180 pmol/l, Metanephrine: 
80 – 510 pmol/l 
 
Figure 8.2  Catecholamine synthesis and metabolism (with thanks to Dr S Ball) 
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8.2.2   Study methods 
Samples were drawn for catecholamine assay at the three study altitudes into 
EDTA tubes as previously described.  The samples were immediately centrifuged 
and plasma frozen at -20 ºC prior to transport back to the UK and storage at -80 ºC 
whilst awaiting assay. 
 
Catecholamine assays are performed at the Royal Victoria Infirmary, Newcastle.  
Free catecholamines in plasma were quantitated in a four-step procedure: the 
catecholamines were adsorbed onto alumina at a pH of 8.6, washed and then 
eluted with a dilute acid.  This elutate was analysed by high performance liquid 
chromatography with electrochemical detection (HPLC-ED) (Anton and Sayre 
1962).  The estimated lowest operating detection levels of metanephrine and 
normetanephrine have been quantified as 4.2 f.molˉˡ and 3.0 f.molˉˡ respectively.  
Blood samples once obtained were analysed using Oasis WCX u-elution plates 
30um (Waters part no.186002499), the plate was first activated by drawing through 
200ul MEOH followed by 200ul 0.01M ammonium phosphate buffer, under vacuum 
conditions.  100ul sample, QC and standard were then added to the plate, followed 
by 25ul, internal standard and 100ul 0.01M ammonium phosphate buffer.  This 
mixture was drawn through the vacuum system at approximately 25psi until all 
wells were empty. A series of washes then occurred starting with 200ul water, 
which was drawn to waste, followed by 200ul methanol drawn to waste, and 200ul 
acetonitrile/0.2% formic acid drawn to waste. Between each wash step, the 
vacuum psi was increased to 40-50psi to ensure each well on the plate is dry 
before the next wash.  The retained samples were then collected into a 1ml elution 
plate (Waters 186002643) by placing the plate directly below the WCX elution plate 
and eluting with 3 x 25ul volumes of elution solution (9.8ml 95% ACN/200ul conc 
formic acid).  The plate was then heat sealed ready for analysis.  Standards and 
QC were made in house (by the analyzing biochemist) by spiking Human Albumin 
Solution 50g/L (for calibrators) and pooled patient plasma (for QC) with stock 
standards purchased from sigma aldrich and QMX labs. 
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Normetanephrine and metanephrine levels were investigated according to the 
present of absence of AMS and the perceived intensity of exercise.   
 
Data distribution was tested using the Shapiro Wilk statistic to determine whether 
or not it was normally distributed.  Differences across altitudes or rest vs. exercise 
where then tested using Kruskal Wallis test.  Data is presented as mean (SD, 
range) pmol/L. 
 
8.2.3   Study results 
Number of subjects studied (metanephrine) SL rest 19, SL exercise 20, 3833m 48, 
4450m rest 48, exercise 44 – 3 subjects chose to journey by road vehicle due to ill 
health (gastrointestinal illness and one case HAPE) and 1 inadequate sample, 
5129m 47 (one subject failed to climb above BC). 
 
The data for metanephrine and normetanephrine was not normally distributed 
(Shapiro Wilk statistic 0.942 and 0.808 respectively p<0.001).   
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 Altitude 
(m) 
Sea Level 3833 4450 5129 P value for 
change with 
altitude 
Metanephrine 
(pmol/L) 
Rest 163.5 (61, 40-
288) 
187.73 
(44.7, 96-
301) 
203.56 (47.3, 
119 – 289) 
195.60 (50.0, 113 
– 338) 
0.078 
 Exercise 193.1 (99.2, 
40-504) 
197.90 
(47.7, 126-
316) 
231.45 (64.3, 
115 – 392) 
204.30 (85.7, 82 
– 415) 
0.012 
Normetanephrine 
(pmol/L)  
Rest 272.7 (117.2, 
109-461) 
518.42 
(183.3, 191 
– 996) 
679.60 
(231.2, 144 – 
1237) 
1093.68 (548.5, 
433 – 3880) 
<0.001 
Exercise 402.5 (158.1, 
104 – 709) 
571.79 
(246.3, 126 
– 1359) 
953.11 
(406.6, 303 - 
2006) 
1423.72 (786.0, 
355 – 4159) 
<0.001 
Data presented as mean  (SD, range) 
Table 8.2 Changes in metanephrine and normetanephrine with altitude and exercise. 
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Fig 8.3.   Mean normetanephrine at rest and exercise with increasing altitude 
(pmol/mL) 
 
 
 
 
Fig 8.4.  Mean normetanephrine at rest and exercise with increasing altitude 
(pmol/mL) 
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The change with exercise vs. rest was significant for normetanephrine (p=0.004) 
but not metanephrine (p=0.12) with a Kruskal Wallis test.  There was a significant 
change in normetanephrine with altitude both rest and with exercise (p<0.001).   
Metanephrine increased significantly with exercise at each altitude (p=0.012) but 
not at rest p=0.078.  The highest value of metanephrine was recorded at 4450m 
whereas normetanephrine increased with increasing altitude. 
 
Normetanephrine levels (pmol/L) changed significantly with more intense exercise.   
When Borg < 15 (N = 95), normetanephrine values were 873 (490.0, 149 – 2490) 
and with Borg RPE > 15 (N=38), 1246 (855.5, 126 – 4159) (p=0.014, Independent 
samples Mann Whitney U test).  This is also supported by the fact that heart rate 
increased with increasing normetanephrine Spearman’s rho 0.303 p<0.001 (figure 
8.5).    
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Figure 8.5  Normetanephrine changes with heart rate 
Metanephrine levels did not change in the same way with exercise intensity Borg < 
15 metanephrine value 217 (72.3, 112 – 415) vs. Borg > 15 195 (59.5, 82 – 392) 
(p=0.069).   There was an inverse correlation between normetanephrine and SpO2 
(rho=-0.363, p<0.001). 
 
 
Figure 8.6  Relationship of normetanephrine to SpO2 
 
There was no correlation between respiratory rate and normetanephrine 
(Spearman’s rho 0.108, p=0.84). 
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There was no significant difference in the levels of normetanephrine or 
metanephrine between those without AMS or with AMS or severe AMS.  
8.2.4   Discussion 
The fact that metanephrines changed only very slightly at all altitudes vs. the 5 fold 
change seen in normetanephrine is interesting.  Anand found a 3 fold rise in 
norepinephrine in Indian soldiers at altitudes above 6000m (albeit over a longer 
time period) but found no rise in epinephrine (Anand, Chandrashekhar et al. 1993). 
A correlation between norepinephrine and SpO2 (r=0.65 p<0.05) has previously 
been reported (Rostrup 1998).  The actions of catecholamines include increasing 
respiratory rate and this could be beneficial as part of the response to the 
increased physiological stress of increasing hypoxia.  The data collected during the 
field study may have shown a weaker correlation as a result of the fact that only 
SpO2 at the end of exercise was recorded and the nadir of the fall in SpO2 may 
have been different.  In fact one of the weaknesses in the study was that heart 
rate, oxygen saturations and respiratory rate were only measured at the end of 
exercise and not continually throughout the exercise period. 
 
8.3   Cortisol and adrenocorticotrophic hormone changes at HA and with 
exercise 
 
8.3.1   Background 
There is good reason why the cortisol response at HA might be an important part 
of the generation of high altitude illness.  There is a strong correlation between 
aldosterone and cortisol at HA (McLean, Booth et al. 1989), excess cortisol may 
contribute to fluid retention, and exercise at SL is also known to cause a rapid rise 
in serum and salivary cortisol (McLean, Booth et al. 1989, Di Luigi, Baldari et al. 
2008, Nunes, Crewther et al. 2011, Usui, Yoshikawa et al. 2011, VanBruggen, 
Hackney et al. 2011).  There have been numerous investigations regarding the 
cortisol response to HA over the last 30 years, the majority of which have reported 
a rise in cortisol at rest at HA (Sutton, Viol et al. 1977, Humpeler, Skrabal et al. 
1980, Richalet, Rutgers et al. 1989, Sawhney, Malhotra et al. 1991, Anand, 
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Chandrashekhar et al. 1993, Martignoni, Appenzeller et al. 1997, Zaccaria, Rocco 
et al. 1998, Barnholt, Hoffman et al. 2006).  However, not all studies have found an 
elevated cortisol at rest (Maher, Jones et al. 1975, McLean, Booth et al. 1989, 
Savourey, Garcia et al. 1996, Basu, Pal et al. 1997, Benso, Broglio et al. 2007) and 
even in those that did the numbers studied have usually been small, between 6 
(McLean, Booth et al. 1989) and 15 (Sawhney, Malhotra et al. 1991). Furthermore, 
while exercise is a central feature of most ascents to HA, studies of cortisol at HA 
have only occasionally included an exercise stimulus and usually one of relatively 
short duration (<1 hour) (Maher, Jones et al. 1975, McLean, Booth et al. 1989, 
Zaccaria, Rocco et al. 1998, Chen, Wang et al. 2006).  
 
There is also an apparent paradox in that elevated cortisol at HA has been 
associated with AMS (Sutton, Viol et al. 1977, Richalet, Rutgers et al. 1989) and 
yet dexamethasone and prednisolone are beneficial both as a prophylactic against 
AMS (Ellsworth, Larson et al. 1987, Basu, Sawhney et al. 2002) and as a treatment 
for AMS and HACE (Hackett, Roach et al. 1988, Levine, Yoshimura et al. 1989). 
The latter effect reflects dexamethasone’s generalised efficacy in combating 
cerebral oedema, anti-emetic effects and ability to induce euphoria (Zafren 2012).  
Nevertheless, very few studies have examined any relationship between resting or 
post-exercise cortisol at HA and AMS.  
 
In a 2009 study of trekkers in Nepal we have previously published data to show 
that morning cortisol (measured on a salivary swab nmol/l, mean+/-sd) at rest went 
from 5.5+/-2.9 to 4.7+/-6.8; 3.5+/-2.1; 14.5+/-30.3 at 1300m, 3400m, 4270 m and 
5150 m respectively.  Afternoon post-exercise cortisol went from 8.5+/-7 to 7+/-6; 
4.2+/-4.8; 9.2+/-10.2 at 1300m, 3400 m, 4270 m and 5150 m respectively.  
 
The statistically significant findings at rest were a rise in cortisol from 4270 m to 
5150 m (p=0.002).  The statistically significant findings post-exercise were an initial 
drop in salivary cortisol between SL and 4270 m (p=0.01) and 3400 m and 4270 m 
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(p=0.001) followed by a significant rise in post-exercise cortisol between 4270 m 
and 5150 m (p<0.001).  
 
From this work it appears that the post-exercise response in cortisol was intact at 
3400 m but an apparent subdued response at 4270 m before a restoration in the 
response at 5150 m.  There are similarities between the subdued exercise 
response to cortisol at 4270 m and that previously found regarding aldosterone.  
Bouissou et al. (Bouissou, Richalet et al. 1989) found a reduction in the exercise-
induced aldosterone rise following graded maximal exercise at 4350 m compared 
to SL. McLean et al. (McLean, Booth et al. 1989) also found a subdued rise in 
aldosterone compared to SL at 4450 m following 25 minutes of exercise.  We 
found a restoration in the cortisol response after a day trekking at 5150 m whereas 
Zaccaria et al. (Zaccaria, Rocco et al. 1998) found no aldosterone response to 
exercise (albeit after a brief stimulus with a graded exercise test) at 5050 m.  
Interestingly Bouissou et al. (Bouissou, Fiet et al. 1988) found that in a hypobaric 
chamber at a simulated 3000 m the ACTH rise in response to 60 minutes exercise 
was unchanged compared to SL but that the cortisol response was subdued. They 
found ACTH and cortisol post-exercise correlated strongly at SL but not at HA, 
suggesting ACTH-driven steroidogenesis at SL but some disconnect at HA with 
apparent reduced cortisol sensitivity to ACTH. This is similar to the known 
dissociated response of aldosterone to increased plasma renin activity (PRA) that 
occurs during hypoxaemic exercise (Shigeoka, Colice et al. 1985) that is thought to 
be partly due to direct inhibition of aldosterone synthesis in the adrenal gland by 
hypoxia (Raff, Jankowski et al. 1996).  A reduced sensitivity of adrenal cortisol 
production to ACTH stimulation may, like that of PRA and aldosterone, be an 
adaptation to reduce potential fluid retention from excess cortisol post-exercise. 
Any damping effect in the cortisol response to exercise around 4270 m is then 
over-ridden by the greater physiological stress at 5150 m.  Unfortunately in this 
study there was no recording of Rating of Perceived Exertion or other measure of 
intensity which might have delineated whether the cortisol response was due to a 
harder exercise stimulus. 
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The fact cortisol is a stress hormone and the environment of HA creates a 
significant physiological stress is the most likely explanation for the rise in cortisol 
at HA.  Part of this stimulus may relate to hypoxia as evidenced by the association 
between lower SpO2 and higher cortisol. 
 
Hypothesis 
The physiological stress of HA would lead to a rise in ACTH and cortisol.  This 
would lead to fluid retention and be linked to the development of AMS. 
 
8.3.2   Methods 
In the study in Bolivia we measured plasma rather than salivary cortisol.   This was 
drawn from an antecubital fossa vein into a serum separator tube before being 
centrifuged, and stored frozen at -20°C until movement back to the UK after which 
it was stored at -80°C.  Assays were performed at Newcastle’s Royal Victoria 
Infirmary (RVI).  The Roche Cortisol assay (used at RVI) is a competitive 
immunoassay using electrochemiluminescence technology.   Serum is the 
preferred sample but heparin (Li-, Na-, NH4+-) or EDTA plasma is acceptable.  A 
minimum sample size of 20µL (+100µL for dead volume) is required. The test is 
fully automated and run on the Roche Modular E unit (Roche Diagnostics, Burgess 
Hill, UK).  The assays take 18 minutes to run.  A calibration sample must be 
performed once per reagent lot using fresh reagent. 
 
During the first incubation step Cortisol, which has been liberated from binding 
protein with Danazol, competes with a ruthenium labeled cortisol derivative for 
binding sites on a cortisol-specific biotinylated antibody.  During the second 
incubation, after addition of streptavidin-coated microparticles, the complex 
becomes bound to the solid phase via interaction of biotin and streptavidin. 
The reaction mixture is aspirated in to the measuring cell where the microparticles 
are magnetically captured onto the surface of the electrode. Unbound substances 
are removed using Procell. Application of a voltage to the electrode induces 
chemiluminescent emission which is measured by a photomultiplier.   
150 
 
Results are determined by measuring the electrochemiluminescence signal 
obtained from the reaction product of the sample against a calibration curve 
generated by 2-point calibration and a master curve provided via the reagent 
barcode.   The analytical range is 0.5 –1750 nmol/L (From pack insert).  Samples 
with concentrations >1750 nmol/L can be checked via the re-run function and the 
results corrected for the dilution factor of 10. Routine samples are reported as 
>1750 nmol/L. Low levels are reported as ‘less than 20 nmol/L’. 
 
Analytical sensitivity (lower detection limit): 0.5 nmol/L (From pack insert)  The 
detection limit represents the lowest measurable analyte level that can be 
distinguished from zero. 
 
Functional sensitivity <8.5 nmol/L (From pack insert)  The functional sensitivity of 
the method is defined as the concentration at which the total coefficient of variation 
is ≤20%.  
 
ACTH is measure on the DPC Immulite machine (Siemens Healthcare, Germany).  
The assay uses a chemiluminescent detection technique in combination with an 
immunometric (i.e. a ‘sandwich’) assay method. Two antibodies to ACTH are 
employed.  The capture antibody is a murine monoclonal anti-ACTH immobilised 
on to polystyrene beads. The second antibody is a polyclonal rabbit anti-ACTH, 
labelled with alkaline phosphatase (AlkP) to facilitate quantitation.  A 200µL sample 
of EDTA plasma is required. 
 
Antibody-coated bead, sample and AlkP-labelled antibody are incubated for two 30 
minute cycles at 37°C followed by a centrifugal wash step.  To the antibody 
sandwich complex is then added the chemiluminescence substrate, in excess. This 
phosphate ester of adamantyl dioxetane is hydrolysed by the alkaline phosphatase 
resulting in an unstable intermediary compound.  Continuous production of this 
results in a prolonged glow.  This allows multiple photon readings by the 
luminometer thus enhancing precision. The signal is directly proportion to the 
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concentration of alkaline phosphatase and therefore ACTH in the specimen.  i.e. as 
for any immunometric assay the signal is directly proportional to the concentration 
of the analyte being measured. 
 
The labs’ quoted imprecision data are; 
Control Material: Bio-Rad Trilevel Control 
Within Batch 
   N Mean (ng/L)  SD CV% 
  Low 20 12.7   0.65  5.1 
  Med 20 125.6   3.53  2.8 
  High 20 446.6   11.8  2.6 
Between Batch 
   N Mean (ng/L)  SD CV% 
  Low 20 13.0   1.53 11.7 
  Med 20 122.8   9.73   7.9 
  High 20 436.2   7.93   9.3 
Results below 5 ng/L are reported as <5 ng/L. 
The upper limit of the calibration range is 1250 ng/L.  Samples with results which are 
above 1250ng/l are diluted 1 in five with ACTH diluent 
Data distribution was tested using the Shapiro Wilk statistic to determine whether 
or not it was normally distributed.  Values for cortisol were compared for rest and 
exercise with increasing altitude (Krukal-Wallis test) and compared for cohorts 
experiencing AMS (LLS>3) or severe AMS (LLS>6) and those reporting high vs. 
low perceived exertion (Mann-Whitney U test).  Correlations were performed using 
Spearman’s rank correlation coefficient.  Data is presented as mean (SD, range).  
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8.3.3   Study results 
Number of subjects studied was 20 at sea level, 3833m 48 at rest, 47 exercise; 
4450m rest 48, exercise 45 – 2 subjects chose to journey by road vehicle due to ill 
health (gastrointestinal illness and one case HAPE), 5129m 45 at rest and 46 post 
exercise due to sampling difficulties and the fact that one subject failed to climb 
above BC. 
 
The data for cortisol and ACTH was not normally distributed (Shapiro Wilk statistic 
0.95 p<0.001 and 0.755 p<0.001).  .   
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Cortisol changes with altitude are shown below;  
 Altitude 
(m) 
Sea Level 3833 4450 5129 P value with 
increasing 
altitude 
       
Cortisol 
(nmol/L) 
Rest 368.7 (133.6, 
132-636) 
459.1 (201.7,151 
– 959) 
407 (183.2, 44 – 
937) 
522.8 (183.5, 223 
– 1198) 
0.02 
 Exercise 262.5 (131.6, 
103-659) 
369.2 (261.2, 97 
– 1591) 
364.8 (206.5, 78 
– 1049) 
632 (182.6, 337 – 
1198) 
<0.001 
ACTH 
(pmol/L)  
Rest 15.9 (6.9, 7-31) 19.7 (12.5, 6-57) 19.6 (9.2, 5-46) 18.6 (8.6, 7-46) 0.494 
Exercise 10.7 (5.6, 5-29) 25.6 (27.4, 6-151) 23.1 (10.3, 8-49) 30.1 (16.2, 5-85) <0.001 
Data presented as mean (SD, range). 
 
 
Table 8.3 Cortisol and ACTH with changing altitude at rest an exercise.  
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Fig 8.7.  Mean cortisol at rest and exercise with increasing altitude (nmol/mL) 
 
Cortisol increased with increasing altitude (p<0.001).  Values were higher at 
3833m than at 4450m but peaked at 5129m.  Overall there was no significant 
change of cortisol with exercise vs. rest (p=0.097).  Individual Mann Whitney U 
tests showed a significant reduction in cortisol with exercise at 3833m (p=0.08), 
no change at 4450m and an increase at 5129m (p<0.001).  
 
Cortisol was increased in those with severe AMS mean 444.8 vs. 650.4 
(p=0.033).  For those with a LLS>3 cortisol was increased mean 439.9 vs. 
517.5 but this did not reach significance (p=0.064). 
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Fig 8.8.  Mean cortisol in subjects with severe AMS (LLS>6) vs. those without 
(nmol/mL) 
 
There was a very weak but significant inverse correlation between cortisol and 
SpO2 (Spearman’s rho -0.188, p=0.002) but not between cortisol and heart rate 
(p=0.170). 
 
Adrenocorticotrophic hormone showed significant change with altitude after 
exercise (p<0.001) but no change in the resting state (p=0.494).   ACTH was 
higher after exercise than at rest (p=0.002).  There was no correlation between 
ACTH and cortisol at 3833m or 4450m at rest but a good correlation with rest at 
5129m (rho 0.436 p=0.003).  With exercise ACTH and Cortisol correlated at 
4450m (Spearman’s rho 0.415, p=0.005) and at 5129m (Spearman’s rho 0.436, 
p=0.003). 
 
If the groups were separated by a Borg score > 15 then the Borg <15 group 
(n=95, mean cortisol 386.4) had a significantly different cortisol to the high Borg 
group (n=38, mean 603.4 p = <0.001).  ACTH in the Borg <15 group was a 
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mean of 20.88 whereas in the Borg >15 group the mean was 24.6, this 
difference was not significant (p=0.308). 
 
 
Fig 8.9.  Plasma cortisol following exercise in the groups with Borg < 15 vs. >15 
 
8.3.4 Discussion 
The fact that cortisol falls after exercise at sea level, 3833m and 4450m is 
surprising, however as described earlier the cortisol response is very dependent 
on the exercise intensity with exercise even up to 62% VO2 max producing no 
rise in cortisol (Jacks, Sowash et al. 2002).  Cortisol secretion also shows 
diurnal variation with a peak on waking.  Our samples were taken at around this 
time on rest days with exercise samples being taken after lunchtime when there 
is a marked decrease in cortisol.  This mechanism probably explains the fall at 
SL, 3833m and 4450m when the exercise stress was not sufficient to provoke a 
significant response.  At 5129m the physiological stress of the strenuous trek 
and hypoxia was sufficient to increase cortisol.  It is significant that there 
appears to be a disconnect between ACTH and cortisol at low altitudes (even in 
our data at near sea level exercise) with correlation only apparent at rest at 
5129m and with exercise at 4450m and 5129m.   Whilst this is an intriguing 
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finding the data can only be viewed as pilot data and future investigation will 
have to control timing of the ACTH response with the use of synthetic ACTH as 
in a short Synacthen test. 
 
Once again the exertion involved during the exercise period seems to be a 
significant stressor leading to a rise in cortisol.  There was an increase in 
cortisol with a high Borg RPE score and an increased cortisol in those with 
severe AMS.  Whether cortisol rises as a response to exercise in hypoxia, 
leading to fluid retention and exacerbates AMS symptoms or whether the acute 
illness of AMS leads to stress and a rise in cortisol cannot be further elucidated 
from this study.   
 
8.4 Conclusions 
A summary of the physiological effects of high altitude ascents are a decrease 
in SpO2, a variable effect on blood pressure and an increase in respiratory rate.   
The novel exploration in this study has been into the relationship of cortisol and 
catecholamines to exercise intensity by measuring perceived exertion during a 
trek.  This differs both in terms of the large numbers of subjects studied and the 
methods used in previous studies and shows a highly significant change in 
plasma cortisol and normetanephrine for those who perceived the trek as 
“hard”.  The increase in cortisol was approximately 60% and this was 
associated with higher cortisol in those reporting severe AMS.  The 
physiological changes seen in terms of the correlation of heart rate to 
normetanephrine and inverse correlation of SpO2 to normetanephrine and 
cortisol support the fact that physiological stress related to exercise is the key 
stimulus for this rise.  The lack of correlation between ACTH and cortisol and 
relative suppression of cortisol response to exercise until 5129m is a fascinating 
finding and worthy of further investigation.  The time course of all these changes 
relative to the development of altitude illness is a key feature that cannot be 
determined from the current data. 
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Summary 
The conclusion developed from earlier work in this MD thesis is that exercise 
intensity plays a key role in development of the symptoms of Acute Mountain 
Sickness (AMS).   Whilst the aim has to be to understand AMS during field 
studies (i.e. the real world situation) performing standardised exercise testing in 
the field is extremely difficult.  It is important to be able to quantify exertion with 
a simpler method such as a rating of perceived exertion (RPE) scale.  Likewise 
standardising exercise protocols, rest and diet can only practically be performed 
in laboratory based studies but studies in hypobaric chambers are difficult to 
perform and there is no consensus on whether normobaric and hypobaric 
hypoxia generate the same stimulus. 
 
The data from the Bolivia field study was analysed to investigate the 
relationship between RPE, physiological variables and AMS scores.   The 
finding was that there is a significant difference between subjects recording high 
and low RPE and AMS supported by some physiological differences.   In a 
second study the physiological response to standardised exercise in normobaric 
and hypobaric hypoxia, as well as in the real world environment, was examined.   
This study showed no difference in heart rate, oxygen uptake or lactate across 
the three environments and further supported the use of a RPE scale. 
 
Hypothesis 
1. A higher rating of perceived exertion will lead to an increase in reported 
AMS symptoms. 
2. There will be no difference in the response to hypoxia in normobaric, 
hypobaric or “real world” environments.  
 
9.1 Background 
The fact that exercise has a major impact on physiological changes during 
acclimatisation is made in earlier chapters.  To briefly recap subjects with a high 
rating of perceived exertion had a higher level of copeptin, cortisol and 
normetanephrine, all suggesting a link between exercise intensity and 
physiological stress.  This neuroendocrine response is an adaptation to 
preserve salt and water, useful if the stressor is hypovolaemia from 
haemorrhage but potentially detrimental in high altitude environments. 
160 
 
Regardless of any neuroendocrine response exercise will have the added effect 
or worsening hypoxia due to increased oxygen demands.  This could have 
beneficial effects of stimulating a greater adaptation but is also likely to increase 
the risk of altitude illness.  The guidance frequently given to mountaineers is 
that some exertion is beneficial whilst hard effort should be avoided.  This is 
based on custom and practice rather than any evidence and is an empirical 
solution to balance the benefits and risks of greater hypoxic stimulus.      
 
9.1.1   Methods of Measuring Exercise Intensity  
In an important study using heart rate to assess exercise intensity Bircher and 
colleagues (Bircher, Eichenberger et al. 1994) investigated whether 
susceptibility to acute mountain sickness (AMS) and high-altitude pulmonary 
edema (HAPE) is related to differences of physical fitness at the outset of an 
expedition and /or the level of exercise during ascent. Heart rate was 
continuously registered during the ascent from 3610 to 4559 m in 41 
mountaineers. During the subsequent stay of 3 days at 4559 m, 12 subjects 
developed AMS, 13 subjects showed radiographic evidence of HAPE, and 16 
subjects remained without significant illness. The level of baseline fitness (as 
measured by work done at heart rate of 170 bpm) and heart rate during ascent 
did not significantly differ between these groups.  The authors conclude “these 
results indicate that physical fitness or exercise intensity during ascent were of 
minor importance for the development of AMS and HAPE in our subjects”. 
The findings of 3 recent chamber studies are summarised below;
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 N NH or HH %VO2 max Duration 
Exercise 
protocols 
Conclusion 
Roach (Roach, Maes et al. 
2000) 
7 HH (4800m) 50% alt 
adjusted 
10 
hours 
1. 4x30 mins 
2. Rest 
4 fold ↑LLS with exercise 
Schommer (Schommer, 
Hammer et al. 2012) 
16 NH (FiO2 
12%) 
50% alt 
adjusted 
18 
hours 
1. 3x45 mins 
2. Rest 
No change AMS with 
exercise 
Rupp (Rupp, Jubeau et al. 
2013) 
12 NH (FiO2 
12%) 
45% alt 
adjusted 
11 
hours 
1.  4 hours 
exercise 
2.  4 hours 
↓FiO2 
3.  Normoxia 
No difference between 
exercise and rest LLS 
 
Table 9.1 Previous published studies investigating AMS and exercise 
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In laboratory settings, work can be performed at a fixed proportion of maximal 
oxygen uptake (VO2 max).   This is a technically difficult process requiring a 
bicycle ergometer and expired gas analysis.   As VO2 max falls with HA an 
adjustment must be made with sea level values to make comparison.   This 
requires a voluntary maximum test in a hypoxic environment prior to 
investigation.   The studies summarised above (Roach, Maes et al. 2000, 
Schommer, Hammer et al. 2012, Rupp, Jubeau et al. 2013) use this technique 
to reach conflicting results. 
 
The Borg rating of perceived exertion score (chapter 3)(Borg 1970, Borg 1973) 
is an attractive way to measure exercise intensity during a trek.  Although not 
part of Borg’s rating scale local and central RPE can also be recorded (Pandolf 
1982).  Local RPE relates to sensations or feelings of strain from the exercising 
muscles and/or joints and a central factor relates primarily to cardiopulmonary 
sensations.  A literature search for perceived exertion and high altitude found 
two relevant publications.  In 1982 Young (Young, Cymerman et al. 1982) 
studied 8 subjects during acute (2 hours) and chronic (18 days) in the setting of 
a hypobaric chamber for the acute exposure and a sojourn at HA (4300m in 
both environments).  He measured local muscular RPE, central 
cardiopulmonary RPE and overall RPE.   Central RPE was the highest during 
chronic HA exposure suggesting that perceptual cues sensed as effort change 
with HA exposure.   Maresh (Maresh, Deschenes et al. 1993) looked at 6 low 
altitude natives on decompression to 447mmHg (4270m) for 2 days.  At low 
altitude local RPE exceeded central ratings whereas at high altitude central 
RPE were greater than local.   Interestingly he reports a correlation between 
cardiorespiratory AMSc scores and central RPE on the morning before the 
exercise (day 2 at HA) (rho = 0.875).  However this study is compromised by 
very low numbers (n=6). 
 
Laboratory based research can solve many of the problems of HA field studies 
by carefully controlling environmental conditions, oral intake and exercise 
intensity.   Unfortunately the solution is not a simple one.  HA can be modelled 
by either field studies, exposure to hypobaric hypoxia or exposure to 
normobaric hypoxia where the fraction of inspired oxygen is reduced to simulate 
a specific altitude.  There is, however, debate about whether or not these two 
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entities are similar.  This depends, in part, on what the model is being used for 
be it sports science, altitude medicine or aviation medicine. Rapid ascent in a 
hypobaric chamber does seem to be associated with more pronounced 
respiratory changes than the equivalent FiO2 (SaO2 62.3% v’s 69.5%) with a 5 
minute exposure to 7500m equivalent (Self, Mandella et al. 2011).  However in 
this study the reported symptoms were similar prompting the authors to 
conclude that normobaric hypoxia was a useful model (for aviation training).  
This pattern of more pronounced hypoxaemia, hypocapnia and alkalosis (with 
hypobaric hypoxia) has been found in other studies and may be due to changes 
in dead space ventilation (Savourey, Launay et al. 2003).   One other factor is 
the calculation of the correct FiO2 which is often not clear from descriptions of 
research protocols (Girard, Koehle et al. 2012).  The saturated vapour pressure 
of water (SVP H2O) is constant at any altitude (pressure) and amounts to a value 
of 47mmHg.  The ambient PO2 must be reduced by 47mmHg as gases are 
saturated with water vapour on inspiration.   In hypobaric environments this 
leads to a greater reduction of inspired oxygen content than in normobaric 
environments.  As an example a reduction of pressure to 430mmHg in a 
hypobaric chamber with a normal FiO2 (0.209) leads to an ambient oxygen 
tension of 90mmHg (430 x 0.209), the same oxygen tension can be generated 
with an FiO2 of 0.119 in normobaricity (760mmHg x 0.119).  However to 
calculate the inspired oxygen tension the SVP of water must be taken into 
account using the equation: 
 
PiO2 = (PATM-SVPH2O) x FiO2 
 
Were PiO2 is Partial pressure of inspired oxygen, PATM is atmospheric pressure, 
SVPH2O saturated vapour pressure of water and FiO2 is the fractional inspired 
percentage of oxygen. 
  
Hence in normobaricity the PiO2 is 85mmHg whereas in hypobaricity it is 
80mmHg and the FiO2 in normobaricity must be set lower to get an equivalent 
stimulus.    
 
Interestingly no studies have yet been published comparing normobaric and 
hypobaric chambers with a field study at high altitude. 
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There are also physical issues with decompression such as changes in air filled 
spaces such as the middle ear and sinuses.   Decompression illness (DCI) can 
also manifest itself with exposure to hypobaricity.   Worrying long term decline 
in neurocognition associated with white matter hyperintensities on MRI has 
been noted in U2 pilots frequently exposed to very high altitudes and low 
pressures (McGuire, Sherman et al. 2012).  DCI and worries about 
neurocognitive damage limit the exposure allowed within the RAF’s hypobaric 
chamber at RAF Henlow, limiting exposure to 3 hours in every 72 hours.  This 
has a major impact on the ability to run studies and is not a sufficient duration to 
make meaningful observations of AMS. 
 
Two studies were carried out as part of this MD to assess the value of the Borg 
RPE during exercise at HA.   One was a pilot study during the Bolivia field study 
to collect the highest perceived exertion during the days trek.   Study 2 was part 
of a more complex study comparing hypobaric, normobaric and the “real world”. 
The aims of these studies were therefore to: 
 
1.  Assess the practicality of using the Borg score during a field study. 
2. To compare the Borg score to heart rate and lactate across hypobaric, 
normobaric and mountain environments. 
 
9.2   Study One - Perceived Exertion, Physiological Variables and Acute 
Mountain Sickness 
 
9.2.1   Methods 
The study was approved by the Ministry of Defence Research Ethics Committee 
and complied with the standards set in the Declaration of Helsinki.  All subjects 
gave written informed consent. 
 
Forty-eight subjects were recruited for the study.   All subjects were members of 
the UK Military taking part in a dual purpose adventurous training and research 
expedition.  
 
Studies were performed at three altitudes.   This was on day 2 at 3833 m 
following exercise (a trek of 6 hrs. 600m ascent and 16.8 km), day 3 at 3833m 
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at rest, day 5 at 4450m following exercise (4 hours 200m ascent, 5.6 km), day 6 
at 4450m at rest, day 9 at 5129m following exercise (4 hrs. 400m ascent, 1.59 
km) and day 10 at 5129m at rest.   The night was spent at the new altitude and 
data collected at rest the following day.  The trekking took place in the Cordillera 
Real region of Bolivia. 
 
Physiological variables (SpO2, heart rate, respiratory rate, blood pressure) at 
rest or within 15 minutes of cessation of exercise were recorded by other, 
medically trained, expedition members or members of the research team.   
Heart rate and SpO2 were recorded on a Nellcor N-20P pulse oximeter (Nellcor 
Puritan Bennett Ltd, Coventry.UK). Three measurements were made on warm 
hands and an average recorded.      
 
Perceived Exertion  
The Borg Rating of Perceived Exertion (RPE) was recorded (Borg 1970) at the 
end of each day to record the hardest perceived exertion experienced during 
the day.  This is a 15 point scale from 6 – 20, with values of 6 representing the 
resting state and 20, exhaustive exercise.   RPE using the Borg 15 point scale 
is related to HR (score is approximately 10x HR) and over 2500 exercise tests 
Scherr found a more precise relationship to HR defined by the equation HR = 
69.34 + (6.23xRPE) (Scherr, Wolfarth et al. 2013).  As the European Society of 
Cardiology recommend exercising at a perceived exertion of 12- 14 (Graham, 
Atar et al. 2007), a value of 15 or greater was taken as the cut off for a high 
Borg score.   A RPE of 15 or greater is perceived as “hard exertion” by the 
subject, relates to a heart rate of around 150 bpm at sea level and is the level at 
which anaerobic metabolism starts to become a significant part of energy 
generation.   
 
AMS scores 
AMS scores were assessed using the Lake Louise score (LLS) (Roach, Bartsch 
et al. 1993). The LLS is a self-assessment questionnaire that allocates a score of 
0 to 3 (symptom not present to severe) for symptoms of AMS (headache, 
gastrointestinal symptoms, fatigue/weakness, dizzy/light-headedness, difficulty 
sleeping). A score of 3 or more in the presence of headache is consistent with 
AMS. 
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Statistical analysis 
For statistical calculations the software package SPSS 21.0 was used.  
Parametric or non-parametric statistical tests were applied after performing the 
Kolmogorov-Smirnov statistic. 
 
For independent variables an independent-samples t test or Mann Whitney test 
was used.  For relationships between categorical variables a Chi-square test was 
used.   Significance was assumed at the p=0.05 level. 
 
9.2.2   Results 
The subjects were of a mean age of 35 years (range 22-54), mean height 
175.6cm (range 155-194) and mean weight 77.8 Kg (range 47-108).   There 
were 34 males and 14 females.   All were physically fit, mean 1.5 mile run time 
9.85 minutes (range 8.07 – 13.5).  All 48 subjects were investigated at 3833m 
and 4450m, 47 out of 48 subjects reached the highest study altitude.     
 
Compliance with recording the scores was good; there were a possible 143 
scores to be collected (48 at 3833m and 4450m and 47 at 5129m), overall there 
were matched Borg and LLS for 136 (post exercise) and 138 (rest) study points.  
The mean Borg score for the trek to 3833m was 13.15 (SD 1.92), for the trek to 
4450m it was 12 (SD 1.8) and for the trek to 5129m it was 14.98 (SD 1.98).  
The incidence of AMS at rest the day after the exercise reflected the RPE from 
the trek.  At 3833m the incidence was 27.1% (n=13), 4450m 8.7% (n=4) and at 
5129m 37.8% (n=17). 
 
Overall there were 97 observations of a Borg < 15 and 39 of Borg > 15 following 
exercise and 99 of a Borg < 15 at rest.   This difference is explained by the fact 
that at 3833m 2 subjects travelled to the high camp by vehicle due to illness and 
did not record a score.   Lake Louise scores differed significantly between the 
groups with a low (Borg<15 or high Borg >=15) RPE score (table 12.2). 
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  Borg < 15 Borg > 15  
  N  N  P 
Heart 
Rate 
Post 
exercise 
98 87(13.7, 
56-120) 
39 94 (15.3, 
60–129) 
0.007 
Following 
morning 
99 80 (11.8, 
45-120) 
39 87 (14.4, 
57–120) 
0.003 
SpO2 Post 
exercise 
97 82 (5.1, 
68-92) 
39 81 (4.9, 
68-94) 
0.371 
Following 
morning 
96 85 (4.7, 
74-91) 
38 83 (5.1, 
66-93) 
0.021 
LLS Post 
exercise 
97 1.65 
(1.95, 0-
9) 
39 2.62 
(2.3, 0-
10) 
0.008 
Following 
morning 
99 1.7 (1.83, 
0-9) 
39 2.67 
(2.19, 0-
8) 
0.012 
       
Table 9.2  Heart rate (bpm), SpO2 (%) and Lake Louise Score (LLS) in high and 
low Borg RPE groups.  Data presented as mean (SD, range) 
Results are presented in tabular form and graphical comparisons (table 9.2 and 
figure 9.1). 
The incidence of AMS at rest the day after the exercise reflected the RPE 
pattern of response from the trek.  At 3833m the incidence was 27% (n=13), 
4450m 9% (n=4) and at 5129m 38% (n=17). 
Lake Louise scores differed significantly between the groups with a low 
(Borg<15 or high Borg>15) RPE score.   Immediately post-trek the group with a 
high RPE LLS was 2.6 +/- 2.3 (0-10) vs. 1.7 +/- 2.0 (0-9) whilst at rest the 
following day the high RPE LLS was 2.7 +/- 2.2 (0-8) vs. 1.7 +/- 1.8 (0-9) (fig 
9.1).    
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Fig 9.1  Mean LLS scores across the groups with Borg < 15 vs. >15 
 
There were 25 recorded Borg RPE scores of 11 or less during the trek; these 
low scores were associated with an AMS rate of 8% (n=2).  This was 
significantly different to the 110 occasions on which Borg RPE scores of 12 or 
greater were recorded when the incidence of AMS was 31% (n=34). 
SpO2 was significantly lower in those with a high Borg score the morning after 
the trek 83% +/- 5 (74-91) vs. 86% +/- 5 (66-93) (p=0.022).  
 
The heart rate was significantly higher both on completion of exercise, 94 bpm 
+/-15 (60-129) vs. 87 bpm +/- 13 (56-120) and at rest 87 bpm +/-14 (57-120) vs. 
80 bpm +/- 11 (45 -120) in the group with a high Borg score.  Borg score 
correlated weakly with heart rate both at the completion of exercise (rho 0.181, 
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p=0.034) and at rest (rho 0.213, p=0.12) across all values. 
 
Figure 9.2  values of LLS, HR and Borg RPE score 
 
9.2.3   Discussion  
This data is the first field study to show a link between the subjects RPE and 
development of AMS. 
 
One reasons why our data may differ from other studies is that the level of 
exercise intensity of a “real world” trek was perceived to be high compared to 
chamber studies.   During the field study in Bolivia the mean Borg score for the 
trek to 3833m was 13.15 (SD 1.92), for the trek to 4450m it was 12 (SD 1.8) 
and for the trek to 5129m it was 14.98 (SD 1.98).   Exercise at 45% altitude 
adjusted VO2 max would be expected to correspond to an RPE of 9 - 10.   
Schommer and Roach’s studies used an exercise intensity of 50% altitude 
adjusted VO2 max (Roach, Maes et al. 2000, Schommer, Hammer et al. 2012) 
whilst Rupp’s subjects cycled at 45% altitude adjusted VO2 max (Rupp, Jubeau 
et al. 2013).   In our study the number of subjects with a Borg score of 11 or 
less (which approximates to the exercise intensity’s used in these studies) 
developing AMS was a third that of those reporting higher scores.  
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It is interesting that in the study by Roach et al (Roach, Maes et al. 2000), rest 
in a hypobaric environment produced less AMS than Schommer or Rupp found 
at rest in normobaric hypoxia despite similar altitude levels and hypoxia (SpO2 
in Rupp’s study 83.5 +/- 4.9% at rest and 73.7 +/- 5.7 % at exhaustion, in 
Roach’s 81.4 +/- 1.8% at rest and 76.3 +/- 1.7% with exercise).   Equally short 
bouts of exercise followed by rest, rehydration and a familiar secure 
environment is very different to the real world where trekking to a new altitude 
takes all day.  Roach’s 10 hour chamber study may not have been long enough 
for AMS to develop and may explain the increase at rest in Schommer’s study 
where the study was carried out over 18 hours.  In contrast our study took place 
during a 10 day trek and some of the changes may have been as a result of the 
significantly longer period of hypoxia.  
 
The physiological data suggest that the Borg score is meaningful at altitude as 
those with high Borg had a high heart rate and lower SpO2 at the end of a 
period of exercise.  Unfortunately we had no way to track changes in heart rate 
and RPE during exercise.  For this reason the correlation of Borg score with HR 
is lower than would be anticipated although the fact that HR (at the end of 
exercise) did correlate weakly with the RPE suggests that there was a 
physiological basis for the higher reported.  The association between high RPE 
and AMS at the end of the trekking day could be anticipated as the effects of 
exercise may well generate symptoms consistent with a high LLS, however, it is 
more significant the LLS remained elevated the following morning with 
associated higher heart rate and lower oxygen saturation. 
 
Using the Borg RPE score during a “real world” exercise stimulus is a logical 
and attractive proposition.   Firstly it requires no specialist equipment and is 
highly reproducible, at least at sea level (Graham, Atar et al. 2007, Scherr, 
Wolfarth et al. 2013), secondly, and importantly, multiple other factors can have 
an impact on perceived exertion during a trek (such as AMS, poor sleep, viral 
illness etc).   This would not alter the work rate required to perform a test at 
fixed proportion of VO2 max (even if altitude specific) but would alter perceived 
exertion and these other conditions may predispose to AMS. 
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One potential criticism of our data is that the study was not designed specifically 
to look at the relationship of exercise intensity to AMS and no effort was made 
to control the pace of individual subjects.  The suggestion that increased 
perceived exertion leads to AMS is intriguing and opens the possibility that 
controlling the exercise intensity could reduce AMS rates.  It could also be 
postulated that efforts to reduce the perception of exertion per se, through 
better education, fitness training or reducing anxiety may lead to reductions in 
AMS, at least as assessed by LLS.  
 
In summary this large field study is the first to link exertion, as recorded using a 
RPE scale to AMS.   Whilst the data should be viewed as pilot data it raises the 
possibility for using perceived exertion scales as a way to influence behaviour 
and reduce the incidence of AMS.  These results lend support to the view that 
hard exercise during acclimatisation is detrimental to acclimatisation. 
 
9.3   Study 2 – Comparison of Exercise in 4  Different Environments 
 
Study aims: 
The aim of the study was to compare the physiological response to submaximal 
exercise in the “real world” ie Alpine environment, normobaric and hypobaric 
hypoxia. 
 
9.3.1   Methods 
The study was designed as a cross over trial involving 16 subjects recruited 
from the Defence Medical Services.  Subjects were military personnel recruited 
by word of mouth from medical units based around Catterick.    
 
Environmental modelling: 
The following sequence of exercise tests was performed: 
 
1. Sea level maximum exercise test 
2. Hypoxic maximum exercise test (NH) 
3. Sea level sub-maximal test at 60% max power output (1) 
4. Alpine hypoxic sub-maximal test (Torino hut, Italy alt 3370m) 
5. Normobaric hypoxic sub-maximal test (see FiO2 calculation below) 
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6. Hypobaric hypoxic sub-maximal test (chamber pressure to replicate 
pressure at Torino hut) 
 
All sub-maximal tests were performed at 60% of power output from hypoxic 
maximum test (2) 
 
The FiO2 for the normobaric chamber was calculated by allowing for the 
saturated vapour pressure of water as follows: 
 
PiO2 = (PATM – PH2O) x FiO2 
 
Participants were screened in accordance with the ACSM guidelines 
(ACSM)(ASCM’s Guidelines for Exercise Testing and Prescription) and were 
classified as ‘low’ risk prior to undertaking the study. Each particpant was 
assessed for Sickle Cell Trait, where haemoglobin carying capacity may be 
imparied. However, all the participants tested negative. An additional medical 
examination was required for hypobaric chamber participants in accordance 
with Royal Air Force policy. 
 
Participants completed two maximal incremental cycle tests to volitional 
exhaustion to determine their individual maximal workload (Wmax (Kuipers, 
Keizer et al. 1987)) and maximal oxygen uptake on a bicycle affixed to a bicycle 
trainer (Compu Trainer Pro Lab, Racer Mate, USA). The cycle ergometer was 
calibrated following the manufacturer’s instructions. The first test was performed 
at sea level (FiO2: 20.9%) with the second test performed a week later during 
acute exposure to normobaric hypoxia (PiO2: 95.25 ± 0.28, ~FiO2: 13.4%, 
~3375m). Participants cycled at an initial intensity of 100 watts (W) for 5 
minutes, after which the workload was increased by 50 W every 2.5 minutes 
until a heart rate of 160 beats per minute, after which the work load increased 
by 25 W every 2.5 minutes to volitional exhaustion. Wmax was calculated from 
Wmax = Wout + (t/150) x 25 W in which Wout is the highest power output (W) that 
the participant completed, and t the number of seconds the final uncompleted 
power output was sustained (Kuipers, Keizer et al. 1987). Wmax was used to 
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determine the relative exercise intensities to be undertaken by each participant 
during the experimental trials (viz., power output (W) at a given % Wmax).  
Participants started their trials at the same time of day (between 9 am and 2pm) 
to avoid any influence of circadian variance, following a 12-h fast.  After 20 
minutes of acute exposure to each environmental condition, oxygen saturation 
(Nellcor N-20,  Covidien, Dublin, Ireland),  was recorded. Over the next 10 
minutes resting oxygen uptake ( 2OV
 ) and carbon dioxide production ( 2COV
 ) 
measurements were made using an online gas analysis system (Metalyser, 
Cortex, Germany). The digital Triple V volume transducer was calibrated using 
a 3-litre syringe (Hans Rudolph Inc, USA) and the gas analyzers were 
calibrated using an ambient standard gas mixture of oxygen and carbon dioxide 
(20.9% O2 and 0.04% CO2) and a mass standard gas mixture (Alpha 
Gravimetric standard, BOC gases, Guildford, UK) of oxygen and carbon dioxide 
in nitrogen equivalent to expired air (15% O2 and 5% CO2). The test-retest 
reliability for 2OV
  and  (l.min-1) had coefficients of variation of 1.3% and 
2.4%, respectively.  
 
After a standardized warm up, which included the calibration of the cycle 
ergometer (Compu Trainer Pro Lab, Racer Mate, USA) to the manufacturer’s 
instructions, participants completed 120 minutes of cycling; 5 minutes at 40% 
Wmax, 5 minutes at 45% Wmax, 5 minutes at 50% Wmax, 105 minutes at 55% 
Wmax. These workloads were calculated from each individuals’ sea level and 
hypoxic Wmax for the sea level and hypoxic environments, respectively.  
Borg RPE score was reported every 15 minutes along with oxygen saturation 
(Nellcor N-20,  Covidien, Dublin, Ireland) and heart rate (Polar® heart rate 
monitor).  The investigator held a card with the 6-20 RPE scale printed on it in 
front of the subject who pointed to the appropriate value.   As some subjects 
were close to exhaustion by the end of the test (120 minutes) and the test was 
not always completed for the full duration the RPE at 90 minutes was taken as 
representative as maximum effort.  The decision to use the Borg score at 90 
minutes was taken as this is indicative of the maximum exertion before 
exhaustion and initial investigation showed this as the plateau of the HR values 
shown in figure 9.3. 
2COV

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Venous lactate was taken from an antecubital fossa vein every 15 minutes.   
These samples were analysed in house, using enzymatic determination of 
lactate (Randox Laboratories Ltd) on a semi-automated analyser (ILab 300 
plus, Instrumentation Laboratories, UK). The precision of the assay is) is as 
followed; Within runs 0.81 CV% (13.1 mg/dl) and 0.86 (53.3 mg/dl) and total 
precision is 5.72% (13.1 mg/dl) and 3.62% (53.3 mg/dl)(from the manufacturers 
information). 
 
Statistical analysis was carried out using SPSS v 21.   The statistical test used 
is reported with individual values throughout the analysis. 
 
Ethical approval was granted by the MoDREC protocol number 417. 
 
9.3.2   Results 
Sixteen subjects were recruited.   Two of these did not complete the study due 
to a low haemoglobin level (1 case) and superficial thrombophlebitis (1 case). 
The subjects’ demographics are shown below: 
 
Age 26 years (21-35) 
Height 174.9 cm (157.6 – 189.5) 
Weight 72 Kg (157.6 – 86) 
Sex M:F   8:6 
 
Table 9.3   Participant demographics 
 
Only 8 subjects completed testing in the hypobaric chamber due to failure to 
pass medicals, lack of chamber medical officer and lack of chamber availability. 
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The FiO2 set for the normobaric chamber was calculated as shown (table 9.4) 
 
Alps 
barometric 
pressure(mbar) 
Alps 
barometric 
pressure 
(mmHg) 
Calculated 
FiO2 
Participant 1 677.0 507.79 0.1393 
Participant 2 677.0 507.79 0.1393 
Participant 3 677.9 508.47 0.1395 
Participant 4 677.9 508.47 0.1395 
Participant 5 678.0 508.54 0.1395 
Participant 6 675.0 506.29 0.1388 
Participant 7 675.2 506.44 0.1389 
Participant 8 675.4 506.59 0.1389 
Participant 9 675.4 506.59 0.1389 
Participant 10 674.1 505.62 0.1386 
Participant 11 674.0 505.54 0.1386 
Participant 12 671.9 503.97 0.1381 
Participant 14 672.0 504.04 0.1382 
Participant 16 672.0 504.04 0.1382 
 
Table 9.4 Required FiO2 to provide desired PiO2 and simulate breathing air at 
target altitude 
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Heart rate in different environments 
Heart rate data were not normally distributed when a Shapiro-Wilk test was 
applied and appropriate non-parametric tests for significance were used. 
 
 
Figure 9.3 Heart rate changes across the 4 environments 
 
  
177 
 
Heart rate increased from rest with exercise in all environments, with the 
exception of HH where the heart rate change at 120 minutes was non-
significant, however there were only 3 matched data points for HR120 in HH.   
 
 SL NH HH  Alps P 
value* 
 N  N  N  N   
HR 
rest 
13 67 (11,  
51-83) 
7 73 (11, 
48-91) 
8 71 (8, 
58-84) 
13 74 (13, 
52-89) 
0.70 
HR 
60 
13 155 (11,  
135-175 
13 158 (13, 
138-174) 
8 147 (18, 
106-165) 
14 162 (9, 
146-175) 
0.16 
HR 
90 
14 161 (10,  
142-174 
13 160 (13,  
140-176) 
7 150 (18, 
114-166) 
13 154 (14, 
129-174) 
0.20 
HR 
120 
12 163 (11,  
132-178 
13 161 (9, 
143-175)   
4 142 (23, 
111-160) 
8 164 (11, 
144-178) 
0.14 
Data presented as mean (SD, range) *Kruskal-Wallis test for significance 
across SL, NH, HH, Alps 
Table 9.5 Heart rate values across the different environments 
 
RPE 
RPE scores were not normally distributed when the Kolmogorov-Smirnov 
statistic was applied (statistic 0.113, p<0.001). 
 
 SL NH HH Alps 
 N  N  N  N  
RPE 104 12.5 (3.4, 
6-20)  
104 12.9 (3.4, 
6-20) 
62 12.2 (4.0, 
7-20) 
108 13.9 (2.4, 
8-18) 
Data presented as mean (SD, absolute minimum and maximum reported 
values) 
Table 9.6 Mean RPE scores across all time points in the different environments. 
 
178 
 
There were no significant differences between the groups (Kruskal-Wallis 
p=0.538) 
 
Borg correlated with heart rate across all time points (Spearman’s rho = 0.419, 
p=<0.001).  This relationship held consistently for the different environments 
(Alps rho 0.319 p=0.001, NH rho 0.375 p<0.001, HH rho 0.619 p<0.001, SL 
0.389 p<0.001).  
 
Fig 9.4.  Heart rate at all time points vs. Borg RPE (rho 0.419, p<0.001) 
 
There is good correlation between the subject’s RPE recorded during a 
submaximal test at sea level and in each of the other environments (Alps rho = 
0.682 p<0.001, NH rho 0.909 p<0.001 and HH rho = 0.861 p<0.001).  
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Figure 9.5  Mean heart rate for each recording of RPE. 
 
Using the formula HR = 69.34 + (6.23xRPE) the correlation between actual 
heart rate and calculated heart rate was rho 0.419, p<0.001. 
 
Oxygen Uptake 
The oxygen uptake data was normally distributed when tested with the Shapiro-
Wilk test and parametric tests were applied. 
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 SL NH HH Alps P vs. 
SL 
 N  N  N  N   
VO2 rest 13 0.49 (0.07, 0.35-
0.59)  
13 0.53 (0.09, 0.39-
0.69)  
7 0.5 (0.05, 0.42-
0.55)  
13 0.49 (0.13, 0.33-
0.77)  
0.564 
VO2 60 
mins 
13 2.50 (0.26 , 2.0-
2.86) 
13 2.12 (0.27, 1.75-
2.47)  
7 2.06 (0.27, 1.68-
2.51)  
14 2.2 (0.35, 1.74-
2.88) 
0.002 
VO2 90 
mins 
13 2.58, (0.33, 1.88-
3.16) 
13 2.14 (0.23, 1.71-
2.45) 
7 2.04 (0.26, 1.67-
2.51) 
13 2.29 (0.34, 1.81-
2.93) 
0.001 
VO2 120 
mins 
13 2.78 (0.48, 1.94-
3.91)  
13 2.14 (0.24, 1.74-
2.5) 
6 2.0 (0.23, 1.66-
2.31) 
13 2.29 (0.34, 1.81-
2.93)  
<0.001 
Data presented as mean (SD, range).  Note that in the hypoxic environments workload was set at 60% of a hypoxic max test 
which explains the VO2 reduction.  
 
 
Table 9.7   VO2 changes in the 4 environments
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Post hoc analysis (Tukey) showed that the significant difference was between 
SL and all hypoxic measurements with the exception of V02 at 90 mins in the 
Alps (p=0.84). 
 
There was a significant drop in maximum VO2 achieved in hypoxia when 
compared to SL with exercise mean+/- sd 46.48 +/- 5.86 vs. 39.28 +/-3.95 
mls/Kg/min (Kruskal-Wallis). Work rate was reduced 230.6 +/- 33.8 vs. 205.3 +/- 
27.4 Watts but this was not significant (p=0.064) 
 
 
 
Figure 9.6 Oxygen uptake in the 4 different environments. 
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Lactate values 
Lactate values were not normally distributed at any time point when the 
Kolmogorov-Smirnov statistic was applied. 
 
 
Figure 9.7 Mean lactate values (with 95% confidence intervals shown) 
 
Lactate values at 90 minutes (mean (SD, range) were lower in the sea level 
environment (mean value at 90 minutes 2.66 mmol/L , 0.71, 1.9-4.0) than in the 
Alps 3.74 (1.34, 2.0-6.3 p=0.011), NH 3.78 (1.88, 2.18-9.51 p= 0.006) and HH 
3.22 (0.80, 2.42-4.77 p=0.069 NS).   There were no significant differences 
between lactate in the NH, HH and Alps environments (p=0.731 Kruskal-Wallis). 
There was no correlation between lactate and RPE in any environment. 
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 SL NH HH Alps 
     
Correlation 0.160 (0.139) 0.119 (0.266) 0.274 (0.101) 0.187 (0.071) 
Data presented as Spearman’s rho (p) 
Table 9.8  Correlation between lactate and RPE  
 
Acute Mountain sickness 
Lake Louise scores are shown below; 
 
 SL NH HH Alps 
     
Observations 14 14 8 14 
Pre-test 0.5 (0.9, 0-3) 1.4 (2.3, 0-9) 0.8 (1.2, 0-3) 1.1 (1.1, 0-3) 
15 mins post 
exercise 
0.9 (1.4, 0-4) 2.3 (2.3,0-6)  3.6 (1.2, 0-
11)  
2.7 (3.1, 0-8) 
2 hrs post 
exercise 
0.7 (1.2, 0-4) 1.9 (2.1, 0-6)  2.75 (3.0, 0-
8)  
2.3 (2.2, 0-7) 
22 hrs post 
exercise 
   1 (1.6, 0-5) 
 
Data presented as mean (sd, range) 
 
Table 9.9 LLS in each environment 
 
Despite the trend towards higher mean values in the hypoxic environments 
there was no significant difference in the LLS across the 4 environments (pre- 
test p=0.407, 15 mins post p=0.170, 2 hours post p=0.112 (Kruskall Wallis).  
Individual Man Whitney tests showed a significant difference between sea level 
and the 3 hypoxic environments at both 15 mins post exercise and 2 hours.  
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Environment 15 mins (p value vs. SL) 2 hrs (p value vs. SL) 
Alps 0.048 0.003 
NH 0.007 0.017 
HH 0.027 0.038 
 
Table 9.10 P value for LLS in hypoxic environments vs. SL (Mann Whitney) 
.  
 
 
Figure 9.8.  Lake Louise scores across the 4 environments at 15 minutes and 2 
hours after exercise.  The line represents the median, box 95% CI, whisker 
range  
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LLS increased significantly over the first 2 hours (Friedmann’s Two way 
analysis of variance by ranks p<0.001), however there was no significant 
difference between the LLS pre-test and at 22 hours in the alps (p=0.675 
Wilcoxon signed rank test).   There was a significant difference in LLS at 2 
hours when compared to pre-test (p=0.003, Wilcoxon signed rank test).  
 
As there were no significant differences across the 4 environments the Borg 
scores and LLS were investigated together (n=50). 
 
The Borg score at 90 minutes correlated with the LLS at 15 minutes and 2 
hours post exercise (Spearman’s rho 0.689, p<0.001 and 0.672, p<0.001 
respectively).  After 22 hours in the Alps Borg score no longer correlated 
although numbers were much smaller (n=14) (Spearman’s rho 0.098, p=0.738).  
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Figure 9.9 Borg scores plotted against LLS at 15 mins and 2 hours post 
exercise 
 
If Borg scores were split according to the previously used criteria of an RPE > 
15 there was an increased LLS in the high Borg group at 15 minutes and 2 
hours post exercise (p<0.001, Independent samples Mann Whitney U test) 
(table 9.11). 
 
 Low Borg  High Borg 
   
Observations 20 28 
15 mins post 
exercise 
0.6 (1.3, 0-5) 3.5 (2.9, 0-11) 
2 hrs post exercise 0.6 (1.1, 0-4)  2.8 (2.3, 0-8) 
 4 10 
22 hrs post 
exercise 
0.25 (0.5, 0-1) 1.3 (1.8, 0-5) 
Table 9.11 LLS divided by Borg RPE post exercise 
187 
 
 
There were no significant differences in AMS rates amongst the groups. 
(Pearson Chi squared p=0.441) (Table 9.12) 
 
 2 hrs post exercise 22 hrs 
post  
 SL NH HH Alps Alps 
      
No AMS 13 (93%) 10 (70%) 5 (36%) 9 (64%) 11 (79%) 
AMS 1 (7%) 4 (28%) 3 (21%) 5 (36%) 3 (21%) 
Severe 
AMS 
0 1 (7%) 2 (14%) 2 (14%) 2 (14%) 
Total 14 14 8 14 14 
 
Table 9.12  Summary of LLS consistent with AMS (3-5) and Severe AMS (>6)  
 
 
If the rates of AMS and severe AMS at 2 hours post exercise were examined 
according to the Borg RPE at 90 minutes then there was a significant increase 
in AMS and severe AMS with increasing Borg score (p=0.001 Kruskall Wallis). 
 
 
 No AMS AMS Sev AMS 
    
Borg@90minutes 13.3 (3.2, 6-18) 16.1 (1.35, 14-
18) 
17.8 (1.64, 16-
20) 
Data presented as mean (SD, range) 
 
Table 9.13  Incidence of AMS according to RPE at 90 mins 
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9.3.3 Discussion 
The most important finding of this study is that there was no change in HR, RPE 
or lactate across 3 environments at well controlled equivalent exercise intensity.   
Furthermore there were no differences in LLS and a consistent difference in 
LLS between those reporting a Borg score > 15 vs. those reporting lower 
scores. 
 
Borg RPE seemed to relate to heart rate when looked at in the four 
environments.  Overall numbers were low with a total number of 378 
observations in 14 subjects across the 4 different environments (SL plus 3 
hypoxic environments) but the relationship between RPE and HR as measured 
by Spearman correlation was consistent.   This is a small number of subjects 
when compared to Scherr’s paper (Scherr, Wolfarth et al. 2013) which 
comprehensively reviewed 2500 exercise tests, however it confirms the validity 
of the RPE as reflecting effort.   Larger numbers would be required to confirm 
Scherr’s relationship of RPE to HR (HR = 69.34x(6.23xRPE) although the 
correlation found was statistically significant using that formula.  
 
Decrease in HR at 120 minutes in HH is reported elsewhere with maximal 
exercise or may just be a function of small numbers (n=4).  Lactate values were 
higher in hypoxic environments (although only significant in NH and Alps (due to 
increased contribution from anaerobic pathways) .  Lactate showed no 
correlation with RPE which is to be expected in a submaximal exercise test.  
The mean RPE recorded in this study was around 13 in all 4 environments, this 
seems higher than the figures used in the Borg score in which 60% maximum 
effort should equate to an RPE of 11.  One reason for this disparity may be that 
our subjects were not trained cyclists and some of the rating was exercise 
specific or related to discomfort of being in the saddle for 2 hours.   Other 
authors have suggested that exercise modality does have a bearing on the RPE 
recorded (Chen, Fan et al. 2002).  Lactate showed a marked rise in the hypoxic 
environments due to a greater contribution from anaerobic metabolism.  
Although it is generally accepted that lactate levels do not rise in acclimatised 
individuals at extreme altitude, the “lactate paradox” (West 2007), this is not the 
case in this relatively short term hypoxic stimulus. 
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VO2 max fell in hypoxia by 15.5% this is in keeping with other literature and has 
been recorded since studies as early as 1906 (Ward, Milledge et al. 2000) 
(Chapter 11, section 9).  Although there was a trend towards a fall in work rate 
this was not statistically significant and HR remained the same.   This suggests 
that work rate remains the same for a given heart rate but consumes less 
oxygen at HA.   This finding has been noted before by Pugh in 1964 who found 
that oxygen consumption at maximal heart rate at altitude was reduced 
compared to sea level values, suggesting for the given work rate much was 
achieved using anaerobic respiration (Pugh, Gill et al. 1964).     
 
LLS did not differ between the 4 environments is surprising.   This study was not 
designed to investigate AMS in isolation as the numbers where small and 
exposure an inadequate length of time, however, interesting conclusions can be 
drawn.  The decision to include sea level data in the analysis is based on 
investigation whether exercise can bring on the symptoms of acute mountain 
sickness, as it can be argued that the study duration was too short to provoke 
true AMS.   One of the obvious problems is using the LLS which has 20% of the 
score allocated towards previous nights’ sleep.  Our research is not unique in 
using the score for studies that do not involve an overnight sojourn at HA and it 
is an obvious criticism.  The other explanation is that whilst there was a clear 
trend towards higher LLS scores in hypoxia numbers where insufficient to make 
a statistically significant result.  The LLS did increase over the first two hours 
post exercise however, by 22 hours there was no significant difference in LLS 
when compared to pre-test values (although 3 subjects reported LLS scores 
consistent with AMS vs. no AMS in pre-test scoring).  Part of this may be the 
small numbers involved in that LLS could only be measured after 22 hours 
hypoxia in the Alps.  These finding have important implications for the timing of 
LLS in future studies and may be one reason why the study of Roach found an 
increase in AMS after exercise (over 10 hours) which contrasted with the results 
of Rupp and Schommer (11 and 18 hours respectively).   
 
As in the Bolivia field study an increased Borg score correlated with increased 
AMS.  The decision to use the Borg score at 90 minutes was taken as this is 
indicative of the maximum exertion before exhaustion and is on the plateau of 
the HR values shown in figure 12.1.  The RPE recorded at this point correlated 
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with the LLS at 15 minutes and 2 hours post exercise.  This suggests that the 
recording of a high LLS is not just reflecting the exertion of the submaximal test 
as by 2 hours recovery could be expected to have taken place.  Overall the 
reporting of LLS consistent with AMS were the same across the 3 environments 
and consistent with other published data (13% at 3050m and 34% at 3650m 
(Barry and Pollard 2003)). 
 
There are a number of weaknesses in the study.  Firstly the numbers were 
lower in hypobaricity.  This reflects the difficulties of performing studies in this 
environment which was a major driver to conduct the study in the first instance.   
Reasons for lower numbers included failure of subjects (and the independent 
medical officer) to pass the fitness criteria due to an inability to clear ears and 
subject availability for what became a prolonged trial.   Neither of these factors 
could have been avoided.  Secondly, as part of a parallel study, fluid balance 
was measured and fluid (in the form of a carbohydrate drink) administered.  A 
total of 2.5 litres of this drink was ingested during the cycle which may have led 
to transient nausea although this is likely to have subsided by the time LLS 
were recorded 15 minutes and 2 hours post exercise. 
 
9.4   Conclusions 
The field study in Bolivia suggested exercise as measured by the Borg RPE 
score seems to be predictive of those developing AMS. 
 
Chamber studies showed no major physiological difference noted between 3 
hypoxic environments (NH, HH, alps) environments in terms of lactate, heart 
rate or oxygen uptake. 
 
Across all four environments LLS and AMS are rates the same which suggests 
it is the exercise stimulus that cause the symptoms of AMS rather than altitude 
per se over these short periods of time in laboratory studies.  For this reason 
timing of LLS recording is critical and a lack of recovery from bouts of exercise 
may be pivotal in generating altitude illness. 
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10.1 Introduction 
During a climbing trip in the Khumbu region of Nepal in 2014 I climbed Island 
Peak, guiding a group of novices with a very experienced military coleague, SM.  
SM had acclimatised well, despite a chest infection earlier on in the trip and we 
both felt strong whilst leading our groups from base camp at 5100m up to the 
summit of the peak at 6189m.  After a brief period on the summit we returned to 
base camp (a 12 hour day) to be well fed and drink plenty of fluids.  SM 
exhibited no signs of altitude illness or undue exhaustion.  The following day SM 
was well but I noticed a significant amount of periorbital oedema.  That morning 
we descended and over the first 400m of the descent (taking about 90 minutes) 
SM and I each stopped to pass urine on six different occasions passing far in 
excess of the half dozen cups of tea we had drunk that morning.  Within a two 
hour period his periorbital oedema had cleared.  This acedote highlights my 
hypothesis and motivation for the initial part of this MD work.  Perceived wisdom 
is that a “climb high sleep low” strategy is the best for acclimatisation.  Had we 
been climbing a higher mountain an ascent to 6000m, as on Island Peak, would 
have been seen as good acclimatisation and been followed (usually the 
following day) by an ascent to a similar altitude to sleep.  What I observed was 
that, in the climb of Island Peak, physiological stress caused SM to overide his 
altitude induced suppression of AVP, a process which required the recovery of 
returning to less stressful altitudes and diuresis to restore “normality”.  Had he 
reascended the following day, despite being well, he may well have started the 
viscious cycle of stress, fluid retention and formation of tissue oedema and high 
altitude pathology.  This is of course conjecture but is in part borne out by the 
research.  I recorded supression of AVP and copeptin with exercise at HA 
relative to SL, a change in copeptin and AVP with more strenuous exercise and 
a change in LLS with strenuous exercise.  The missing link was to show a link 
between AVP levels and AMS or fluid retention, potential weaknesses in this 
part of the study will be considered later in this chapter. 
 
In a recently book reviewing the contribution of the physiologist Griff Pugh to the 
success of the 1953 Everest expedition the author, his daughter Harriet Tuckey, 
refers to Pugh’s ascertion that recovery is important during high altitude 
expeditions (Tuckey 2013) and the, then novel, guidelines he put in place during 
the expeditions he was involved in.  None of the quotes from Pugh’s work 
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mention acclimatisation per se but rather recovery.  I think this is an important 
distinction – I would argue that SM had acclimatised to the 6000m altitude but 
the following day had not recovered placing him at risk had he ascended 
further.  There are many other interesting insights into the previous history of 
high altitude medicine and physiology in this book including Pugh’s belief that 
climbers should drink liberally during ascent.  I have often wondered where the 
evidence comes from for this as contraction of plasma volume is an important 
part of adaptation.  During the early expeditions to high mountains stove 
technology was practically incapable of melting significant amounts of snow for 
water at high altitudes, Pugh pushed hydration as many mountaineers came 
down from summit attempts severely dehydrated exacerbating frostbite and 
exhaustion such as Moreshead and Somervell during the 1922 Everest 
expedition or Tenzing and Lambert on Annapurna melting snow with a candle!  I 
believe maintaining normal hydration was Pugh’s goal.  Before the Second 
World War any application of science was seen as at odds with the gentlemanly 
nature of mountaineering as “sport” and began to smack of professionalism 
(training was equally frowned upon).  In a presentation to the Alpine Club in 
1924 Leslie Stephen (the Club’s President) stated “true alpine traveller’s loved 
the mountains for their own sakes and considered scientific intruders with their 
barometers and theorising to be a simple nuisance”. 
 
10.2   Personal Reflection 
This MD has been 3 years in completion but really started with my first field 
study in 2007.  Each study has seen a step up in complexity through basic 
physiological data collection, to point of care monitoring systems through to 
generators, echo machines and freezers.  This has given me great insights into 
data collection and the pros and cons of this field study is considered later.  
Even throughout the writing period, preparation of manuscripts for submission 
has made me consider data presentation and the format of tables and graphs 
throughout the thesis.  Some I have made changes whilst some remain in their 
orginal form and as I think the evolution is interesting to see.  I am indebted to 
my colleagues Dave Woods and Chris Boos for their help and advice in this.  
Overall I have benefited hugely in terms of my grasp of academic concepts, 
ability to critically appraise other work and communicate with others. 
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Field studies of this nature are a challenge, not just in the reseach methods but 
in maintaining collaborations, relationships with other investigators and, perhaps 
most importantly, with the subjects themselves who had to endure some pretty 
gruelling regimens.  
 
To date six papers have been published as a result of this work with more in the 
pipeline (Boos, Holdsworth et al. 2013, Boos, Holdsworth et al. 2014, Mellor, 
Boos et al. 2014, Mellor and Woods 2014, Mellor, Boos et al. 2014, Mellor, 
Woods et al. 2014).  I have also had the oportunity to present findings within the 
military and to wider audiences at national meetings. 
 
10.3   Study design 
Field studies of this nature are complex to design and difficult to control.  There 
are a number of potential short comings with the data collected in Bolivia.   
These are discussed below; 
 
10.3.1   Baseline data collection 
Data collection during the near sea level trek in Wales could only be collected 
on a small sub group of subjects.  The main reason for this is that the main field 
study required participation over a three week period and many of the subjects 
did not feel able to commit a futher weekend to the study.  This meant that data 
for baseline AVP, copeptin, BNP, catecholamines and cortisol was only 
available for 20 (2 of whom did not take part in any further analysis).  For this 
reason repeat measures statistics could not be used on some of the results and 
group means or other appropriate tests had to be used to investigate the 
significance of changes.   
 
10.3.2   Lack of control of activity 
There was a lack of control of individuals activity on the trek.  Whilst trekking 
distances etc were common to the whole group, some individuals made other 
treks to surrounding view points for acclimatisation purposes or photography.  It 
was not considered ethical to restrict this when an individual’s financial 
contribution was key to financing the expedition.  The impact of this on the 
overall results would have been minimal although it may have resulted in 
improved acclimsatisation in some individuals. 
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10.3.3   Period of time at new altitude 
The only way to perform this study was judged to be using the trek as the 
exercise component.  This created a fundamental problem in that the “rest” day 
values reflected an increase in time at the new altitude as well as rest.  The only 
way around this would have been to have performed a predetermined exercise 
test at the new altitude (such as a step test or further trek) during the “rest” day.  
This would have been difficult for a number of reasons.  Most importantly 
subjects are unlikely to have tolerated several hours of exercise which was the 
intended duration i.e. a real world trekking stimulus.  Effectively removing the 
rest day would have had an impact on the acclimatisation profile of the 
expedition and would have been ethically challenging.  In this respect field 
studies cannot be as provocative for AMS as laboratory studies due to the 
potential risk of both the disease and the hazards of rescue.  Performing a 
calibrated exercise test may have meant more complex equipment and added 
to the logistic burden.  The impact of this would be small overall and the results 
reflect what happens in the “real world” scenario which was always the 
intention. 
 
10.3.4   Physiological Data Collection 
The majority of the team were medical (doctors, nurses and allied health 
professionals).  The team members collected data on each other to assist the 
research team.  This may have led to some inaccuracy and ideally data 
collection should have been blinded from the subjects.  In particular, resiratory 
rate was not well collected. 
 
10.3.5   Borg Score Was Collected Retrospectively 
The Borg RPE was collected retrospectively at the end of the trekking day.  This 
was done on completion of the activity and had the advantage of giving one 
value to define the perceived exertion of the trek.  It would have been 
interesting to have a peak heart rate or nadir of saturation during the trek to 
correlate with and validate the Borg score.  There is also the possibility that 
those individuals who finished the trek and began to feel unwell would 
automatically record a higher RPE than those feeling well which would lead to 
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higher RPE scores in those with AMS without, necessarily, demonstrating 
effect. 
 
10.3.6   Three way environment study 
This study, by nature of design, was easier to control and make direct 
comparisons.  The main short coming of this study is that 2 hours of cycling a 
static bike is a significantly difficult activity, regardless of intensity, for those not 
used to racing bike saddles.  One cannot rule out a learning effect or perhaps 
an anticipatory effect.  This may have influenced Borg RPE scores or heart 
rates.  During the study in the Alps the group were camped at around 1400m, 
this could have an an unknown effect on the physiology of those later in the 
study. 
 
10.3.7   Lake Louise Score 
As mentioned early in the thesis no “gold standard” exists for the diagnosis of 
AMS.  Recent work published has looked at the evolution of symptoms for 
subjects in a 10 hour chamber study at 4800m (Burtscher, Wille et al. 2014).  
This paper tends to suggest that there are two distinct clusters of symptoms 
which is further supported by some retrospective analysis from Hall and the 
Edinburgh study group (Hall, Maccormick et al. 2014).  The chamber study may 
provide a blueprint for future work and would be a particularly useful way to 
investigate the role of AVP/copeptin and relationship to the development of 
symptoms of AMS. 
 
10.4   Important Conclusions For High Altitude Medicine And Research 
Perhaps the most important conclusion from the Boliva field study is that 
exercise has a profound influence on physiological parameters with 
Norepinephrine, Cortisol and Copeptin showing a split between those with a low 
perceived exertion and those individuals who recorded a higher RPE.  This 
helps to explain some of the inconsistencies in other published work. 
One interesting finding was that two similar ascent profiles in two different 
countries can lead to different rates of AMS (figure 10.1). 
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Figure 10.1 Differences in LLS in Bolivia and Nepal 
 
This may also explain differences in the data from other field studies.  On the 
face of it the ascent profile in Bolivia (flying in to 4061m) would be judged to be 
more provocative for AMS than the trek to 3500m in Nepal, but this does not 
seem to have been the case.  Exercise has been considered above as a 
potential difference.  One other difference, not considered in other studies, is 
the potential difference in anxiety.  On arrival in La Paz one is in a comfortable 
hotel, eating in restaurants and familiar surroundings.  At a corresponding 
altitude in Nepal the expedition had had 2 nights under canvas and was eating 
in a cold mess tent.  Anxiety in itself is a very important consideration for those 
planning future studies and expeditions.  Missoum reported that trait-anxiety 
and anxiety prior to an ascent is associated with higher AMS rates on an 
expedition to the Dhaulagiri area in 1992 (Missoum, Rosnet et al. 1992).  Many 
anxiety scores exhibit symptoms in common with the LLS.  This has two 
important implications.  Firstly, future studies should record anxiety concurrently 
with AMS scores and secondly if anxiety can be controlled and manipulated can 
self reported AMS be reduced?  It also stands to reason that studies of climbers 
on technical routes cannot be compared to those exposed to HA for the first 
time or those with experience on a non-demanding trek.  Pre-existing anxiety 
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traits may have an impact on catecholamine levels at higher exercise intensities 
(Peronnet, Blier et al. 1986) and in turn, catecholamine levels may influence 
respiratory rate, heart rate and therefore SpO2 and potentially BNP, cortisol or 
AVP. 
 
One other possible confounder is that some of the LLS score difference could 
be accounted for by caffeine withdrawal headache.  This is more likely to have 
been the case in Nepal rather than Bolivia where good coffee was available 
until a later stage in the expedition. 
 
Many studies cited in this thesis are less than 24 hour duration notably (the 
exercise chamber studies, some AVP ones etc).  These studies all quote LLS 
as a diagnostic test for AMS.  None of the authors account for how subjects 
answer the question about sleep.  The assumption is that it will be the same 
throughout but clearly sleep the night before is not influenced by hypoxia in a 
chamber the following day and the sleep component for the LLS accounts for 
20% of the numerical score.  Thus a subject who had slept poorly the night 
before could easily be diagnosed with mild AMS with only a slight headache.  
Once again this highlights the need for a biomarker as a diagnostic test for 
AMS. 
 
10.5   Implications For The Military 
There are a number of potential considerations for the military from the findings 
of this research. 
 
10.5.1   Setting Strategies For Pre-acclimatisation 
Future military work will focus on strategies to “pre-acclimatise” troops prior to 
high altitude deployment.  Part of this will involve a period of pre-acclimatisation 
in a chamber environment.  The results of the three environment study suggest 
that normobaricity can provide as great a physiological stress as hypobaric 
hypoxia at least when exercise is conducted.  Monitoring of the exercise stress 
can also be carried out using Borg RPE, avoiding pushing the subject beyond a 
Borg RPE of 15 to allow physiological stress but adequate recovery.  The use of 
BNP as a marker also enables the degree of exercise and hypoxia to be 
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individually assessed to create a response but allow resolution between 
exposures. 
 
10.5.2   Consideration Of Anxiety 
Mental strategies to deal with the anticpated effects of anxiety could be useful to 
reduce any cross over between AMS and anxiety.  This would be improved by 
exercise in hypoxia but could be augmented with visualisation techniques in line 
with military research into virtual environments for analgesia. 
 
10.5.3   Future Collaborations 
A key part of this work has been to develop and cement collaboration with 
Leeds Beckett University with their expertise in sports science and access to a 
wide range of cardiopulmonary testing and environmental chamber. 
  
10.6   Future Research 
This work has led to a range of ongoing projects to investigate links between 
AMS and anxiety, strategies for pre-acclimatisation and the relationship 
between Borg score and exercise during hypoxia. 
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